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Abstract 
Macronutrient digestion is a major factor in health and metabolic diseases such as 
obesity and diabetes and presents a huge global challenge.  
Modulating macronutrient digestion with food additives and pharmaceuticals has been 
shown to be a fruitful approach to the treatment of obesity (Orlistat) and diabetes 
(Acarbose).  Previous work has shown that bioactive agents have novel modulatory 
effects on the major enzymes of digestion, and work in this lab has shown that specific 
alginates can inhibit pancreatic lipase up to 70%. Alginates are now being investigated 
as a potential anti-obesity agent.  
The purpose of this thesis was to develop in vitro methodologies and an analytical 
approach for investigating the effects of exogenous compounds on the major digestive 
enzymes; α-amylase, pepsin, trypsin, and lipase. A 3-step process was developed 
consisting of; higher-throughput single enzyme analysis, selected enzyme kinetics and 
model gut analysis.  
Alginates were shown to inhibit the action of pepsin, but have no effect on trypsin 
activity in vitro. The structure of alginate is key to the inhibition of pepsin, and 
rheological and viscometric data suggested that this effect was due to a pH dependent 
interaction between alginate and protein substrate as well as direct enzyme-inhibitor 
interactions. A similar effect was observed with Fucoidan and sulphated carrageenans. 
In the model gut analysis, these effects manifested as inhibition of proteolysis in the 
simulated gastric phase, but not in the small-intestinal phase.   
Alginates were shown to increase the activity of α-amylase during in vitro single 
enzyme analysis, but have no significant affect on carbohydrate digestion in a model gut 
simulation. Fat digestion in the model gut simulation was inhibited by specific 
alginates, adding further weight to the potential use of alginates as a therapeutic 
treatment of obesity.   
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There was never a sound beside the wood but one, 
And that was my long scythe whispering to the ground. 
What was it it whispered? I knew not well myself; 
Perhaps it was something about the heat of the sun, 
Something, perhaps, about the lack of sound— 
And that was why it whispered and did not speak. 
It was no dream of the gift of idle hours, 
Or easy gold at the hand of fay or elf: 
Anything more than the truth would have seemed too weak 
To the earnest love that laid the swale in rows, 
Not without feeble-pointed spikes of flowers 
(Pale orchises), and scared a bright green snake. 
The fact is the sweetest dream that labor knows. 
My long scythe whispered and left the hay to make. 
  
Robert Frost 
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Chapter 1 
Introduction 
 
1.1 Introduction & Justification of Research 
 
 The digestion and absorption of the major macronutrients fat, protein and carbohydrate 
is a major factor in health and metabolic diseases such as obesity and diabetes. By 2015 
it is projected that 2.3 billion people will be overweight and 700 million obese [1]. This 
presents a huge global challenge in terms of health, cost and sustainability. Obesity 
already currently costs the NHS around £5 Billion annually [2].  
 
Modulating macronutrient digestion with food additives and pharmaceuticals has been 
shown to be a fruitful approach to the treatment of obesity (Orlistat [3]) and diabetes 
(Acarbose [4]). Previous studies have shown a number of dietary fibres to have 
regulatory effects on the activity of digestive enzymes and work in this lab has shown 
that specific alginates can inhibit pancreatic lipase up to 70%. This is now being 
investigated as a potential anti-obesity agent.  
Alginates are bio-active dietary fibres commonly used at low levels in the food industry 
which have been shown to have inhibitory action on both pepsin and lipase [5-7]. As 
current approaches to obesity treatment and management are often ineffective, high-risk 
or carry with them side-effects the prospect of alginate inhibition of lipase is an exciting 
and important area of research.  
The aim of this project was therefore to develop methodologies for the practical 
examination of bioactive exogenous compounds on the major digestive enzymes; 
pepsin, trypsin, α-amylase and lipase. These studies were undertaken with a view to 
explore the potential to develop novel therapeutics which would modulate the activity 
of these digestive enzymes. 
Nutrition research is a key strategic priority for bioscience research both in terms of 
food security and in understanding the role of diet and the mechanisms that underpin 
health and disease [8]. This approach aims to provide a system for analysis of 
macronutrient digestion and the screening of novel therapeutics, which will aid food 
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research and present an ethical alternative to animal models and a cost effective pre-trial 
system that can be used to inform and improve human trials.  
Furthermore the introduction of EFSA (European Food Standards Agency) requires a 
much higher threshold of scientific evidence for food health claims in the EU. This 
means that costly and financially risky human studies must be undertaken to support 
health claims.  
A potential benefit of the methodological approach which has been developed, and 
particularly a model gut system is that it provides a robust and physiologically relevant 
in vitro system of analysis which can be used to improve and inform human studies. 
The methodology may potentially be used to provide data that can be used to investigate 
efficacy, dosage, delivery methods and allow them to make decisions that will 
potentially save costs and improve results.  
1.2 Bioactive alginates and obesity 
 
In 2010 Wilcox et al showed that specific alginates were capable of inhibiting 
pancreatic lipase by a maximum of 72.2% (± 4.1) using a synthetic substrate DGGR 
(1,2-o-dilauryl-rac-glycero-3-glutaric acid-(6'-methylresorufin) ester) and 58.0% (± 9.7) 
with a natural substrate (olive oil triglyceride) [5, 6]. Pancreatic lipase is responsible for 
the breakdown of the major dietary fat triacylglycerol and inhibition of triglyceride 
breakdown with alginate may reduce fat breakdown and provide a potential treatment 
for obesity.  
 
The inhibitory effect was shown to be related to alginate structure, alginates are 
composed of guluronic and mannuronic acid residues, and alginates high in guluronic 
acid were shown to be more potent inhibitors of pancreatic lipase. High-G alginates 
extracted from the Laminaria hyperborea seaweed inhibited pancreatic lipase to a 
significantly higher extent than High-M alginates from the Lessonia nigrescens species 
(Figure 1).  The invention of alginate as an inhibitor of pancreatic lipase is now under 
patent, and is being investigated as an anti-obesity agent in human trials [6].   
As the in vitro assays for lipase activity have already been developed, the purpose of 
this study was to develop methodologies to analyse the effects of bioactive compounds 
on the other enzymes of macronutrient digestion 
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Figure 1  Comparison of lipase inhibition by Lamanaria and Lessonia alginates. Inhibition is 
shown as a percentage reduction in the presence of 2.43mg/ml alginate as compared to normal lipase 
activity. The alginates in order as shown are LFR5/60, SF120, SF/LF, LF10L, LF120L, SF60 and H120L. 
Error bars are shown as the standard error of the mean (n=6). Taken from Wilcox, 2010 [5]. 
1.2.1 Current Treatments Of Obesity  
Obesity and metabolic diseases are a significant and growing problem, particulary in the 
developed world with obesity and diabetes at epidemic levels. As of 2005, almost 25% 
of the worlds population (1.6 billion people) were considered overweight by BMI (BMI 
≥ 25 kg/m2) and 400 million obese (BMI ≥ 30 kg/m2)1. This is projected to rise to 2.3 
billion overweight and 700 million obese by 2015 [1].  
                                                 
1
 BMI has been observed to correlate with body fat percentage (BF%) and therefore provides a ‘surragate measure’ 
of body fat. The relationship between BMI and BF% has however been shown to be dependent on age, gender and 
ethnicity so universal cut off points between weight categories may not be appropriate . Furthermore cut-off points 
between weight categories are defined relative to populations, overweight generally corresponding to ≥85th percentile 
and obesity to ≥95th percentile. BMI therefore offers a crude but useful surrageate measure of BF% [9]. 
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Obesity, excess fat storage and high energy, high fat diets are associated with an array 
of health complications (Table 1). Finding effective treatments and interventions for 
obesity and associated diseases is therefore paramount.  
 
Table 1  Health issues associated with obesity. Adapted from Power & Schulkin, 2009 [9]. 
Obesity and weight gain in general are caused by a sustained imbalance of energy intake 
and expenditure, more calories are consumed than burned off and the excess energy is 
stored as fat. Treatments of obesity therefore aim to restore this energy balance through 
either increasing activity or reducing calorie intake. 
Managing obesity through exersise and diet is the preferred treatment due to lower cost 
and risk of complications [10]. However, the long term efficacy of dieting as a treatment 
of obesity has been questioned, in a review of dietary studies, Ayyad et al 2000, suggest 
an average long term success rate of just 15% for dietary treatment [11].  
Bariatric surgery has proved to be the most succesful intervention. Gastric bands, 
gastric bypass, gastric reduction surgery and intra gastric balloons all seek to physically 
reduce the capacity of the stomach so that smaller meals can satiate, thereby reducing 
calorific intake. A meta-analysis of 136 studies accounting for 22,000 patients showed 
that significant weight loss was achieved in 61.2% of all types of bariatric surgey [12]. 
A comorbid improvement of diabetes, hyperlipidaemia, hypertension and sleep apnoea 
was also observed. However, on the NHS, barriatric surgery is normally only 
considered for those with a BMI greater than 40, or for patients with a BMI between 35 
and 40 and a comorid condition which would benefit.  
Metabolic Disease 
Type II Diabetes 
Cardiovascular disease 
Hypertension 
Stroke 
Hyperlipidaemia 
Nonalcaholic fatty liver disease 
Reproductive Disorders 
Infertility 
Stillbirth 
Miscarriage 
Birth defects 
Fetal Macrosomia 
Pre-eclampsia  
Maternal death 
Cancer 
Kidney cancer 
Endometrial cancer 
Postmenopausal breast cancer 
Oesophageal Cancer 
Gall bladder cancer 
Colon Cancer 
Other 
Osteoarthritis  
Sleep apnoea 
Asthma 
Depression 
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A number of anti-obesity agents have been suggested as medical treatments of obesity. 
Haddock et al conducted a meta-analysis of suggested drug treatments, showing most of 
the drugs studied to have a moderate effect with none showing particular superiority 
[13]. However, due to side effects, many of these agents are not approved for use (e.g. 
amphetamine, fenfluramine, methamphetamine, phenylpropanolamine) [13]. Orlistat, a 
pancreatic lipase inhibitor, is the most commonly prescribed obesity medication in the 
UK [14]. A randomised double-blind study showed that when used in conjunction with 
a calorie restricted diet orlistat can cause a mean weight loss of 5.9% of body mass 
compared with 2.3% for those on a calorie restricted diet and placebo [15]. However, 
side effects including sterrathorea and incontinence, can make it an unpleasent treatment 
for the patient [16].  
Bariatric surgery and orlistat provide effective treatment options for obesity, they are 
however not without risk or side effect and bariatric surgery is only appropriate in the 
most severe and advanced cases of obesity. Furthermore, the questionable long term 
efficacy of traditional dietary interventions suggest a need for new approaches to 
obesity management.  
1.2.2 Treatment Of Obesity With Enzyme Inhibitors 
Orlistat (Tetrahydrolipstatin) was developed from Lipstatin, a natural lipase inhibitor 
isolated from Streptomyces toxytricin and is capable of reducing fat absorption by up to 
35% [17]. Orlistat has been shown to irreversibly inhibit lipase by covalently binding to 
the active site, inducing a conformational change in the enzyme. The lactone ring of 
Orlistat (Figure 2) forms a covalent bond with the catalytic serine residue in the lipase 
active site inhibiting lipase activity in a ‘quasi-irreversible’ manner [18-22].The term 
quasi-irreversible is used as the enzyme-inhibitor complex can be unstable in low levels 
of bile salts, suggesting that bile salts stabilise the reaction [23].  
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Figure 2  Structure of Orlistat (Tetrahydrolipstatin). 
As orlistat demonstrates, inhibition of digestive enzymes presents a therapeutic target 
for obesity treatment and orlistat is neither the first nor the only anti-obesity agent that 
works through enzyme inhibition. In the 1980’s starch blockers became a leading area 
of research in the treatment of obesity and other ‘carbohydrate-dependent’ diseases such 
as diabetes and insulin resistance as researchers sought to find ways of inhibitting α-
amylase in order to block carbohydrate digestion. Although starch blocker tablets are 
still widely marketed, their efficacy is the subject of dispute [24-26].  
The active agents in starch blockers are proteins extracted from a number of plants; 
Phaseolus vulgaris (Common bean) [27], Triticum aestivum (wheat flour) [28] and 
Type 1 α-amylase Iinhibitor (α-AI) from Amaranthus hypochondriacus seeds [29]. It is 
thought that these natural amylase inhibitors evolved as a defense mechanism to protect 
the plant against predation [30]. Relatively recent work has again supported the use of 
Phaseolus vulgaris extract. In a small human trial weight-loss with Phaseolus vulgaris 
extract was shown to be higher than placebo when 25 healthy individuals were fed 
Phaseolus vulgaris extract or placebo with meals [25]. 
The α-glucosidase inhibitor acarbose has been shown to significantly reduce 
development of Type 2 Diabetes in patients with glucose intolerance [31]. In a 
randomised control trial involving 714 patients, 32% of patients taking acarbose went 
on to develop diabetes as compared to 42% on placebo, furthermore acarbose 
significantly increased reversion to normal glucose tolerance (p<0.0001).  By slowing 
carbohydrate digestion, acarbose reduces the glycaemic-hit of a meal and reduces post-
prandial insulin secretion with benefits for the treatment of insulin resistance [32]. 
Acarbose is a pseudooligosaccharide similar in structure to maltotetraose (Figure 3) and 
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is effectively absorbed through the maltose-maltodextrin transport system. Acarbose is 
however a poor substrate for α-glucosidases and can not be metabolised [33].  
Acarbose is derived from the Actinoplanes fungus and inhibits α-glucosidase by 
reversible competitive inhibition by competing for the active site. It is effective against 
the brush border α-glucosidases of the small intestine and is a weaker but effective 
inhibitor of pancreatic α-amylase. This reduces the rate at which monosaccharides are 
cleaved from carbohydrates [34]. 
In a 5-year study of nearly 2000 individuals with Type II diabetes, 4.7% showed 
adverse effects believed to be linked to acarbose. Side effects included; flatulance, 
diarrhoea, nausea, abdominal pain, loss of appetite and heart burn [35].  
 
 
 
 
Figure 3  Structure of Acarbose: (A) amino-cyclitol moiety (B) deoxyhexose (C and Maltose 
 
Acarbose 
Maltotetraose 
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1.3 Dietary Fibre 
1.3.1 Overview 
Dietary Fibre is not a discrete and chemically identifiable nutrient, but a nutritional 
concept referring to a group of dietary constituents sharing similar characteresitics. 
There is no single agreed upon definition and it is therefore important to clearly define 
what is included as dietary fibre. 
Trowell et al 1976, define fibre “simply as the plant polysaccharides and lignin which 
are resistant to hydrolysis by the digestive enzymes of man.” [36]. This definition would 
however exclude fibres of animal origin such as chitin and chitosan. For the purposes of 
this report, dietary fibre shall therefore be defined as the carbohydrate constituents of 
the diet that are resistant to digestion and absorption in the human small intestine (i.e. 
escapes pre-colonic digestion and absorption) [37].  
Dietary fibres are widely used in the food industy as gelling, thickening and stabilising 
agents, as well as as prebiotics and as such they can be incorporated into a wide range of 
foods.   
1.3.2 Health Benefits of Dietary Fibre (DF) 
DF is recommended because of its known benefits to digestive physiology; stool 
bulking, gastro-intestinal motility, stool frequency and maintainance of intestinal flora 
[38]. Recommendations for daily intake vary from country to country between 15-
40g/day however these levels of intake are consistently not met in the general 
population [38]. DF is also considered to have wider health benefits and a high intake of 
DF is inversely associated with total mortality risk and reduced risk in a number of 
diseases [39, 40].  
High long term intake of DF is associated with decreased risk of coronary heart disease 
[41], hypertension [42, 43], diabetes [44], obesity [45] and colorectal cancer [46]. A 
study in a subgroup of 632 Israelis showed those consuming more than 25g of DF a day 
had a 43% lower mortality risk [47].  
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However, when considering the health benefits of DF in epidemiological studies it must 
be noted that high fibre intake is associated with a generally healthier lifestyle; more 
physically active, lower likelihood of smoking and a generally healthier diet including 
more vegetables and less fat [48]. Therefore a causal link can not be assumed.  
1.3.3 Dietary fibre as an Enzyme Inhibitor 
Research into fibres as inhibitors of digestive enzymes began in the late 70’s and early 
80’s.  The inhibitory effects of a number of dietary fibres against trypsin, chymotrypsin, 
amylase and pepsin were investigated in vitro by Ikeda et al 1983. The investigation 
claimed to show in vitro inhibitory activity from a number of dietary fibres; 
Hemicellulose, pectin and xyal were shown to inhibit trypsin (up to 80% inhibition). 
Pectin and cellulose showed inhibition of α-amylase  of up to 35%, and pectin and 
cellulose demonstrated inhibitory activity against pepsin of up to 60% [49]. 
Rats fed a high fibre diet containing 20% cellulose have shown a significant decrease in 
intestinal proteolytic, lipolytic and amylolytic enzyme activity upon analysis of 
intestinal contents [50]. Dilution of stomach contents with DF has been suggested as a 
possible factor during in vivo studies of enzyme activity [50]. However, the same 
investigators were also able to demonstrate in vitro inhibiton of pancreatic enzymes in 
samples of human pancreatic juice. Activity of lipase, amylase, trypsin and 
chymotrypsin was compared in samples of human pancreatic juice incubated with or 
without a range of DFs. With the exception of pectin, the fibres examined (alfalfa fibre, 
oat bran, hemicellulose, wheat bran and cellulose)  all brought about a reduction in 
enzyme activity, with cellulose and hemicellulose producing the largest effect [51].  
As well as the work from the 1980s, more recent work has also looked into the potential 
of DFs as inhibitors of digestive enzymes. El Kossiri et al 2000, measured casein 
digestion with pancreatin in the presence of DF. A range of soluble fibres including 
carrageenan, locust bean gum, alginate and pectin brought about a reduction of protein 
digestion [52].  
The observation of pectin inhibition of casein digestion contradicts the results of Dunaif 
et al 1983, who suggested pectin had no inhibitory effect on proteolytic activity [51]. 
Pectins are an heterogenous group of molecules with diverse structure and the degree of 
methyl esterification of pectin carboxyl groups has been suggested to affect the 
inhibitory activity of pectins, this may offer an explanation for the conflicting evidence 
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and it is discussed later in the report how esterification of pectins affects viscosity and 
gellation of pectins. which may explain the varying results of pectin inhibition [53]. The 
current reasearch aims to address this conflicting evidence of pectin inhibition by 
designing a robust high-throughput methodology which, may be able to link the 
regulatory properties of pectins (and any other fibres) to their structure and properties.  
El Kossiri et al 2000, also investigated a viscosity effect as the potential mechanism for 
inhibition. A direct relationship between fibre viscosity and inhibition would suggest a 
viscosity effect reducing the pedesis of solutes therefore reducing substrate-enzyme 
contact. As no significant correlation was found between viscosity and inhibition, the 
author argues viscosity alone is insufficient to explain the inhibition [52].   
As stated previously, current work in this lab is investigating alginate inhibition of 
pancreatic lipase. A key benefit of using alginate as an inhibitor of lipase is that the 
properties of the DF may help mitigate the side effects seen with Orlistat. DF is 
generally beneficial to digestive health, causing stool bulking and improved gastro-
intestinal motility and stool frequency which may help to prevent the incontinence seen 
with Orlistat. It is also thought that DF may bind up some of the undigested lipids 
reducing sterrathoroea. Two groups of 30 obese women were treated with orlistat, one 
group was also given DF supplement (Psyllium mucilloid) and the other placebo. Both 
groups showed significant weight loss, but while 71% of placebo group suffered GI side 
effects, in the DF group this figure was 29% [54]. 
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1.3.4 Mechanisms of Dietary Fibre Inhibition 
While there is a clear body of evidence showing that DFs can regulate the activity of 
digestive enzymes, the mechanism of this regulation is unclear and is an area into which 
further work is needed. A number of mechanisms have been proposed (Figure 4), and it 
is likely that there are a number of different ways in which enzyme activity is affected 
by the presence of DF. 
As stated previously dilution of digesta has been suggested as an explanation of reduced 
digestive enzyme activity in vivo. However, DF has also been shown to inhibit enzyme 
activity in vitro where dilutions are controlled and can therefore not be responsible for 
the loss of activity.  
DFs can be highly viscous, and it is for their gelling and thickening properties that they 
are often used as food additives. In vivo, the viscosity of DF opposes the peristaltic 
mixing process, slowing enzyme access to substrate [55]. Both in vitro and in vivo, 
viscous DF slows the pedesis of solutes, decreasing the rate of enzyme-substrate 
interactions. However, as El Kossiri et al and others have shown, viscosity effects 
cannot offer a full explanation of the inhibitory action that DF.  
A number of other inhibitory mechanisms have been suggested; fibre binding of 
enzyme/substrate causing reduced enzyme-substrate binding [56, 57], interaction with 
fibre causing a conformational change to the enzyme and sequestering of calcium ions 
[52]. Sequestering of calcium ions by DF is suggested as a mechanism by which 
enzyme activity is reduced. A number of enzymes require calcium ions for stability or 
activity (e.g. trypsin, α-amylase). DF with a higher affinity for calcium than the enzyme 
would  sequester calcium from the enzyme and could lead to decreased activity or an 
increased rate of enzyme degredation [58]. 
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Figure 4  Potential mechanisms of DF mediated enzyme inhibition  
Sequestering of ions  
Many enzymes bind ions for stability, 
and/or activity. Sequestering of ions by DF 
my lead to reduced activity by or 
degradation. 
Direct Binding Of Enzyme or Substrate 
Binding of substrate or enzyme leading to 
reduced enzyme-substrate interaction 
 
Dilution of Digesta 
Increased fibre content and reduce water 
absorption for gut causing dilution of 
digesta leading to reduced rate of digestion 
 
Viscosity Effect 
Addition of viscous dietary fibre slows the 
pedesis of solutes, decreasing the rate of 
enzyme-substrate interactions 
Reduced Peristaltic Mixing 
Viscosity of fibre in solution opposes the 
action of peristaltic mixing 
 
In vitro & In vivo  In vivo 
Unknown Mechanism 
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1.4 Fibres Included In this study 
For the purpose of the literature review the focus shall be on alginates as previous work 
in this lab has centred around alginates. Other fibres including fucoidan, carrageenan, 
pectin and agar have also been included in the study and are discussed in Error! 
Reference source not found..  
1.5 Alginate 
1.5.1 Overview 
Alginate is an indigestible polysaccharide and as such can be considered a DF. Found in 
cell walls and intercellular space of brown seaweed (Phaeophyceae) alginate is involved 
in cell structure and ion exchange [59]. Alginate is also produced by some bacteria of 
the Azotobacter and Pseudomonas genii as a component of the extracellular matrix [60, 
61]. 
Commercially, alginates are produced from the harvesting of brown seaweed off the 
coasts of the British Isles (Outer Hebrides), Norway, Iceland, France, and Canada (east 
coast) where it grows in the colder waters of the Northeren Hemisphere and Australia, 
Chile and New Zeeland in the Southern Hemisphere [62, 63]. Alginates are commonly 
harvested from Giant Kelp, a Laminarialean algae in the class Phaeophyceae (Brown 
algae) which can reach a maximum length of 40m. Kelp is collected by kelp mowers; 
boats with large rotary blades similar to a lawn mower which cut and collect the fronds 
of the seaweed. Harvesting just the fronds rather than the whole seaweed allows for 
regrowth. Harvested kelp lanes have been shown to recover the same biomass and kelp 
density as control (unharvested) lanes within two years, making it a very sustainable 
method of production [64]. The same study showed that cutting close to the base of the 
fronds (less than 20cm) can seriously hamper regrowth. 
Seaweeds can be correctly referred to as multicellular benthic
2
 marine algae. While they 
are sometimes referred to as primitive plants or algal plants because of their relative 
complexity, seaweeds are algae and therefore belong to Kingdom Protista and are 
                                                 
2
 Living in sedimentary zones on or near the sea bed or in tidal pools 
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distinct from the ‘higher’ plants in that they do not form true leaves, stems or roots [65]. 
There are four groups of seaweed algae; green algae (Chlorophyceae), red algae 
(Rhodophycae), blue-green algae (Cyanophyceae) and brown algae (Phyophyceae) from 
which alginates are harvested (Figure 5).   
 
 
 
 
 
 
 
Figure 5  The four species of seaweed algae from which alginates are harveste, clockwise from 
top-left; green algae (Chlorophyceae), red algae (Rhodophycae), blue-green algae (Cyanophyceae) and 
brown algae (Phyophyceae).   
Alginates have a number of industrial uses. In the food industry they are used variously 
as thickening, gelling, foaming, emulsifying and stabilisation agents [65]. Alginates also 
have medical and scientific applications; cell encapsulation, drug encapsulation as a 
controlled delivery system adsorbent wound dressings and anti-reflux therapies [7, 66] 
They are also thought to have a number of bioactive properties; Induction of pro 
inflammotary cytokines tumour necrosis factor (TNF) and interleukin-1 (IL-1)[67]. 
Oligo-G alginates have also been shown to have anti-bacterial properties, distrupting 
biofilm structure and growth [68].  
1.5.2 Alginate Structure 
Alginates are unbranched polysaccharides composed of (1-4)-α-L-guluronic acid (G-
Residues) and (1-4)-β-D-mannuronic acid residues (M-Residues). In seaweeds these 
polyuronans are found as salts of different metals (usually sodium and calcium). The 
polyuronic chains are composed of blocks of about 20 residues which are either G-rich, 
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M rich, or MG rich (Figure 6). The characteristics of the alginate are dictated by the 
arrangement of these blocks [59].  
G-rich blocks form relatively stiff blocks as there is limited rotation around the 
glycosidic bond. The presence of mannuronic acid residues increases chain flexibility 
with M blocks and MG blocks forming relatively flexible chains because of freer 
rotation around the glycosidic bonds [69]. 
 
 
 
Figure 6  Suggested sturucture of alginate. (a) β-D-mannuronic acid and α-L-guluronic acid, (b) 
chain conformation, (c) block structure. Taken from Draget et al (2002) [69]  
Alginates are hydrocolloids and are able to form gels, there are two mechanisms by 
which they can do this. Interchain binding of cations causes the formation of ionic gels 
and lowering the pH of an alginate solution below the pKa of the alginate can cause 
acid-gel formation [70]  
1.5.3 Ionic-Gel  
Alginates are able to form ionic gels through the binding of cations and the formation of 
interchain associations between fibres [71]. Homopolymeric regions (M or G blocks) 
better support the formation of junction zones between adjacent polmers and therefore 
increase viscosity in solution, with G-Blocks forming the most stable gels [72].  The 
affinity of an alginate for cations increases with G content as G-blocks have a greatly 
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increased selectivity for divalent cations. Alternating blocks (MG blocks) increase the 
flexibility of the polysaccharide chain and therefore decrease alginate gel viscosity [73, 
74] 
As well as being related to overall G-Content, mechanical strength is also influenced by 
the length of G-Blocks. Polymannuronan forms a flat ribbon-like chain, whereas 
polyguluronon forms a ‘buckled’ ribbon-like structure [65]. This buckled ribbon forms 
regular folds into which calcium ions can fit. The binding of cations and formation of 
interchain associations were described by Rees as the “egg-box model” with the (1-4)-
α-L-guluronic acid forming regular folds between chains within which ions can be 
bound [75]. Figure 7 shows the egg box structure, and a schematic model of calcium 
binding which has generally been accepted as the structural mechanism of gellation 
[76]. 
 
Figure 7   “Egg-box” structure in alginate junction zone and suggested model for calcium co-
ordination in a calcium (Black circles represent oxygen atoms”. Taken from Braccini et al (2001) [76] 
1.5.4 Acid-Gel Formation 
Although the model for ionic gels has been well characterised, less is known about acid 
gels. Acid gels are formed when the pH of an alginate solution is lowered below the pKa 
of the alginate polymer. It is believed that the gel is stabilised by intermolecular 
hydrogen bonds connecting the polyuronan chains [77, 78]. The carboxyl group of the 
alginate monosaccharide residue becomes protonated at low pH forming carboxylic 
acid, which is then able to form hydrogen bods. 
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Tests of gel strength through measurements of Young’s Modulus3 in longitudinal 
deformation tests have shown that as with ionic gels, the strength of alginate gels 
formed by polyuronan blocks is in the order GG>MM>GM/MG [79] . It is believed that 
the arrangement of the monomers within the chain effects the formation of 
intermolecular bonds. Draget et al also showed acid gel formation has a dependence on 
molecular weight. A clear relationship was demonstrated whereby high molecular 
weight alginates form the strongest gels, and low MW alginates the weakest as 
measured by Young’s modulus [79].  
1.5.5 Modification of Alginates 
Alginates are biosynthesised predominately as polymannuronic acid in the cytoplasm 
and are modified by acetylation and epimerisation during periplasmic transfer [66]. 
During epimerisation M-residues are converted to G-residues by Mannuronan C-5 
epimerases [60].The extent and distribution of epimerisation determines the alginates 
characteristics which is important in algae and bacteria for controlling the mechanical 
properties of alginate. Epimerases therefore have applications both in research and 
industry as the gelling properties of alginates are dictated by the M:G ratio and 
organisation of these residues [80]. 
Ertesvag et al 1999, characterised the activity of alginate epimerses AlgE1-7 from 
Azotobacter vinelandii. The seven AlgE epimerases were expressed in E. coli and 
epimerase activity ascertained by H NMR (Nuclear Magnetic Resonance) measurement 
of M and G content.  AlgE4 was shown to convert solely to MG blocks, all other 
epimerases were shown to  convert to a mixture of G and MG blocks [60].  
Knowledge of alginate epimerases opens up the potential for ‘designing’ alginates. If 
alginates are found to have regulatory activity towards digestive enzymes, alginate 
epimerases could be used to manufacture the ‘optimum’ alginate which provides the 
most inhibition or activation.  
                                                 
3
 Young’s Modulus provides a measure of elasticity/stiffness calculated by the ratio of tensile strength to 
tensile strength in N/m
2
 and can be calculated by the gradient of a stress-strain curve.  
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1.6 Overview of digestive physiology and macronutrient breakdown 
The primary function of the gastrointestinal tract is to process ingested food into a form 
that can be absorbed across the gut lumen and in to the blood stream and lymphatic 
system. The mechanical breakdown of food through chewing in the mouth and churning 
in the stomach eases the movement of food through the digestive tract, mixes the food 
with digestive secretions and increases the surface area for enzyme action. Peristaltic 
action keeps the digesta moving and mixing as it is passed throught the organs of the GI 
tract.  Digestive secretions from accesory glands mediate the chemical breakdown of 
food through the catalytic action of enzymes aided by the emulsifying effects of bile and 
optimisation of pH through acid/bicarbonate secretions.  
The GI tract is a succession of functionally and structurally distinct organs adapted to 
provide the optimum environment for its role in the digestive process. pH variation 
throughout the GI tract allows for optimum activity of digestive enzymes at distinct 
sites. This pH variation has been profiled in healthy subjects using a pH sensitive 
‘radiopill’ capable of transmitting pH readings during passage through the GI tract [81]. 
Secretion of HCl from parietal cells in the gastric pit makes the gastric juice highly 
acidic with a pH range of 1.0-2.5. In the small intestine the pH is raised to near neutral 
by bicarbonate secretion from the pancreas, bile ducts and intestinal mucosa. Proximal 
small intestine was measured at an average of pH 6.6, rising to around 7.4 in the distal 
and mid small intestine. Measurements of pH in the large intestine ranged from 6.6 to 
7.5. 
The major sites of digestive secretions are the salivary glands, gastric glands, the 
pancreas and the liver. A fuller list of these digestive secretions is available in Table 3 
below. 
As summarised by Pedersen et al 2002, in Table 2 saliva contributes to a number of 
important roles in GI function; taste, mastication, bolus formation, enzymatic digestion 
and swallowing [82]. Saliva is produced by serous and mucus acinar cells and secreted 
from the parotid, sublingual and submandibular salivary glands (90%) and hunreds of 
minor salivary glands in the wall of the mouth and pharynx (10%) [83]. Saliva is a 
watery solution containing salivary amylase which begins carbohydrate digestion, 
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mucus to lubricate food and protect the mouth and bicarbonate to create a slightly 
alkaline environment [84]. Saliva also contains lysozyme, an enzyme which is active 
against bacteria. In humans, 0.9-1.5L of saliva is produced daily [83]. 
 
Table 2  Functions of saliva in the upper gastrointestinal tract. Taken from Pedersen et al, 2002 
[82].  
Chewing of food (mastication) acts to breakdown food, increasing the surface area upon 
which enzymes can act. Mastication also serves to form food into a bolus by mixing 
food with saliva, a bolus is a portion of food  that has been softened and lubricated 
through mechanical breakdown and mixing with saliva. Bolus formation allows food to 
be more easily swallowed; water in saliva makes the food moist and softens it, salivary 
mucins serve to bind the bulus together and give it a slippery surface for swallowing.   
After passing through the lower oesophageal sphincter salivary amylase is inactivated 
by the acidic conditions of the stomach. The acidic conditions of the stomach favour 
pepsin mediated proteolysis, this is assisted by the ‘antral pump’ action of the stomach 
which breaks up the food particles and forms a chyme which is passed into the 
duodenum through the pyloric sphincter.  The wall of the fundus and body of the 
stomach contain gastric pits composed of various secretory cells. Mucus is secreted by 
neck cells and surface mucosal cells, pepsinogen by chief peptic cells and parietal cells 
(also known as oxyntic cells) secrete HCl to acidify the stomach.  
In the duodenum the acidic chyme is neutralised upon mixing with the pancreatic juices 
which are rich in bicarbonate (secreted by duct cells). The pancreas secretes a whole 
range of digestive enzymes as shown in Table 3. 
Although digestion is well underway by the time food reaches the small intestine, the 
majority of food is digested by pancreatic enzymes which are secreted into the 
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pancreatic duct by acinar cells of the exocrine pancreas [85].  Before the pancreatic 
juices are released into the duodenum through the sphincter of Oddi, they are mixed 
with bile in the ampulla of Vater, where the pancreatic duct and common bile duct 
merge [86].   
The common bile duct transports bile from the gallbladder where it is stored after 
secretion from the liver. Bile is composed of bicarbonate, phospholipids, inorganic ions 
and bile salts [84]. Bile aids the digestion of dietary fats through its detergent effect, 
dispersing fats into micelles thereby increasing the surface area upon which digestive 
lipases can act. 
Bile acids are cholesterol derivatives. Primary bile acids cholic acid and 
chenodeoxycholic acid are synthesised in the hepatocytes of the liver, these form either 
glycine or taurine conjugates. The amphiphillic nature of bile acids causes them to form 
into micelles with the hydrophobic steroid side of the molecule pointing inwards [87]. 
In the colon the primary bile acids are deconjugated and can then be converted to the 
secondary bile acids lithocholic acid and deoxycholic acid by the bacterial flora. Bile 
acids are recycled through enterohepatic circulation and trasported back to the liver 
where they are reconjugated [88].  
The small intestine is also the major site where the products of these combined digestive 
processes are absorbed by cells of the mucosal epithelia. The absorbative capacity is 
increased by folding of the mucosal membrane in to villi, and the brush border 
membranes of the epithelial cells, microvilli.  
Most of the energy and nutrient content of food is ingested in polymeric form as 
protein, carbohydrate and triglycerides, macronutrients must therefore be broken down 
by these processes of digestion for uptake and transport around the blood stream; amino 
acids and glucalogues in the case of protein and polysaccharides respectively. Or in the 
case of triglycerides reconstituded in to chylomicrons – water soluble lipoprotein 
particles that allow for the transport of fats and cholesterol in the bloodstream. The 
surface area of the small intestine is specialised to provide a large absorbative surface. 
Kerckrings folds, villi and microvilli together result in a 600 fold increase in surface 
area as compared to a smooth cylidircal tube [89]. Absorption across the small intestinal 
epithelium occurs through a number of processes; passive diffucion, carrier mediated 
diffusion, active transport and pinocytosis (a form of non-specific endocytosis). The 
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intestinal epithelium is coated with an ‘unstirred layer’, composed of adherent mucus 
protecting the intestinal epithelia and the associated solution which resist peristaltic 
motion. The unstirred layer has the effect that only dissolved substrates can diffuse 
across for uptake, and that the rate of this diffusion and therefore uptake is affected by 
the thickness and constitution of the unstirred layer. It has been shown that by 
thickening the unstirred layer, the gelling agent guar can reduce intestinal absorption 
rates [90].  
Finally the colon then re-absorbs water, salts and salvages any other useful products 
from the digesta prior to removal of waste by defacation. 
 
Table 3   Adapted from Vickerstaff Jonega (2004) [91] 
Site Source Enzyme Substrate Effect 
Mouth Saliva α-amylase Starch Catalyses cleavage of α14 glycosydic bonds 
Stomach Gastric 
Secretions 
Pepsin Protein Catalyse cleavage of peptide bonds 
  Gastric Lipase Lipids Catalyse hydrolysis of dietary fats 
Small 
Intestine 
Pancreas α-amylase Starch Catalyses cleavage of α14 glycosydic bonds 
  Pancreatic Lipase Lipids Catalyse hydrolysis of dietary fats 
  Proteases Protein Catalyse cleavage of peptide bonds 
  Trypsin Polypeptides Hydrolyses peptide bonds prefferentially of 
arginine and lysine residues 
  Chymotrypsin Polypeptides Hydrolyses polypeptides at the carboxyl end of 
hydrophobic amino acids 
  Elastase Polypeptides Hydrolyses peptide bonds containing the carboxyl 
group of alanine, glycine, isoleucine, leucine or 
valine 
  Carboxypeptidas
e  
A and B 
Polypeptides Cleave amino acids from the carboxyl end of 
polypeptides with the exception of arginine, 
lysine and proline 
 Gall 
Bladder 
Bile Salts Lipids (fatty 
acids and 
triglycerides) 
Formation of micelles and emulsification of 
dietary lipids 
 Brush 
Border 
Cells 
Lactase  
(β-galactosidase) 
Lactose Cleaves lactose into glucose and galactose 
  Maltase  
(α-D-
glucosidase) 
α14 
glycosidic 
linked limit 
dextrins  
Cleaves into glucose 
  Sucrase Sucrose Cleaves into glucose and fructose 
  Isomaltase Maltose 
Maltotriose 
Cleaves into glucose 
  Amino-
oligopeptidases 
Oligopeptides 
of 2-6 amino 
acids 
Cleaves N-terminal amino acids 
  Dipeptidyl 
peptidases 
Peptides and 
oligopeptides 
Cleaves N-terminal amino acids 
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1.7 Overview of Enzymatic Breakdown of Macronutrients 
This section contains an overview of the sites and processes of enzymatic breakdown of 
macronutrients and uptake of metabolites, more detailed explanations of enzyme 
structure and mechanism are included in Chapter 3Chapter 5.  
1.7.1 Fat Digestion and Uptake 
Fat is thought to constitute approximately 40% of energy intake in the western world 
[92]. The major source of dietary fat is triacylglycerol (TAG) which makes up 90-95% 
of dietary fat [93]. Remaining fat sources comprise a mixture of phospholipids, 
glycolipids and sterols (eg cholesterol). [92, 93] 
Triacylglycerol consists of a glycerol backbone with three fatty acid side chains of 
varying length, in the human diet fatty acid chains can vary in length from C2 to C24 
[92]. The fatty acids may be saturated, containing only single bonds between carbon 
atoms in the fatty acid side chains, or unsaturated, containing one or more double bond 
between carbons.  
Fat digestion is initiated in the mouth, mastication begins the mechanical dispersion of 
fats and the formation of food in to a bolus. Lingual lipase is secreted from a set of 
lingual serous glands on the tongue called von Ebner’s glands in response to a meal 
[94]. Chewing serves to mix lingual lipase in with food bolus which is passed into the 
stomach through swallowing [92, 95]. Lingual lipase has a pH optimum of 5.5 and is 
resistant to acid inactivation. Lipase activity is therefore retained in the stomach when 
the pH environment is buffered with the intake of a meal [95, 96].  
Gastric lipase is also secreted into the stomach from gastric chief cells [94]. It is 
believed that 10-30% of dietary fat is digested in the stomach before passage into the 
small intestine [97]. The stomach is also responsible for creating a crude emulsion of 
dietary fats, through peristaltic action and initial lypolysis [93]. Fats therefore pass into 
the duodenum as a crude emulsion of fine lipid droplets, an important aspect of pre-
duodenal fat digestion which aids small-intestinal fat breakdown. It has been shown that 
droplet size of the fat emulsion influences the rate of fat digestion, with emulsions of 
fine droplet size being hydrolysed at a faster rate [98].  
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The first step of triglyceride digestion is the hydrolysis of TAG to diacylglycerol 
(DAG). Gastric and Lingual Lipase both preferentially cleave the fatty acid at the SN3 
position, Figure 8.  
 
 
 
Figure 8  Orientation of Fatty Acids in triglyceride molecule. Taken from Mu et al [92]  
This release of fatty acids from TAG stimulates the secretion of cholecystokinin, a 
peptide hormone synthesised in the mucosal epithelium of the duodenum. The secretion 
of pancreatic juice and release of bile is triggered by Cholecystokinin. Secretin release 
is also triggered in the duodenum by the entrance of gastric acid with the chyme, this in 
turn triggers bicarbonate and water secretion [93] . 
Bile aids the digestion of dietary fats through its detergent effect. Bile acids are 
amphipathic molecules synthesised in liver hepatocytes and are vital to the 
emulsification of dietary fats [88]. As lipase acts at the lipid-water interface, the level of 
emulsification is an important factor in the rate of fat digestion as it determines the area 
over which lipase can act [85]. With the breakdown products of lipids including fatty 
acids, cholesterol and phospholipids bile acids form mixed micelles [99] . As the mixed 
micelles pass through the small intestine pancreatic lipase acts to further digest dietary 
fats. In the illeum up to 95% of bile acids are reabsorbed, and passed back to the liver 
through enterhepatic circulation, this process can occur several timess during a single 
meal [99]. 
Pancreatic lipase acts at the lipid-aqueous interface of TAGs and DAGs, its presence is 
stabilised by the co-enzyme co-lipase which is secreted as precolipase and activated by 
trypsin in the duodenum. The typical digestion system is that after TAGs have been 
hydrolised to DAGs by cleavage of the fatty acid at the SN3 position, the SN1 fatty acid 
is cleaved, leaving an SN2-Monoacylglycerol sn2-MAG. The spontaneous 
rearrangement of the SN2-FFA to position SN1 Allows for the complete hydrolysis into 
glycerol and FFAs.  
sn1 
sn2 
sn3 
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The first step of the uptake of fat metabolites is the diffusion of mixed micelles across 
the unstirred layer to the brush-border membrane. Some free metabolites may diffuse 
indipendently to the membrane, but the poor solubility of lipid metabolites means 
micellar solubilisation is required to enhance uptake. Models of both protein dependent 
and protein independent uptake have been described for transport of fat metabolites 
across the brush border epithelium [93].  
Within the smooth endoplasmic recticulum cholesterol, monoacylglycerol and retinol 
are esterified by cholesterol acyltransferase, diacylglycerol acyltransferase and 
lecithin:retinol acyltransferare respectively so that they can be incorpotated into 
chylomicrons and low density lipoprotreins. Chylomicrons and LDLs exit the cell via  
exocytosis and for transport through the lymphatic system.  
Phospholipid digestion is predominantly carried out by pancreatic phospholipase A2; 
Cholestrerol esterase hydrolyses free sterols to cholesterol for incorporation into 
micelles and uptake; micelles are also important for the uptake of fat soluble vitamins 
such as Vitamin E.  
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1.7.2 Carbohydrate Digestion   
Carbohydrates may be digestable or indigestable (DF) depending upon their glycosidic 
bonding. Of the nutritionally available carbohydrates, a reported 3-6% of carbohydrate 
consumed is in the form of monosacharides, the vast majority of carbohydrate is in the 
form of starch (53-64%) and the remainder oligosaccharides (33-42%), and therefore 
must be broken down for absorption (See  
Table 4) [100]. Starch is composed of amylose and amylopectin. Amylose is a linear 
α(1-4) polysaccharide and amylopectin; α(1-4) polysaccharide chains with α(1-6) 
branching side-chains.  
Carbohydrate Compostion (%) 
Polysaccharides 
Starch 
Glycogen 
Oligosaccharides 
Sucrose 
Lactose 
Maltose 
Monosaccharides 
Glucose 
Fructose 
 
52.6-64 
0.5 
 
26-33.2 
6.5-6.6 
1.8 
 
4.2 
1.6-3 
 
Table 4  Carbohydrate composition of the human diet. Adapted from Elsenhans et al 1983 [100] 
Carbohydrate breakdown can be thought of as a two step process; the initial breakdown 
of starch by α-amylases, and then the cleavage of oligosaccharides by membrane bound 
glucosidases into monosaccharides (hexoses, predominantly glucose, galactose and 
fructose).  
Physiologically amylolysis begins in the mouth with the action of salivary α-amylase, 
also referred to as ptyalin which is secreted from serous acinar cells of the parotid and 
submandibular gland. Salivary α-amylase is mixed throughout the food bolus during 
chewing and begins carbohydrate breakdown by cleavage of α (1-4) glycosidic bonds. 
Salivary amylase is thought to be of limited significance in the digestion of 
carbohydrates, due to the preompt deactivation in the acid environment of the stomach. 
However Rosenblum et al, 1998 have suggested that starch polymers can protect α-
amylase from acid and pepsin inactivation, so that amylase may maintain some activity 
in the stomach, and therefore remain active through to the small intestine [101].  
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Figure 9  α(1-6) linkages in amylopectin 
After passage through the stomach, further carbohydrolysis occurs in the small intestine. 
Small intestinal α-amylase is synthesised in the pancreas. Both pancreatic and salivary 
α-amylases only have activity towards α (1-4) glycosidic bonds. The cleavage of starch 
predominantly generates maltose and maltotriose from both amylose and amylopectin. 
In addition the cleavage of amylopectin generates the α-limit dextrins; oligosaccharides 
composed of approximately 6 residues which are created because of the limited 
cleavage of α(1-4) bonds in the proximity of α(1-6) linkages (Figure 9).   
Starch breakdown into maltose, maltotriose and α-limit dextrin is thought to occur very 
rapidly and within 10 minutes of transit into the duodenum [100]. The next phase of 
carbohydrate digestion occurs at the brush border membrane of intestinal enterocytes.  
Brush border enzymes are localised to the apical membrane in close proximity to 
glucose carrier proteins [102]. Maltase is responsible for the breakdown of maltose to 
D-Glucose. Glucoamylase cleaves end terminal glucose residues from maltotriose and 
α-limit dextrin. Isomaltase and sucrose have been shown to form a single enzyme 
complex; sucrase cleaves sucrose to D-Glucose and D-Fructose, Isomaltase has activity 
towards α (1-6) glycosidic bonds and is responsible for cleaving α-limit dextrin down 
into maltose. Finally lactase is responsible for the breakdown of lactose in to D-Glucose 
and D-Galactose. Lactase deficiencies can result in lactose intolerance [103]. 
Carbohydrates are broken town to hexose monosaccharides. Glucose, fructose and 
galactose are the most common monosaccharide products of carbohydrate digestion. 
Following absorption, galactose and fructose are converted to glucose for metabolism, 
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transport and storage [104]. The uptake of monosaccharides is a highly regulated 
process, with both specific and non-specific mechanisms of regulation. The rate limiting 
step of sugar absorption from the lumen are brush border membrane transport into 
enterocytes and basolateral membrane transport into the blood stream [105]. 
Nonspecific mechanisms of sugar uptake regulation have been shown to be regulation 
of the number and length of intestinal villi during pregnancy and lactation [106]. 
Specific regulation is achieved by the regulation of glucose transporters, and this 
process has been shown to be highly responsive to dietary carbohydrates.  
The paths of possible monosaccharide uptake are shown in Figure 10 below. 
Monosaccarides may transit the enterocytes by transcellular transport or paracellular 
transport through tight junctions.  
 
Figure 10  Taken from Traber, 2004 [107] The classical model of sugar absorption. 
Glucose and galactose are actively transported across the brush border membrane by the Na+-dependent 
glucose transporter. Fructose is transported by facilitative GLUT 5 and GLUT2 transports glucose, 
galactose, fructose across the BLM via facilitative diffusion. 
Intestinal brush border membrane uptake of glucose and galactose into the cell 
cytoplasm is governed by the Na
+
/glucose co-transporter SGLT1, passive fructore 
transport occurs through the GLUT5 uniporter. Glucose, galactose and fructose all exit 
the cell via passive dffucsion through GLUT2 and GLUT5 uniporters [108]. SGLT1 
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also contains a number of phosphorylation sites. PKA activation has been shown to 
increase glucose transport by 30% and PKC to reduce glucose transport by 60% [104] 
While SGLT1 is predominantly a glucose transporter, it has affinity for other sugars in 
the order; D-Glucose > α-methyl-D-Glucose > D-galactose > 3-O-methyl glucose> L-
glucose and 2 deoxyglucose [109]. 
 
1.7.3 Digestion and absorption of protein 
 
The gastrointestinal proteases of the stomach, pancreas and small intestine result in the 
efficient hydrolysis of polypeptides into amino-acids and small oligopeptides that can 
be absorbed by small intestinal enterocytes [74].  Luminal protein digestion occurs in 
both the stomach and small intestine. Gastric protein digestion of polypeptides is 
mediated by gastric pepsin in the acid environment of the stomach and results in a 
mixture of large polypeptides, smaller oligopeptides and some free amino acids [74]. 
Pepsin is part of the aspartate protease super family (EC 3.4.23.-) [110]. As the major 
proteolytic enzyme in gastric juice, pepsins are responsible for protein digestion. 
Pepsins are broad specificity endopeptidases with a preferance for cleavage between 
hydrophobic amino acids. Pepsin is an acid protease secreted as the zymogen 
pepsinogen from Chief/Peptic Cells in the Gastric Glands of the stomach. Pepsinogen is 
activated to pepsin only in acidic conditions. Pepsinogen is reported to be stable within 
the pH range 6-9 [111]. Above pH 9.0 pepsinogen is reversibly denatured, and below 
pH 6.0 pepsinogen is activated by an autocatalytic mechanism. This activation of pepsin 
occurs faster at lower pH [112]. Further information about the structure, classification 
and catalytic mechanism of pepsin is included in Chapter 3. Patients with a full 
gastrectomy are capable of digesting and absorbing protein without difficulty, therefore 
gastric protein digestion may not be critical to protein digestion [113] 
Protein digestion is completed in the small intestine. Caspary 1992, characterises small 
intestinal protein digestion as consisting of three phases; 1) luminal protein digestion 2) 
brush border membrane digestion and 3) Cytoplasmic assimilation of polypeptides. An 
array of proteolytic enzymes are secreted into the small intestine from the pancreas as 
zymogens which are activated during the proteolytic enzyme cascade (Figure 11) which 
also causes the activation of pancreatic lipase and colipase [114]. Trypsinogen, 
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proelastase, chymotrypsinogen, procarboxypeptidases and kallikreinogen are secreted 
from the pancreas. The mucosal enzyme enterokinase catalyses the activation of 
trypsinogen to trypsin. Enterokinase is a glycosylated protein synthesised by small 
intestinal enterocytes. While trypsinogen is capable of autocatalytic activation, 
activation by enterokinase is reported to be 2000 times more efficient [115].  
Activated trypsin then activates the secreted pancreatic zymogens to their active forms. 
Small intestinal zymogen activation is likely a far more complicated process than Figure 
11 suggests, with autocatalytic and secondary activation of zymogens as well as the 
influence of various factors including zymogen concentrations, levels of active  trypsin,  
total  luminal protein content,  pH, presence of ions  and  length  of  incubation.   
 
Figure 11 The pancreatic enzyme cascade of protease activation Taken from Rinderknecht, 1986 
[115]. 
The endopeptidases trypsin, elastase and chymotrypsin are serine proteases that cleave 
interior peptide bonds. The carboxypeptidases are zinc-containing metallopeptidases 
with exopeptidase activity and cleave single amino acids from the carboxyl terminal of 
polypeptides [115]. Protease specificity and activity is described in Table 5 below.  
Enzyme Family Enzyme Favoured Site of Activity 
Serine proteases 
(endopeptidases) 
Trypsin 
cleaves on the carboxyl side of basic 
amino acids (Arg, Lys) 
chymotrypsin 
cleaves on the carboxyl side of amino 
acids with aromatic carbonyl groups 
(Tyr, Phe, Trp) 
Elastase cleaves on the carboxyl side of 
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aliphatic amino acids residues (Ala, 
Leu, Gly, Val, Ile) 
Zinc-containing 
metallopeptidases 
(exopeptidases) 
Carboxypeptidases A 
and B 
single amino acids from the carboxy 
terminal ends of 
proteins and oligopeptides 
Table 5  Pancreatic proteases. Adapted from Erickson et al 1990 [74] 
Luminal digestion of polypeptides by proteolytic enzymes results in short oligopeptides 
of 2-8 amino acids in length which can then diffuse to the brush border membrane for 
further hydrolysis by brush border peptidases. Short oligopeptides are further 
hydrolysed by brush border amino oligopeptidases to their constituent amino-acids, or 
small di and tri-peptides for uptake by specialised amino-acid and peptide transporters.  
The brush border peptidases are summarised in Table 6, of particular significance are 
the prolyl-peptidases; Dipeptidyl aminopeptidase IV, Aminopeptidase P, 
Carboxypeptidase P and Angiotensin converting enzyme which can cleave peptide 
bonds involving proline, to which luminal peptidases have limited activity [74]. 
Aminopeptidase N Cleaves amino acids from the N-terminal  of short chain 
oligopeptides 
Dipeptidyl 
aminopeptidase IV 
Cleaves Prolyl peptides from the N-Terminal of oligopeptides 
Aminopeptidase P Cleaves Prolyl peptides from the N-Terminal of oligopeptides 
Carboxypeptidase P Cleaves Prolyl peptides from the Carboxyl Terminal of 
oligopeptides 
Angiotensin 
converting enzyme 
Cleaves Prolyl peptides from the Carboxyl Terminal of 
oligopeptides 
Neutral 
Metalloendopeptidases 
Cleave internal peptide bonds of large proteins such as α-
casein, fibrinogen and histone 
Glutamyl 
aminopeptidase 
Cleaves peptides containing glutamic or aspartic acid at the N-
Terminal.  
Table 6  Brush-border peptidases. Adapted from Caspary 1992 [114] 
These brush border metabolites are absorbed in to the enterocytes. Di and tri-peptides 
are transported through peptide carriers and further hydrolysed to free amino acids in 
the cytoplasm of enterocytes, only highly resistant peptides such as glycyl-proline pass 
in to the blood stream without having undergone complete hydrolysis [116]. A wide 
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array of amino acid transport systems have been characterised and are summarised in 
Table 7. Broer et al 2008, categorise these carrier systems in to 5 groups; 1) Neutral 
amino acids, 2) Cationic amino acids and cysteine, 3) Anionic amino acids, ) Proline, 
hydroxyproline and glycine and 5) Taurine and other β-amino acids. 
 
Table 7  Epithelial amino acid transport systems and their mediators. Taken from Broer et al 
2008 [116].  
The resulting amino acids are then passed into the portal venous system for transport to 
the liver and on to the whole body.  
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Chapter 2 
Aims & Approaches 
 
 “Thus the body is in a constant state of flux; we do not consist of particular 
molecules but of a pattern imposed on continuously changing molecules. The 
dynamic state enables us to adapt to a continually changing environment, which 
presents now an excess of one type of food, now an excess of another; which demands 
different levels of activity at different times, and which is apt to damage the 
organism” Tanner, 1989 [117]. 
2.1 Macronutrient Regulation 
2.1.1 Introduction 
The human body is in a constant state of energy and nutrient turnover. Metabolism and 
homeostatic control have evolved to maintain healthy body function and meet the 
nutrient and energy requirements of the body under constantly changing levels of 
energy intake and expenditure and varying nutrient supply.  
 
A range of behavioural and biological controls of eating behaviour, macronutrient 
digestion and processing have been identified which are involved in maintaining energy 
and nutrient homeostasis. The macronutrients protein, fat and carbohydrate play an 
essential role in this balance, both as the major source of energy, and as a source of the 
chemical compounds and elements required for anabolism of organic compounds and 
cell components. As such, ensuring appropriate supply and processing of 
macronutrients is absolutely essential to health.  
Excess, shortage or impaired processing of macronutrients can and will lead to disease 
and ill health. This is particularly apparent with the modern day epidemics of diabetes 
and obesity, driven by a mismatch between the biological systems that humans have 
evolved to regulate diet and activity and the modern environment of readily available 
energy dense food and sedentary lifestyles. The human and economic costs of metabolic 
disease and other diet related syndromes is immense and as discussed herein current 
treatments, whilst effective have limitations and risks.  
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Researchers therefore aim to find therapeutic targets for treatment both in terms of 
digestive physiology and appetite and exercise regulation which can be exploited for 
disease treatment and management.  
As has been shown with enzyme inhibitors such as Orlistat, Acarbose, and latterly 
alginate, using exogenous agents as regulators of digestive enzyme activity and 
therefore macronutrient availability provides a way of affecting and regulating this 
balance as a paradigm for disease treatment and control of nutrient intake.  
2.2 Overview of dietary control, Energy Balance and Nutritional State  
The major behavioural influences of nutrition state are an individual’s eating behaviour 
and level of physical activity. Dietary behaviour and physical activity are influenced by 
the complex interaction of multiple biological, genetic, behavioural, psychological, 
social and environmental factors. These factors are incorporated in to a complex 
decision making process which determines food choice and physical activity levels 
[118].  
Booth et al 2009, have developed a framework model of the ‘Determinants of Physical 
Activity and Eating Behaviour’ which describes the varying influences that interact to 
determine exercise and eating behaviour. The authors argue that physical activity and 
eating behaviour are influenced ‘by a wide variety of internal and external factors, and 
all should be considered when planning interventions’ [119]. At the centre of the model 
is (i) The Psychobiological Core – The individuals genetic makeup and early 
conditioned behaviour. This also includes the phenotypic response to environment. 
Then comes (ii) Cultural and (iii) Societal influences – how the values and beliefs of 
an individual, and roles, relationships and trends can influence behaviour. (iv) Enablers 
of choice are described as environmental factors that can seen as barriers or enhancers 
of change which can be targeted in interventions to influence an individual’s behaviour 
and lifestyle. (v) Behaviour settings are the physical and social settings of the 
individual within which choices are made. The Leverage points described in the model 
are those influences which the authors believe present targets for interventions to 
‘leverage’/change behaviour. (vi) Proximal Leverage Points  are the ‘close’ micro-
environmental points which directly influence the individual (vii) Distal Leverage 
points describe the more indirect factors which influence behaviour such as politics, 
economics and industry. 
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The use of exogenous enzyme inhibitors clearly aims to target the psychobiological core 
by aiming to modify the energy and nutrient yield of a meal while aiming to minimise 
effects on satiety, enjoyment of a meal and lifestyle. However as stated by Booth et al 
diet and exercise choices and behaviours are pervasive through life and interventions 
must be considered within the wider context to improve effectiveness [119]. In 
particular therapeutic interventions targeting digestive enzymes must be considered with 
regard to the body’s natural control, of diet and activity.   
 
2.2.1 Satiety and Feeding 
 
Blundell et al 1994, characterise three levels of appetite control in their model of the 
satiety cascade; (i) Psychological and behavioural events (ii) peripheral physiology and 
metabolic events (iii) Neurotransmitter function and metabolic interactions with the 
brain [120]. Appetite is dictated by the interactions of these processes and appetite and 
food intake is therefore the result of both biological and environmental forces.  
The sight, smell and taste of food provide pre-ingestive inputs that influence eating 
behaviour and stimulate digestive secretions to prepare the digestive organs for the 
receipt of food. During feeding and digestion, chemo-receptors and mechano-receptors 
supply information about meal size, nutrient content and digestion which provide post-
ingestive satiety signals; and metabolites absorbed across the intestinal epithelia provide 
post absorptive satiety signals. All of these stages therefore represent targets for dietary 
interventions. 
 
35 
 
 
Figure 12 The Blundell Appetite model, taken from Blundell, 2001 [121]. The model shows the three 
levels ofappetite control: the behavioural pattern, peripheral physiology and metabolism, and brain 
activity.  
Cephalic phase responses occur as a result of the pre-ingestive inputs provided by the 
sight smell and taste of food.  Cephalic phase responses begin before and during eating 
to stimulate digestive secretions and prepare the digestive tract for food to be ingested. 
Rather than being satiety signals, these processes give a positive feedback for eating and 
ready the digestive tract. Smith et al 1990, state that ‘afferent information from ingested 
food acting in the mouth provides primarily positive feedback for eating; that from the 
stomach and small intestine is primarily negative feedback’[122]. 
During digestion, chemo and mechano-receptors located throughout the digestive tract 
supply afferent information to the brain through the vagus nerve. These post-ingestive 
satiety signals feedback information about meal size, nutrient content and digestion 
which provide and act as post-ingestive negative feedback. Finally post-absorbative 
satiety signals are provided when digested nutrients cross the intestinal wall and enter 
circulation.  
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Digestion and satiety signalling is regulated by the enteric nervous system, which 
innervates the GI tact, hormonal and chemical signalling from cells of the GI tract and 
post-absorbative nutrient interactions [123]. Woods 2004, argues that eating patterns are 
regulated primarily by habit, behaviour and environment, the regulatory control 
mechanisms of the body must therefore control how much food is consumed once 
feeding has begun, allowing flexibility over eating patterns [123]. 
Woods defines three categories of signalling influencing food intake; satiety signals, 
adiposity signals and central effectors. Satiety signals function to promote a sense of 
fullness and reduce food intake. Sham feeding using a closed/open fistula in animal 
studies have shown that sight, smell and taste are not sufficient to estimate meal size 
and energy consumption. In a ‘sham feed’ where swallowed food is removed from the 
fistula, animals eat continuously as their appetite remains unsated [122]. There are 
therefore more complex methods of feedback for estimating portion size. 
Mechanical satiety signals detect stomach distention, stretch receptors and 
mechanoreceptors signal satiety to the brain [124]. Chemical signals may act on the 
brain either by acting on receptors in the GI tract and signalling through the vagus 
nerve, or by circulating hormones in the bloodstream and acting on the brain [123]. A 
number of anoretic satiety-inducing peptides have been identified which suppress 
hunger. The release of the hormone cholecystokinin (CCK) in response to protein or fat 
is thought to play an important role in satiety. CCK activates CCK-A receptors in the 
pylorus of the stomach which act on the hypothalamus. CCK administration and CCK-
A agonists have been shown to have a suppressive effect on the appetite [125]. Other 
sensing mechanisms have also been suggested, for example, the activation of 
procolipase to colipase by cleavage of the activation peptide enterostatin has been 
shown to decrease food intake in rats.  
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Table 8  Gastrointestinal peptides that influence food intake. Taklen from Woods 2004 [123] 
Ghrelin is the only pro-appetite peptide which has so far been identified.  Ghrelin is 28 
amino acid chain esterified on the Serine at position 3 with octanoic acid [126]. It acts 
as a ligand for the growth hormone secretagogue receptor and plasma ghrelin levels 
have been shown to increase between meals, peaking immediately before a meal and 
decrease afterwards [127]. Ghrelin has been demonstrated to be appetite and hunger 
stimulating, intravenous injection of ghrelin into human subjects stimulated appetite and 
caused a significant increase in thought and ‘imagination’ of meals [128]. As shown in 
Figure 13 Ghrelin acts in the arcuate nucleus of the hypothalamus to stimulate the 
release of Neuropeptide-Y a potent appetite stimulator. NPY also acts to inhibit 
secretion of GABA (gamma-aminobutyric acid), inhibition of which results in 
increasing stimulation of corticotrophin-releasing hormone expressing neurons which 
results in secretion of Adrenocorticotropic hormone and cortisol [129]. 
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Figure 13  Peptides regulation of appetite in hypothalamic neural networks. Neurons in 
the arcuate nucleus (ARC) produce ghrelin which act to presynaptically induce neuropeptide Y (NPY) 
release from NPY neurons, which stimulates food intake, increase GABA secretion (which may 
postsynaptically modulate the release of the an anorexigenic neuropeptide POMC). Ghrelin stimulates 
NPY release in the paraventricular nucleus (PVN), which suppresses GABA release, simulating 
corticotropin releasing hormone (CRH)-expressing neurons, leading to ACTH and cortisol release. Taken 
from Kojima et al 2005 [129] 
Leptin acts as a negative feedback in appetite regulation. Leptin is a 16kD protein 
produced by adipocytes which acts on the hypothalamus to suppress appetite. As shown 
in Figure 14 increased circulating leptin encourages increased energy expenditure and 
sympathetic tone and decreased energy intake. Conversely decreasing leptin acts to 
stimulate appetite and reduce energy expenditure [130].  
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Figure 14 Leptin response in vivo Taken from Friedman 2002 [130]. 
Carbohydrate intake has been shown to be well regulated and accurately sensed by the 
body. Pre-load studies with carbohydrate have shown that after a polysaccharide pre-
load meal there is an equivalent reduction of energy intake at later free feeding [131].  
2.3 Impairment of regulation  
A range of behavioural and biological controls of eating behaviour, macronutrient 
ingestion and processing have been identified which maintain energy and nutrient 
homeostasis. However impairments to the regulatory mechanisms of digestion can lead 
to disease. Using exogenous agents as regulators of digestive enzyme activity and 
therefore macronutrient availability provides a way of affecting and regulating this 
balance as a paradigm for disease treatment and control of nutrient intake.  
2.3.1 Obesity.  
Obesity presents a prime example of how multiple environmental, social and cultural 
factors can interact with a susceptible ‘Psychobiological Core’ leading to sustained over 
eating and under exercising in segments of the population. In a review of the Human 
Obesity Epedemic, 2009, Power describes three types of obesity: (i) metabolic obesity; 
where identifiable syndromes or diseases result in weight gain, (ii) socio-cultural 
obesity; where historically obesity may have been seen as a status symbol or sign of 
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wealth and (iii) Environmental obesity; which encompasses the modern epidemic where 
otherwise physiologically normal individuals become obese [9].  
Regulation of appetite and eating is a key control of macronutrient supply, and in an 
ideal state, eating behaviour is controlled and maintained relative to the biological need. 
However it is observed by Blundell et al 1994 that in a state of overconsumption and 
accumulation of body fat, there is a failing of homeostasis, and there does not seem to 
be a drive towards under-eating as a response, therefore weight gain can occur passively 
without a biological feedback. As Blundell et al put it, ‘biological defences against 
overconsumption are weak or inadequate’ [120].  
Fat is an essential aspect of our diet and fats/lipids are essential throughout the body as 
structural components, in cell membranes, as hormones and certain fatty acids which are 
integral to brain development and function. Adipose tissue therefore exists as a store of 
fat, however excessive fat storage as has been discussed can become pathological.  
Not only are the negative feedbacks against fat accumulation inadequate, but the picture 
is complicated by the function of adipose tissue as an active endocrine organ. Adipose 
tissue secretes cytokines and hormones including leptin, adiponectin, interleukins (IL-6, 
Il-8 and Il-10) and is also involved in steroid hormone metabolism. The hormones 
secreted by adipose tissue influence a range of processes including appetite, eating 
behaviour, energy metabolism neuroendocrine function and the immune system [9]. 
Excess adipose tissue is therefore associated with insulin resistance, hyperglycemia, 
dyslipidemia, hypertension, and prothrombotic and proinflammatory states [132].  
Lipid deficiency can also associated with aspects of metabolic syndrome and pathology 
characterised by insulin resistant diabetes [132, 133]. 
As discussed in the introduction, obesity and metabolic diseases are a significant 
problem, particulary in the developed world, with obesity and diabetes at epidemic 
levels. In 2005, almost 25% of the worlds population (1.6 billion people) were 
considered overweight and 400 million obese and in 2010 the global prevelance of 
Diabetes was 6.4% (285 million) people, with 90% of these cases being Type 2 
Diabetes [1, 134].  
The health effects and co-morbdities of obesity and current treatments were discussed at 
length in the introduction. Obesity is caused by a positive energy balance maintained 
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over a period of time and treatments aim to redress this balance. Downregulation of 
digestive enzyme activity in order to reduce the energy yield of a meal and could play a 
part in restoring this energy balance, furthermore the calorific load could be decreased 
without affecting the sensation of satiety.  
Downregulation of lipase activity would reduce dietary availability of fatty acids. 
Acetyl CoA which is required for cholesterol biosynthesis is produced during fatty acid 
metabolism, so reducing dietary fatty acids could hypothetically reduce cholesterol 
synthesis with benefits to cardiovascular health. Bile acids are derivatives of 
cholesterol, therefore reduced cholesterol production could potentially lead to reduced 
bile acid production. For the efficient digestion of lipids, bile acid is required for 
emulsification. Reducing bile acid production would reduce emulsification, resulting in 
a smaller lipid-water interface and therefore lower lipase activity.  
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2.3.2 TTDM 
In 2010 the global prevelance of Diabetes was 6.4% (285 million) people, with 90% of 
these cases being Type 2 Diabetes [134]. It is estimated that this figure will rise to 7.7% 
of the population, or approximately 439 million people by 2030 [135]. As with obesity 
Type 2 Diabetes is seen as a disease of the developed world, with the rise in prevelance 
occuring much more rapidly in the developed world. In the year 2000, 2.9 million 
people died as a result of diabetes [136]. Diabetes is also related to the co-morbidities of 
heart disease, stroke, blindness, renal failure and limb amputations.  
Type 2 Diabetes is estimated to have a heritability of over 50% however chronic 
overeating is the leading cause of diabetes. Insulin resistance, insuficient insulin 
secretion or a combination of the two leave type-2 diabetics unable to maintain normal 
blood glucose levels. In over-eating, non-susceptible individuals are able to process 
excess energy into subqutaneous fat. However in susceptible individuals, the β-islet 
cells can not produce enough insulin to compensate leading to increased glucose 
release, adipose tissue inflamation and ultimately insulin resistance. As the energy is not 
deposited as sub-cutaneous fat, it is deposited elsewhere as Visceral adipose tissue 
around the organs and can cause tissue damage [135].  
In nature, sugars are stored predominantly as the polysaccharides cellulose, starch and 
glycogen; the ability to hydrolyse polysaccharides is therefore of great importance to 
biological organisms as it confers access to a vast supply of glucose, and a major source 
of energy  [137] .  
β(1-4) linked cellulose remains resistant to human digestion as humans do not produce 
β(1-4) hydrolysing enzymes. Starch and glycogen on the other hand are both α(1-4) 
linked and can be cleaved by a number of human enzymes, principally the α-amylases. 
Starch, the major carbon reserve of plants and as the most common polysaccharide 
found in food, accounts for more than half of the carbohydrate ingested by humans 
[138].  
Modulation of α-amylase activity is therefore a target for regulation of carbohydrate 
digestion. Downregulation of carbohydrase activity would reduce the glycaemic load 
following a meal and therefore lower the insulin response; this has potential application 
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in the management of Type 2 Diabetes as is seen with the α-glucosidase inhibitor 
acarbose which is a poor substrate for α-glucosidases and competetively inhibits them 
[31]. 
As mentioned in the introduction, the α-glucosidase inhibitor acarbose has been shown 
to significantly reduce development of Type 2 Diabetes in patients with glucose 
intolerance and promote a return to normal glucose tolerance [31]. By slowing 
carbohydrate digestion, acarbose reduces the glycaemic-hit of a meal and reduces post-
prandial insulin secretion. [32].  
Furthermore, dietary fibres have also been investigated as potential treatments of 
diabetes and metabolic disease. The dietary fibre guar gum was shown to have anti-
hyperlipidaemic and anti-hyperglycaemic effects when given as a dietary supplement to 
diabetic rats [139]. Partially Hydrolysed Guar Gum has been investigated as a human 
intervention in a randomised clinical trial and was shown to have benneficial effects 
towards markers of metabolic syndrome with a significant reduction in waist 
circumferance in the intervention group (average 1.2cm) and a significant 
hypoglycaemic effect and was shown to blunt the post-prandial increases in blood 
glucose and insulin [140].  
Dietary fibre including pectin, alginate, xantham gum and guar gum have been shown to 
attenuate post-prandial blood glucose response and to be an effective treatment of 
diabetes [141]. It has been argued that this is due to the soluble dietary fibres increasing 
the viscosity of the meal which slows digestion and delays gastric emptying. Alginate 
has been investigated as a dietary additive to be used in diabetes management. 
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2.3.3 Pancreatic Insuficiency 
A loss of pancreatic function will lead to pancreatic insufficiency: the insufficient 
production of digestive enzymes leading to an inability to properly digest food. 
Pancreatic insufficiency may result from pancreatitis, cystic fibrosis, pancreatic duct 
obstruction, tumours of the pancreas, coeliacs disease, alcoholic pancreatitis and acid-
mediated enzyme inactivation [142]. The main symptoms are malnutrition, weight loss, 
steatorrhea, abdominal pain and micronutrient deficiency.  
Treatments for pancreatic insufficiency aim to relieve symptoms and to restore a normal 
nutrition state with enzyme supplementation. A fat restricted diet may be recommended 
to reduce steatthorrhea resulting from undigested fats. Dietary fibres have been shown 
to reduce the side-effects of undigested fats in the case of Orlistat treatment [143]. 
Psyllium mucilloid was effective in controlling the gastro-intestinal side-effects of 
orlistat administration.  
In pancreatic enzyme replacement therapy, exogenous enzymes are supplemented orally 
[143]. The common delivery is in ‘enteric-coated’ minimicrospheres which deliver a 
high lipase activity enzyme load to the small intestine to avoid acid inactivation. These 
treatments have been shown to increase fat digestion and absorption, reduce fat 
excretion and improve stool consistency [144, 145]. Proton pump inhibitors have been 
shown to improve the efficacy of enzyme replacement therapy, this is done by 
increasing the pH of the stomach and reducing the activity of gastric pepsin [146].  
Pancreatic secretion has been shown to respond to the diet and interestingly in a study 
of six healthy subjects supplemented with 20g dietary fibre (predominantly pectin) per 
day over four weeks resulted in significantly increased levels of lipase secretion in 
response to a meal. Lipase secretion 120 minutes after a test meal was increased by 64% 
[147].  However, another study showed that dietary fibre could inhibit pancreatic 
enzyme activity in vitro, and led to increased fat excretion in vivo and gastro-intestinal 
side-effects [148].  This suggests that increases in lipase secretion as observed in the 
Dukehart et al 1989, study may have occurred as a response to lipase inhibition by the 
dietary fibre.  
Pancreatic enzyme supplementation has been shown to improve outcomes in pancreatic 
adenocarcinoma as part of a programme of nutrition supplementation and detoxification 
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support, with one year survival in a group of 11 patients increasing to 81% as compared 
to a normal one year survival of 25% [149].  
Exogenous compounds which increase the activity of digestive enzymes may have 
potential for improving remaining pancreatic enzyme function, and increase the efficacy 
of enzyme replacement therapy.  
2.3.4 Protein disregulation 
Proteolytic enzymes catalyse the breakdown of dietary proteins into amino acids and 
short oligopeptides capable of crossing the small intestinal epithelia to be circulated 
through the blood and resynthesised to proteins in cells. Due to this central role in 
protein metabolism, protease activity is impicated in many downstream effects on 
health and disease.  
From a nutrition perspective, the ability to affect protein digestion and absorption by 
eliciting an increase or decrease in pepsin activity has potential therapuetic benefits for 
protein deficiency and hyperproteinaemia respectively. Modulation of protein digestion 
and alteration of luminal protein and amino acid levels may also have effects on 
digestive regulation through the amino acid sensing system. Luminal amino-acid 
sensing is thought to contribute to control of digestive processes, sensory stimuli from 
within the digestive tract can initiate signalling pathways which are involved in 
regulating digestion, absorption gut motility, food intake and satiety [150].   
The proteolytic enzyme pepsin is an agressor in gastro-oesophagul reflux with the 
ability to cause damage up to pH6.0, inhibition of pepsin is thererfore seen as a potential 
treatment [151]. It is thought that alginate based treatments of heartburn and acid reflux 
may be in part effective both through inhibition of pepsin as well as their raft-forming 
mechanism [7].  
Protoeolytic activity is also important in drug delivery, with luminal metabolism and 
first-pass intestinal metabolism affecting the oral bioavailability of protein based drugs 
during pre-systemic metabolism [152]. Inhibition of gastrointestinal enzymes has been 
shown to increase the bioavailability of orally administered drugs [153]. 
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2.4 Experimental Approach 
 
Given the need for novel therapies for a range of metabolic and nutrition related 
diseases and the growing evidence of dietary fibres as novel interventions for enzyme 
inhibition it is the aim of this study to develop a methodological approach for the testing 
of exogenous bioactive compounds. Within this, the project has had three major goals: 
i. Identify and develop assays for single enzyme analysis in order to carry 
out high throughput screening of a library of bioactive compounds 
ii. Develop a model gut system in order to investigate the effects of any 
compounds identified in (i) on macronutrient digestion in an in vitro 
simulation of the human GI tract 
iii. Investigate the mechanisms of enzyme regulation through enzyme 
kinetics and enzyme/substrate interactions with bioactive agents 
A 3-step process has been developed to test the action of biopolymers on the major 
enzymes of macronutrient digestion, pepsin, trypsin, α-amylase and lipase: 
High Throughput Analysis 
Selected Kinetic Analysis 
Model Gut Analysis 
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2.5 Higher throughput analysis 
Methods for higher throughput analysis of biopolymer samples will be developed on 96 
well microplates in order to quickly and efficiently screen a library of biopolymers for 
regulatory effects. The observed effects will be compared and correlated to structural 
characteristics and properties of the samples in order to find the optimum candidates for 
enzyme regulators and to attempt to define their mechanisms.  
Eighteen alginates provided by Technostics Ltd and FMC biopolymer were tested in a 
pepsin activity assay. Alginates are linear biopolymers composed of guluronic and 
mannuronic acid, their structural and bioactive properties are dictated by the proportion 
and arrangement of guluronnate and mannuronate. The eighteen samples tested provide 
a catalogue of alginates of varying degrees of F[G]. F[G] represents the frequency of 
guluronic acid residues in the alginate backbone, therefore the remaining residues in the 
backbone are mannuronate. As can be seen in Figure 15, this catalogue of alginates 
provides a range of samples from Low-F(G) to High-F(G).  
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Figure 15  Freguency of guluronic residues in alginate backbone F(G) for all sample 
alginate biopolymers.  
The structures of the alginate samples were characterised by 
13
C-NMR neighbour diad 
analysis and the full characteristics of all samples are shown in 
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Table 9 and represented in Appendix 8.1  
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FMC 2 0.66 0.34 0.54 0.11 0.23 0.038 0.076 0.51 15.47 
FMC 3 0.68 0.32 0.57 0.11 0.21 0.042 0.069 0.53 14.66 
FMC 4 0.51 0.49 0.34 0.17 0.32 0.043 0.124 0.3 8.97 
FMC 5 0.53 0.47 0.36 0.16 0.31 0.042 0.123 0.32 9.67 
FMC 6 0.52 0.48 0.35 0.17 0.31 0.048 0.122 0.3 8.15 
FMC 7 0.42 0.58 0.24 0.18 0.4 0.044 0.133 0.2 6.47 
FMC 9 0.45 0.55 0.26 0.19 0.36 0.054 0.136 0.2 5.78 
FMC 
10 
0.42 0.58 0.21 0.21 0.37 0.07 0.14 0.14 3.96 
FMC 
12 
0.35 0.65 0.19 0.16 0.49 0.053 0.111 0.13 4.54 
FMC 
13 
0.34 0.66 0.17 0.17 0.49 0.046 0.124 0.12 4.63 
LF120 0.424 0.576 0.24 0.185 0.391 0.057 0.156 0.183 4.7 
LFR560 0.633 0.367 0.505 0.128 0.239 0.054 0.096 0.45 9.9 
LF10L 0.45 0.553 0.257 0.19 0.362 0.068 0.153 0.19 4.4 
H120L 0.45 0.551 0.276 0.173 0.379 0.051 0.15 0.22 5.9 
SF120 0.664 0.336 0.545 0.119 0.218 0.061 0.083 0.484 9.6 
SF200 0.68 0.322 0.573 0.105 0.218 0.036 0.079 0.537 16.7 
SF/LF 0.66 0.336 0.548 0.116 0.22 0.042 0.081 0.506 13.8 
SF60L 0.411 0.589 0.219 0.195 0.393 0.077 0.155 0.133 3.3 
 
Table 9  Codes and molecular characteristics for alginates used in this study. F(G) is the fraction 
of the alginate polymer composed of guluronate and F(M) the fraction of mannuronate. N(G>1) is the 
number of consecutive guluronate residues above 1.  
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2.6 Enzyme Kinetics 
Microplate assays will be modified to allow for selected kinetic analysis. Michaelis 
Menten and Lineweaver Burke analysis of samples will be carried out in order to study 
mechanisms and potency of regulatory effects.  
2.6.1 Michaelis Menten Kinetics 
In single molecule enzymology, the reaction is a two-step process, firstly the enzyme 
[E] and substrate [S] combine to form an enzyme-substrate complex [ES] before being 
converted to product [P]. The Michaelis-Menten equation as represented by Briggs and 
Haldane in 1925 shows this reaction.  
 
     
   
 
As this equation shows, the rate of product formation, and therefore velocity of the 
reaction will be restricted by the rate of formation of ES complex. The rate of ES 
formation will increase from when enzyme and substrate are initially mixed until a 
steady state is reached in which ES formation and dissociation in equilibrium. 
Michaelis and Menten observed that the kinetics of this reaction alters with substrate 
concentration (or ratio of substrate to enzyme). Enzyme catalysed reactions increase in 
velocity with substrate concentration until saturation is achieved and addition of further 
substrate can no longer increase the reaction rate as all active sites are saturated with 
substrate. This can be graphically represented by a Michaelis-Menten plot (Figure 16).  
Figure 16 Generalised example of a michaelis menten plot. 
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This plot can also provide useful information about the kinetics of an enzyme catalysed 
reaction. The maximum velocity of the reaction (Vmax), is the theoretical concentration 
of substrate at which all active sites are saturated with substrate and functioning at a 
maximal rate. This value can be determined from where the Michaelis-Menten curve 
plateaus, this levelling of reaction rate occurs due to substrate saturation. 
The constant Vmax can be used to calculate the Michaeles Constant (Km), which is the 
substrate concentration required for half of maximal enzyme activity. As such the Km 
provides an important measure of the affinity of an enzyme for its substrate. A low Km 
means high affinity. Inversely a higher Km would indicate a lower affinity. 
The Michaelis Constant can be described as the rate of enzyme-substrate complex 
dissociation (either in to product and enzyme or back in to substrate and enzyme) 
divided by the rate of enzyme-substrate complex formation: 
                   
2.6.2 Lineweaver Burk Plots 
As well as deriving kinetics constants from Michaelis Menten plots and the formulas 
listed above,  Lineweaver and Burk stated that by drawing a double reciprocal plot of 
the substrate velocity data it is possible to establish the  and   from the x and y 
intercepts of a linear regression (Figure 17). 
 
 
Figure 17 Generalised example of a lineweaver-burke plot 
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2.6.3 Regulation of enzyme reactions 
The rate of enzyme reaction can be influenced by many factors such as enzyme 
concentration, substrate concentration, substrate-enzyme affinity, temperature and pH. 
As well as this, certain extrinsic compounds may have effects on the rates and kinetics 
of an enzyme catalysed reaction. Inhibition and activation can be described in a number 
of ways; linear or non-linear, reversible or irreversible and competitive, non-
competetive, uncompetetive or mixed. In the presence of a ‘regulator’ either the , 
   or both will be changed and the Michaelis Menten and Lineweaver-Burk profiles 
will be altered. The way in which these factors are changed can tell us a lot about the 
type of regulation that is being seen.  
2.6.4 Enzyme Inhibition  
2.6.5 Reversible Competitive inhibition 
Reversible Competitive Inhibition occurs when an inhibitor [I] combines with the 
enzyme, blocking substrate binding to the active site. Likewise, a competitive inhibitor 
cannot bind to the enzyme when substrate is bound. This is why this method of 
inhibition is referred to as competitive. However, as the binding is reversible, the 
inhibitor will dissociate from the enzyme, and all substrate will eventually be converted. 
In competitive inhibition rate of enzyme action is slowed by the competition of inhibitor 
for enzyme active sites and so  is increased. The  however will not be altered, 
because addition of sufficient substrate will overcome the competition of the inhibitor. 
The model of reversible competitive inhibition and all other models of inhibition is 
included in the appendix (Chapter 8, Figure 166a-d). 
2.6.6 Non-Competitive Reversible inhibition 
In Non-Competitive Reversible inhibition, the inhibitor binds the enzyme at a point 
other than the active site, either when the enzyme is free of in complex. As substrate 
binding is unaffected the  will be unaltered as [ES] complex formation and 
dissociation will be unhindered.   will however be reduced as the presence of 
inhibitor blocks the formation of product. 
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2.6.7 Uncompetetive Inhibition 
In uncompetitive inhibition, binding of substrate modifies the enzyme such that an 
inhibitor binding site is exposed. Inhibitor can then bind to the enzyme substrate 
complex, preventing product formation.  
Binding of inhibitor to the [ES] complex reduces the rate of [ES] dissociation. As such 
the   will be decreased as can be seen from the equation below: 
Km =  (k2+k3) 
      k1  
 
Therefore in the case of uncompetitive inhibition neither the  nor   correspond 
on the MM and LB plots. 
2.6.8 Mixed Inhibition 
Mixed inhibition may be a combination of the inhibitor binding the active site and 
binding the [ES] complex. So the inhibitor can compete with substrate for the active 
site, but when the active site is occupied with substrate, the inhibitor may also act upon 
the enzyme substrate complex. This therefore results in both a decreased   and an 
increase in . The two routes of inhibition are shown in the appendix (Chapter 8, 
Figure 166d). 
2.6.9 Irreversible Inhibition 
Irreversible inhibitors act by covalently binding to the enzyme and modifying its 
structure such that it is no longer active either through blocking the active site or 
inducing a conformational change that renders the enzyme inactive. For example, 
Penicillin covalently modifies the transpeptidase enzyme in bacteria preventing cell wall 
synthesis. They are referred to as irreversible due to the slow disassociation of inhibitor 
from the enzyme [154].  
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2.7 Quantification of Regulatory effects 
The kinetic constants Km and Vmax provide useful indicators of the type of inhibition or 
activation. Using Vmax and Km it is possible to calculate the Ki or inhibition constant. 
The Ki is the amount of inhibitor required to halve the Vmax.  
Ki therefore describes the relationship between the uninhibited and inhibited enzyme, 
and is best understood using a Lineweaver Burk plot (Figure 18).  
 
Figure 18 Generalised representation of inhibition on a Lineweaver-Burk plot 
The gradient of the line on the double-reciprocal Lineweaver Burk plot can be 
calculated as the Michaelis Constant ( ) divided by the Maximum Velocity ( ). 
The relationship between these two slopes is determined by the Inhibitor Concentration 
[I] and Inhibitor Constant  as shown below: 
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While there is not specifically such thing as an ‘activation constant’, a negative 
inhibition constant can be taken to indicate an activation, or increase in enzyme activity. 
Although the relationship between  and activation is somewhat more complicated 
than in the case of inhibition, as is discussed in Appendix 8.3. 
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2.8 Model Gut analysis  
 
 A physiologically relevant in vitro Model Gut System (MGS) has been developed 
which simulates the digestive processes of the gastrointestinal tract from mouth to 
terminal small intestine. This model can be used to study the chemical and enzymatic 
digestion of the macronutrients fat, protein and carbohydrate and to analyse the effects 
of exogenous compounds on digestion with a view to developing novel therapeutics. 
The model has been validated with known inhibitors, and used to characterise novel 
modulators of digestive enzyme activity. The efficacy of the MGS has been 
demonstrated by the role it has played in building a case for the novel lipase inhibitor 
alginate as a weight loss treatment, which has now progressed to the BBSRC funded 
human weight-loss trial titled “Designing the most effective vehicle to deliver alginate 
to effectively reduce fat digestion and absorption”. 
An artificial model of the human upper GI tract was designed to simulate the conditions 
of macronutrient digestion in vitro. The model gut system provides a methodology for 
the investigation of fat, protein and carbohydrate digestion and a tool for quantitatively 
analysing the effects of exogenous regulators on digestion. As such the model provides 
an in vitro system that can be used to validate effects seen with bioactive compounds in 
single enzyme analysis in a physiologically relevant mixed model.  
Model gut analysis provides a well controlled, reproducible and cost-effective 
alternative to in vivo studies.  
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Chapter 3 
Modulation of Pepsin Activity 
 
3.1 Pepsin 
3.1.1 Categorisation 
Pepsin is part of the aspartate protease super family (EC 3.4.23.) [110]. As the major 
proteolytic enzymes in gastric juice, pepsins are responsible for the digestion of dietary 
protein in the low pH environment of the stomach. Pepsins are broad specificity 
endopeptidases with a preferance for cleavage between hydrophobic amino acids. 
There are 5 types of pepsin, pepsins A, B, C, F and Y. Of these pepsins A and C are 
found in humans, derived from two immunological pepsinogen groups PGI and PGII 
respectively. PGI and PGII comprise 7 pepsinogens that are each activated to a unique 
pepsin. PGI comprises pepsinogens 1-5 and is secreted in the stomach by oxynitic 
glands. PGII consists of pepsinogens 6 and 7 and is secreted in the stomach by the 
pyloric glands of the antrum as well as the fundus oxynitic glands, and in the proximal 
duodenum by ‘pepsin secreting tissue’[112].   
3.1.2 Structure 
Pepsinogen, the zymogen precursor of pepsin is a protein of approximately 40kDa, and 
the active form of pepsin is in the region of 35kDa, although there is a wide variation in 
this with sub-species of active human pepsin varying from 31-44kDa.  
Like all aspartate-proteases pepsin is a monomeric enzyme. Native human pepsin is 
composed of 2,438 atoms which make up the protein structure, co-ordinated with 102 
water molecules [155].  
Pepsin is composed of two lobes (Figure 19), of similar size and structure, referred to as 
the N-terminal lobe and C-terminal lobe, in porcine pepsin these comprise amino acids 
1-175 and 176-326 respectively [156]. The active site region backbone  (Residues Val 
1-Leu 6, Asp 149-Val 184 and Gln 308-Ala 326) consists of a six-stranded antiparallel 
beta sheet containing the active site which is formed by a deep 30 Angstrom cleft 
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between the two lobes. All pepsins contain two conserved aspartate residues in the 
middle of this cleft [157]. In porcine pepsin the two aspartates Asp32 and Asp215 are 
about 3 Angstrom (0.3nm) apart, close enough to share a proton [157]. The two aspartic 
residues are covered by an N-terminal flap (aa 60-90 in porcine pepsin) which forms a 
hairpin loop with a highly conserved Tyr 75 residue at the tip.  
 
Figure 19  Diagrammatic representation of pepsin structure. Taken from Pepsins, Pearson 
et al 2010 [158] 
An extensive hydrogen-bonding network, and the co-ordination of seventeen water 
molecules stabilise the active site. Both the hydrogen bond network and the water 
molecules within the active site are essential for pepsin structure and function [155]. 
Outside of the active site region, the N-terminal lobe consists of three layers of β-Sheets 
(GLn 308-Ala 326), and a C-terminal lobe consisting of 2 layers of β-Sheets (Thr185-
Arg148) [155]. 
3.1.3 Activation 
The major site of pepsin activity is the stomach. Pepsin is secreted as the inactive 
zymogen pepsinogen from Chief/Peptic Cells in the Gastric of the stomach. Pepsinogen 
is reported to be stable within the pH range 6-9 [111], above pH 9.0 pepsinogen is 
irreversibly denatured. 
Pepsinogen is activated to pepsin below pH6 by a pH-driven auto-catalytic mechanism. 
This activation of pepsin occurs faster at lower pH [112]. 
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In porcine pepsinogen the active site is blocked by a 44 amino acid N-terminal peptide. 
Pepsin is highly acidic and therefore negatively charged, the 44 aa propeptide is highly 
basic and therefore positively charged. Therefore at neutral pH this propeptide is held 
over the active site by electrostatic interactions between the amino groups of basic 
amino acids, and carboxyl groups of acidic amino acids [151]. Below pH 5.0 carboxyl 
groups become protonated, disrupting charge-charge interactions and allowing the N-
terminal peptide to move into the active site where there are two possible activation 
pathways; 1) a 16 amino-acid peptide is cleaved and the enzyme/protein becomes a 
partially active ‘pseudo-pepsin’, a further 28 amino-acid peptide is then cleaved from 
the N-terminal by either a partially or fully active pepsin. 2) alternatively pepsinogen 
can be activated to active pepsin by complete cleavage of the 44 amino-acid chain 
blocking the active site.  
Site directed mutagenesis has shown that the catalytic aspartate residues are essential for 
auto-catalytic activation of pepsinogen. When substituted with glutamate, the mutant 
pepsin retains proteolytic activity as a glutamyl protease, however lacks the ability of 
autocatalytic activation. The relative size of glutamate residues block alignment of the 
N-terminal segment for autocatalytic cleavage [159].  
3.1.4 Catalytic Mechanism 
The two aspartate residues (Asp32 and 215 in pig pepsin)  which form an acid base pair 
in the middle of the active site cleft hold between them a water molecule which 
facilitates nucleophillic attack on the peptide bond. Asp32 is the basic partner and 
Asp215 the acid. The extensive hydrogen bonding network is required to maintain the 
basic Asp32 in the COO
-
 state. Nucleophillic attack by the water molecule on the 
peptide bond NH-CO generates –NH2 and –COOH. The six-stranded antiparallel beta 
sheet between the N and C-terminal lobes contains an active site binding region which 
can bind a peptide region of 7-9 amino acids [160].  
Pepsins are endopeptidases and therefore preferentially cleave peptide bonds within the 
polypeptide chain as opposed to cleaving amino acids from the terminal ends. Pepsins 
are of broad specificity, but preferentially cleave bonds between  hydrophobic and 
aromatic amino acids [161]. The residue at the P1 position at the cleavage site has been 
shown to have the strongest influence on pepsin cleavage, with the enzyme favouring 
Phe, Leu, Met, Cys, Glu, Trp and Tyr residues at P1. Little pepsin cleavage occurs after 
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a charged amino acid at P1 such as His, Lys or Arg, or after the cyclic amino acid Pro. 
Aromatic residues are also favoured at the P1’  position such as Tyr, Trp or Phe. The 
same study showed that pepsin favours cleavage of smaller peptides to larger ones 
Further data is available for favourable cleavage sites [162]. Figure 20 shows an 
explanation for the P1 and P1’ terminology with P1 representing the residue on the 
amino side of the cleavage site and P1’ on the carboxyl side.  
 
Figure 20 The two  possible  enzyme-substrate complexes  of papain with a hexapeptide molecule.  There 
are 7 subsites in the enzyme active site. Complex A yields two  tripeptide molecules, and B  one 
tetrapeptide  and one  dipeptide. Taken from Schechter et al 1967 [163]. 
3.1.5 pH Optima and Inactivation 
 
The pH optima of human pepsin has been shown to be in the range pH1.5-2.5 
depending on both substrate and pepsin sub-family [164].  Figure 21 shows an activity 
and stability curve for human pepsin against serum albumin. In this study, pH optimum 
is reported as 1.5-2.5, with pepsin maintaining approximately 60-70% activity up to 
pH5. The range pH5 to 7.5 represents the range within which pepsin has little or no 
activity, but a return to acidic pH will fully restore activity. Above pH 7.5 pepsin is 
irreversibly inactivated [165].  
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 Figure 21 pH stability and activity curve of pepsin Piper et al, 1965 [165] 
 
Interestingly, pepsin is denatured at pHs above neutral, whereas pepsinogen  is not.  It is 
thought that the N-terminal pro-peptide domain is essential for stability of the N-
terminal domain at high pH. After activation of pepsinogen to active pepsin, while the 
C-terminal domain retains the capability of reversible folding after pH denaturation, the 
cleaved N-terminal domain will misfold upon return to a lower pH [166].  
In addition to functioning as a digestive proteinase, pepsin also has a key role in the 
innate immune protection in conjunction with the acid environment of the stomach, 
creating a bacteriocidal barrier to protect the body from infection via the digestive tract. 
Pepsins are also an important biomarker of, and believed to be an aggressor in gastric 
reflux. 
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3.2 Alginate inhibition of Pepsin 
 
In 2000, Sunderland et al showed alginates could inhibit pepsin activity by 52% in vitro 
[57]. Subsequent studies suggested that the levels of inhibition were related to the 
molecular weight of the alginates. Highest inhibition was shown to occur between 
molecular weights of 40,000 and 350,000, with a peak inhibition between 150,000 and 
200,000 MW [167]. However, a subsequent study by Strugala et al 2005, found no 
correlation between levels of inhibition and molecular weight and suggested the 
inhibitory effect was related to alginate structure [7]. A catalogue of well characterised 
alginates were tested which showed inhibition levels in the range 39-81% reduction in 
activity by 5mg/ml alginate. In this study, significant correlations were shown between 
alginate structure and levels of inhibition, with high F[M] alginates tending to inhibit 
better than those high in F[G], although as can be seen from Figure 22, the data points 
are spread widely around the line of best fit. 
 
 
Figure 22  Scatter plot of correlation between percentage pepsin inhibition anf frequency 
of mannuronic acid residues Strugala et al, 2005 [7] 
The Strugala et al study used a colourimetric assay of proteolytic activity originally 
described by Lin et al [168]. The assay is based on the detection of newly generated N-
terminals from a succinylated albumin substrate. Trinitrobenzo Sulfonic Acid (TNBS) is 
used to detect N-terminals exposed through proteolysis by reacting and forming a 
coloured product. Colour development is measured spectrophotometrically and is 
proportional to the rate of cleavage. The assay was performed using pepsin and 
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substrate titrated to pH2.2 with HCl, however the alginates tested in the study were 
made up as aqueous solutions. Alginates have pKa’s in the range 3.38 to 3.65 and an 
aqueous alginate will have a pH of approximately 6-7 [169]. Addition of aqueous 
alginates to a reaction mixture will affect the pH and therefore affect the rate of enzyme 
activity. This chapter aims to investigate this issue.  
Sunderland et al 2000, carried out some simple binding studies to investigate the 
mechanism of alginate inhibition [57]. An alginate-pepsin mixture was centrifuged and 
the pepsin content of the supernatent was assayed to determine if pepsin had bound to 
alginate and been pulled out of solution. These results showed levels of pepsin to be 
significantly lower after centrifugation with alginate. It was therefore suggested that 
alginate binding of pepsin was a possible mechanism of inhibition.  
Alginates have been shown to inhibit the activity of pepsin, and have been utilised in 
the treatment of reflux. The alginate based anti-reflux agent Gaviscon has proved an 
effective treatment of GORD (Gastro-Oesophagul Reflux Disease) [57]. Reflux is the 
retrograde flow of gastric and/or duodenal contents into the oesophagus [170]. The 
primary mechanism of alginate based reflux suppressants was originally thought to be 
the viscous acid-gel formed by alginate upon contact with stomach acid. The alginate 
raft that is formed creates a physical barrier to the reflux by floating on the top of the 
stomach contents [171].  
Acid alone will not cause experimental damage in animal models, and pepsin is thought 
to be a major aggressor in reflux [172]. In experimental animal mode is addition of 
pepsin results in reflux-like oesophagitis [173]. As stated previously, pepsin retains 
activity up to pH5.5, so still has potential to cause damage to the oesophagus in the 
refluxate. Alginate has been shown to inhibit pepsin in vitro, it is therefore thought that 
alginate inhibition of pepsin may be a secondary mechanism for the anti-reflux activity 
of alginate based agents [172].  
3.2.1 Protein Digestion Kinetics 
 
Postprandial protein utilisation and retention has been shown not just to depend upon 
protein quantity and amino acid composition, but also upon rate of protein digestion 
[174]. Dangin et al 2001, showed a relationship between the kinetics of protein 
digestion, and subsequent absorption, utilisation and retention. In a comparison of the 
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digestion and utilisation of ‘slow and fast-digested’ protein meals, 22 healthy male 
volunteers were fed slow and fast digested protein meals matched for weight and 
content. One group was fed either slow or fast digested casein (30g casein or 30g free 
Amino-Acids matching casein composition) and another group slow or fast whey 
protein (30g whey protein in one sitting or 30g whey protein in 13 feeds over 4 hours). 
All meals contained 
13
C radio-labelled leucine, and blood and breath samples were 
taken over 300mins after feeding. Circulating plasma Leucine levels and radio-labelled 
[
13
C]CO2 expiration were measured.  
 
Figure 23  Postprandial leucine balance 7 hours after a meal. Protein digestion rates 
differed between AA and CAS mealsand between WP and RPT-WP meals, but amino acid profiles were 
identical. Taken from Dangin et al 2001 [174].  
 
With both casein and whey protein, the fast digested meals showed rapid peaks in 
circulating leucine as would be expected, however these increases were transient and 
fell back to resting levels. Whereas with the slow digested protein, the increase in 
circulating leucine was much less pronounced, but was maintained through to the final 
measurement at 300min. Furthermore, the rapid peak in circulating amino acids was 
mirrored by a similar rapid increase in protein synthesis, as measured by NOLD (Non 
oxidative Leucine Disposal) which is thought to have stimulated protein synthesis. In 
the slow-digested protein meals, there was not a similar stimulation of the rate of 
protein synthesis. However, in both test cases, overall total postprandial leucine balance 
420mins after feeding was higher in the patients who had been fed the slow-digested 
protein meals. From this data, Dangin et al 2001, calculated that there was an overall 
better rate of protein utilisation in the slow digested meals than the fast over a 7 hour 
period (Slow casein 0.78±0.04μmol·kg−1·min−1, fast casein AA, 0.62±0.06 
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μmol·kg−1·min−1; slow whey protein 0.80±0.07 μmol·kg−1·min−1, fast whey protein 
0.66±0.03μmol·kg−1·min−1)[174]. 
Therefore rate of protein digestion may be of consequence to the efficacy of protein 
supplementation in the diet. There is a variation in protein digestibility and utilisation 
which depends on protein structure, and the behaviour of different proteins in the 
gastrointestinal tract. Whey protein is much more rapidly digested than casein. This is 
thought to be due to the fact that casein coagulates in the acidic conditions of the 
stomach, and therefore the accessibility of the substrate to pepsin is greatly reduced, 
whereas whey protein remains soluble and is easily available for pepsin digestion in the 
stomach [175]. Furthermore, the coagulation of casein delays gastric emptying [176].  
3.2.2 Proteinase Inhibition and Drug Delivery 
 
Protoeolytic activity is also important in drug delivery, with luminal metabolism and 
first-pass intestinal metabolism affecting the bioavailability of orally delivered protein 
based drugs during pre-systemic metabolism [152]. Drug vehicles such as nanoparticles, 
microparticles and liposomes are commonly used to protect drugs from proteolytic 
degradation, but co-administration of enzyme inhibitors is becoming increasingly 
commonplace to reduce proteolytic degradation and increase the bioavailability of 
drugs. Langguth et al 1994, showed that inhibition of gastrointestinal enzymes 
increased the bioavailability of the pentapeptide drug Metkephamid 20-fold in a rat 
model [153]. 
 
Many peptide based drugs are administered parenterally in order to bypass pre-systemic 
metabolism. Insulin is a prime example of this. Yamamoto et al 1994, looked at the oral 
delivery of insulin, co-administered with the proteinase inhibitors both in animal models 
and in ex vivo tissue homogenates [177]. In the rat model, aprotinin, Soybean trypsin 
inhibitor, Na-glycocholate, camostat mesilate and bacitracin all promoted insulin 
absorption from the large intestine, with 20mM Bacitracin being the most effective. The 
degradation of insulin in mucosal homogenates was studied and it was found that Na-
glycocholate, camostat mesilate and bacitracin were most effective in reducing insulin 
degradation.  
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3.3 Aims 
The aim of this chapter therefore was to investigate the effects of bioactive compounds 
on pepsin activity. A library of bioactive alginates, was tested in high throughput assays 
to screen for regulatory effects, and structure-function relationships were investigated. 
Selected enzyme kinetics were carried out to attempt to elucidate the nature of any 
regulatory effects.  
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3.4 Experimental Section 
3.4.1 Materials 
 
All biopolymer samples tested were supplied by FMC Biopolymer and Technostics Ltd 
(Hull, UK). cBovine Serum albumin was purchased from VWR Jencons. Unless 
otherwise stated, all other chemicals and reagents were purchased from Sigma Aldrich 
(Poole, UK). 
 
3.4.2 Equipment 
 
A Biotek 96 well plate reader set at 340nm was used for spectrophotometric 
measurements (Elx808 Biotek, Bedfordshire, UK). An Autoblot microhybridization 
oven was used for temperature incubations at 37°C and 55°C (Bellco Glass Inc, 
Vineland, NJ). A Martini Mi150 pH meter was used for all pH measurements, 
(Milwaukee Instruments, Inc. NC, U.S.A.). 
3.4.3 Preparation of Succinyl albumin 
Succinyl albumin was prepared following the method described by  Hutton et al 2003 
[178]. 20g Bovine serum albumin (Fraction V) was dissolved in 200ml phosphate buffer 
pH7.5. 2.8g of Succinic anhydryde was slowly added while stirring, maintaining pH at 
7.5 with dropwise addition of 2M Sodium hydroxide. This solution was then 
exhaustively dialysed against deionised water at 4°C and freeze dried.  
Protein + Succinic Anhydride  Succinyl albumin + Water 
COOH-[CH-R
1
-NH-CO]n-CH-R
2
-NH2 + CO-CH2-CH2-COO 
 
COOH-[CH-R
1
-NH-CO]n-CH-R
2
-NHCO-CH2-CH2-COH 
67 
 
 
3.4.4 Preperation of TNBS 
 
TNBS was prepared according to the method described by Hutton et al. 1.5ml of 1M 
2,4,6-trinitrobenzenesulphonic acid (TNBS) from Fluka was mixed with 10mg of 
activated charcoal. Charcoal was removed by centrifugation at 5000rpm for 10 minutes. 
The resulting supernatant was then diluted to the required concentration. 
3.4.5 Assay Principle 
 
Activity of pepsin was measured using the N-terminal assay developed by Lin et al 
1969 [168] and modified by Hutton et al 1986 [178]. Pepsin activity can be measured 
through the generation of new terminal amino groups formed during peptide hydrolysis. 
As pepsin cleaves peptides, new terminal carboxyl and amino groups are exposed. At 
pH7 and above primary amine groups are trinitrophenylated with 
Trinitrobenzosulphonic Acid (TNBS) to generate a yellow colouration which can be 
measured at 340nm.  The trinitrophenylation reaction is shown below. A flow diagram 
of the N-Terminal methodology is shown in Figure 24. 
 
 
 
TNBS Reaction With Protein: 
 
Protein + TNBS  Trinitrophenylated Protein + Sulphorous acid 
 
COOH-[CH-R
1
-NH-CO]n-CH-R
2
-NH2 + C6H2(NO2)3SO3H 
 
COOH-[CH-R
1
-NH-CO]n-CH-R
2
-NHC6H2(NO2)3 + H2SO3 
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Figure 24  Schematic representation of Pepsin N-Terminal Reaction 
 
 
3.4.6 Modification of Assay 
Following the methodology of Strugala et al 2005, biopolymer samples are made up in 
deionised water before being mixed 1:1 with 5µg/ml pepsin (in 0.01M HCl at pH 2.2) to 
give concentrations of 2mg/ml and 2.5µg/ml respectively and samples were pre-
incubated for 30 minutes at 37˚C. Substrate (8mg/ml) succinyl albumin was also made 
up in 0.01M HCl titrated to pH2.2 [7]. 
Alginates themselves are weakly acidic, and have a pH of ~5.75-7.25 in deionised water 
depending upon concentration as shown in Figure 25. Strugala et al 2005, argued that 
this did not have a significant effect on the overall pH of the reaction solution, raising 
the mean pH to 2.3 and having little effect on the rate on the reaction [7].  
Protein 
5° 
Cover and let stand at 
room temp for 60min 
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pH Variation of aqueous alginate
SF60 H120L LFR5/60 LF120L SF120 SF/LF LF10L SF200
5.5
6.0
6.5
7.0
7.5
0.25mg/ml
1mg/ml
4mg/ml
Alginate
p
H
 
Figure 25  pH variation of aqueous alginates. 0.25mg/ml,  1mg/ml,  4mg/ml. 
Measurements in this lab however have shown a greater variation in pH of the reaction 
mixture than previously reported, especially at higher concentrations of biopolymer as 
shown in Figure 26. Furthermore, in the reaction solutions, addition of aqueous alginate 
causes a precipitant to form , as seen in Figure 27. This may be either the alginate or 
substrate coming out of solution or a precipitate formed through interaction between the 
two. 
pH Variation of reaction solution with addition of alginate
SF200 LF120L SF/LF SF60 SF120 LF10L H120L LFR5/60
2.0
2.1
2.2
2.3
2.4
2.5
0.25mg/ml
1mg/ml
4mg/ml
Alginate
p
H
 
Figure 26  pH variation of N-terminal reaction mixture with addition of aqueous alginate. 
0.25mg/ml,  1mg/ml,   4mg/ml. 
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Figure 27  Picture of reaction mixture of N-terminal assay with aqueous alginates. (a) 
SF200 alginate - 0.25mg/ml, 1mg/ml and 4mg/ml from left to right. (b) LF10L alginate - 0.25mg/ml, 
1mg/ml and 4mg/ml from left to right. 
 
 
3.4.7 Adaptation of methodology with orthophosphate/phosphoric acid buffer 
A variation of 0.2 units of pH would have significant effects on the rate of reaction 
reaction. Variations in pH could affect this assay in two specific ways: firstly pepsin 
activity is pH dependent, and moving away from the optimum pH would lower pepsin 
activity; secondly succinyl albumin substrate is soluble only within a certain pH range 
and alteration of pH may cause succinyl albumin to come out of solution, which may 
cause a reduction in substrate digestion.  
In the Strugala methodology 0.01M HCl acid (pH2.2) is used as a diluent for other 
solutes in the assay (i.e. pepsin and succinyl albumin) [7]. However 0.01M HCl is 
ineffective at buffering pectins, and will not take alginates into solution. This is 
presumably why Strugala et al chose to work with aqueous alginates.  
Finding a buffering system for the N-terminal assay presented a number of difficulties. 
The N-terminal Assay is pH dependent and requires a number of pH changes and 
running the assay in a buffer may affect the pH changes required for trinitrophenylation 
and colour development. Furthermore, succinyl albumin must be taken fully into 
solution at pH 2.2 and dietary fibres,  particularly alginates, can be difficult to get into 
solution at low pH. 
A number of buffer systems were investigated and the method had to be adjusted 
slightly to accommodate the buffer.  
(a) (b) 
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Substrate (8mg/ml) and pepsin (5µg/ml) were made up in a 0.05M potassium 
dihydrogen orthophosphate/phosphoric acid buffer pH2.2. All fibres were made up at 
4mg/ml in buffer. Alginates added to buffer at pH2.2 will not go into solution. The 
alginates were therefore made up in the basic component of the buffer initially and then 
mixed with the acidic component of the buffer. As can be seen from Figure 28 that in 
this system the final reaction mixture is buffered within 0.05 units of pH.  
The methodology of Lin et al was followed with 0.05% TNBS, 10% (w/v) sodium 
bicarbonate, 10% (w/v) SDS (Sodium Dodecyl Sulphate) and 1M HCl. Note that the 
sodium bicarbonate concentration has been raised to accommodate for the effect of the 
buffer.  
pH Variation of reaction solution with addition of alginate in buffer
SF200 SF60 SF/LF LFR5/60 SF120 H120L LF120L SF200
2.0
2.1
2.2
2.3
2.4
2.5
0.25mg/ml
1mg/ml
4mg/ml
Alginate
p
H
 
Figure 28 pH variation of reaction solution with addition of buffered alginate.  0.25mg/ml,  
1mg/ml,  4mg/ml. 
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Figure 29 Comparison of alginate mediated pepsin inhibition in buffered and unbuffered systems. 
 Unbuffered system  Buffered system. 
Alginate inhibition of pepsin was compared in a buffered and unbuffered system 
(Figure 29). These results indicate that some of the inhibition effect observed were due 
to changes in the pH of the reaction mixture and that a buffered N-Terminal Assay 
system offers a more robust method of analysis of pepsin inhibition.  
3.4.8 Scaling down to 96 well microplate 
The assay was scaled down to a 96 well microplate from the original methodology, 
modifications were made to concentrations and volumes of substrates and reagents. 
Buffering of the assay was shown not to affect the validity of the assay. 
30µl of buffer sample was pre-incubated with pepsin at a range of concentrations (2.5-
17.5µg/ml) for 30 minutes. At T0 50µl of succinyl albumin solution (10mg/ml) was 
added and the plate was incubated for 30min at 37˚C. At T30 50µl NaHCO3 (10% w/v) 
and 50µl TNBS at a range of concentrations (0-5%v/v) was added and the plate 
incubated at 55˚C for 15 minutes. At T45 50ul SDS (10%) and 50ul 1M HCl were 
added. The plate was then left to stand for 15 minutes until effervesce had stopped.  
Absorbance was then measured at 340nm on the Biotek plate reader.  
Figure 30 shows the assay tested at a range of pepsin and TNBS concentrations in order 
to work out optimal reaction conditions. It was determined from this data that a 
concentration of pepsin of 10µg/ml and TNBS of 2µl/ml would give sufficient colour 
development to be reliably detected at 340nm.  
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Figure 30 Colour development with Pepsin N-Terminal assay at varying pepsin and TNBS 
concentrations.  
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3.5 96-Well Plate N-Terminal Method 
3.5.1 Preperation of Solutions 
For high-throughput analysis, biopolymer samples were prepared at 10mg/ml in the 
acidic side of the buffer (5.7988ml Phosphoric Acid in 500ml) and then diluted at a 1:1 
ratio with the basic side of the buffer (32.646g KH2PO4 in 500ml). 10mg/ml succinyl 
albumin was prepared in 0.05mM phosphate buffer and the solution was to pH 2.5.  
Trinitrobenzosulfonic acid (TNBS) was prepared at 2µl/ml in deionised water. 
10µg/ml pepsin was prepared 10 minutes prior to T0. 
3.5.2 Method 
30µl fibre sample was pre-incubated with 50µl Succinyl albumin substrate for 60 
minutes on a shaker. At T0 30µl pepsin solution or buffer blank was added as 
appropriate and the plate was incubated for 30min at 37˚C (Figure 31). 
After 30 minutes, 50µl sodium bicarbonate and 50µl TNBS was added, mixed and the 
plate was incubated for 15 minutes in Autoblot Microhybridisation oven at 55˚C. 
At T45, 50µl SDS and 50µl 1M hydrochloric acid were added and the plate was left to 
stant until all wells had stopped effervescing, and samples were read at 340nm. 
To calculate percentage pepsin inhibition the following formula was used: 
 
 
 
All data is presented as the mean of at least three repeats with error bars as standard 
deviation. 
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3.5.3 Plating – Higher Throughput Microplate Assay 
 
Figure 31 Plating layout for Pepsin N-Terminal microplate assay.  
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3.5.4 Kinetic assay of Pepsin Activity 
 
The kinetics of dietary fibre interactions with pepsin was measured using a modification 
of the 96 well-plate N-Terminal method previously described. Trinitrobenzosulfonic 
Acid was prepared fresh at 2µl/ml in deionised water.  
Succinyl albumin substrate was prepared fresh at 25mg/ml in Phosphate Buffer 
(Phosphoric Acid (30mM)/Monopotassium Phosphate (47mM)) and 50µl plated out as 
below. Substrate dilutions were prepared from a stock of 25mg/ml Succinyl Albumin 
and plated out as shown in Figure 32, including a control and blank lane both at 
10mg/ml succinyl albumin. 200µl was added into each well so that there would be 
sufficient substrate for 3 plates to be run in triplicate. 
 
Table 10 Substrate dilutions for Pepsin N-Terminal Kinetic assay.  
In sample plates 30µl of sample (4mg/ml) was pre-incubated with 30µl pepsin 
(10μg/ml) for 15 minutes at 37˚C to give sample concentrations of 2mg/ml and 5µg/ml 
respectively.  
At T0 50µl of of substrate was added into the appropriate wells and incubated for 30 
minutes. After 30 minutes 50µl NaHCO3 and 50µl of TNBS was added and the 
temperature raised to 55°C for colour development.  
After 15 minutes at 55˚C, 50µl SDS and 50µl HCl was then added and the plate was left 
to stand until effervescence had stopped. Absorbance was then read at 340nm.  
All samples tested were compared to a control pepsin digestion of 10mg/ml Succinyl 
albumin. The absorbance reading for the control lane at 30minutes was taken as 100%, 
and all test samples were converted to fractions of this 100% absorbance reading. These 
data was then converted into velocities. This standardisation was necessary to account 
for variations in backround absorbance of succinyl albumin substrate. Because of this 
Blank 
Lane 
Control 
Lane 
Substrate Dilutions 
10 10 25 20 15 10 5 2.5 1.25 0.625 0.3125 0 
10 10 25 20 15 10 5 2.5 1.25 0.625 0.3125 0 
10 10 25 20 15 10 5 2.5 1.25 0.625 0.3125 0 
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the raw absorbance data would not give an accurate comparison between replicates. 
However, by standardising to an internal control before conversion to a velocity, 
comparisons could be made between replicates. These percentage values were then 
divided to give percentage change per minute.  
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3.5.5 Plating Kinetic assay 
Figure 32 Plating layout for Pepsin N-Terminal Kinetic microplate assay.  
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3.6 Alginate and pepsin 
3.6.1 Higher-throughput assays 
 
As described in the experimental section, pepsin activity in the presence of dietary 
biopolymers was measured using a 96 well microplate adaptation of the N-Terminal 
Proteolysis assay. Succinylated bovine serum albumin was used as the substrate, 
cleavage of polypeptides generates new terminal amino groups, which are 
trinitrophenylated above pH7 at 50°C. Trinitrophenylation causes a yellow-orange 
spectrophotometrically quantifiable coloration, and pepsin activity was measured as an 
increase in optical density at 340nm. 
 
Colour development was measured in the presence of dietary bioplolymers and pepsin 
inhibition was calculated as a percentage change in optical density as compared to 
uninhibited pepsin control. The assay system was validated using pentosan polysulphate 
(SP54) as a positive inhibition control. SP54 is a heparin analogue with a molecular 
weight of 4000-6000 Daltons and like heparin is a highly sulphated polysaccharide. 
Heparin and other highly sulphated polysaccharides are known to inhibit pepsin activity 
[179, 180]. The structure of a Pentosan polysulphate subunit is shown in Figure 33 
below.  
 
Figure 33 Molecular Structure of Pentosan Polysulphate SP54. Taken from Balaji et al 2012 [181] 
 
Maximum inhibition with SP54 was achieved at a concentration of 5mg/ml, reducing 
activity to 24.5% (±11.2 SD) of control pepsin activity Figure 34, an inhibition of just 
over 75%. 
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Figure 34 - Concentration dependent inhibition of pepsin in the presence of pentosan polysulphate 
(SP54). Activity is shown as a percentage of control pepsin activity at a range of concentrations (0-5 
mg/ml). All samples were tested in triplicate (n=3) with error bars showing standard deviation. 
 
The catalogue of eighteen alginates provided by Technostics Ltd and FMC biopolymer 
was tested in the pepsin activity assay. All alginate samples were tested at three 
concentrations; 5, 2.5 and 1.25mg/ml. This gave concentrations in the reaction mixture 
of 1.36, 0.68 and 0.34mg/ml respectively. All alginates tested showed the ability to 
inhibit pepsin activity at the highest concentration (5mg/ml).  
In Figure 35 the results for all eighteen alginates have been collated.  Taken together, a 
clear and significant dose response effect can be seen. Average pepsin activity was 
reduced by 6.8% ± 6.1 at 1.25mg/ml, by 18.3% ± 7.5 at 2.5mg/ml and by 31.9% ± 6.1 at 
5mg/ml.  
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Figure 35- Concentration dependent inhibition of pepsin in the presence of sample alginates. Activity is 
shown as a percentage of control pepsin activity at three concentrations,    1.25mg/ml  2.5mg/ml,  
5mg/ml. All samples were tested in triplicate (n=3) with error bars showing standard deviation. 
 
Figure 35 demonstrates that alginate per se shows a dose dependent inhibition effect on 
pepsin activity. However, alginates have a high degree of structural and functional 
variation depending on their guluronic:mannuronic acid content and as such levels of 
pepsin inhibition varied between alginate biopolymer samples. As will be discussed 
later, this is related directly to the structure of the alginates.  
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Figure 36- Concentration dependent inhibition of pepsin in the presence of 4 examplar sample alginates. 
Activity is shown as a percentage of control pepsin activity at three concentrations,    1.25mg/ml  
2.5mg/ml,  5mg/ml. All samples were tested in triplicate (n=3) with error bars showing standard 
deviation. 
Figure 36 shows the data from 4 examplar alginates. A dose response effect can be seen 
in the inhibition of pepsin activity with the degree of inhibition of pepsin activity 
increasing with alginate concentration. H120L and FMC13 are alginates low in G-
residues (F[G]= 0.45 and 0.34 respectively) and high in M residues and show a higher 
degree of inhibition than SF/LF and FMC 3 which are high in G residues (F[G]= 0.66 
and 0.68 respectively) and low in M-residues.  
The distinct difference in level of pepsin inhibition and the relation to alginate structure 
is further demonstrated by comparing the 8 alginates provided by Technostics Ltd. 
These 8 brown seaweed alginates were extracted from two separate species of seaweed; 
four from High-G Lamanaria, and four from High-M Lessonia (Fig 5). Alginates from 
Low-G, High-M lessonia inhibited to a significantly higher degree than Low-M High G 
Lamanaria (Two-Way Anova, p<0.0001). The full catalogue of alginates was tested to 
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see if this was just a species effect, or if the negative correlation between F[G] and 
pepsin inhibition was present across the range of F[G].  
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Figure 37 – Comparison of pepsin inhibition levels between high-G Lamanaria alginate and high-
M Lessonia Alginate.  The boxplots show four High-G alginate samples from Lamanaria and four High-
M from lessonia. All samples were done with 6 repeats. The plot shows significantly higher inhibition 
levels with the Lessonia alginates. 
The full results for the eighteen alginate samples tested can be seen in Figure 38, full 
structural data for all samples can be found in Table 9. The strongest inhibitor at 
5mg/ml was H120L which has an F[G] of 0.45 and reduced pepsin activity to 53.9% 
(±9.5SD) of control activity. The weakest inhibitor at 5mg/ml was FMC3 which has an 
FG of 0.68 and reduced pepsin activity to 88.6% (±10.6%SD) of control activity.  
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Figure 38- Concentration dependent inhibition of pepsin in the presence of sample alginates. Activity is shown as a percentage of control pepsin activity at three 
concentrations of alginate,    1.25mg/ml  2.5mg/ml,  5mg/ml.. All samples were tested in triplicate (n=3) with error bars showing standard deviation.  
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All alginates showed significant inhibitory activity against pepsin at the highest 
concentration (5mg/ml), and all samples apart from FMC3 and FMC6 showed 
significant dose response effects. The effects were most apparent when comparing 
inhibition at 5 and 1.25mg/ml. 
Using the data from Figure 38 it was therefore possible to correlate percentage 
inhibition of pepsin activity against alginate F[G] and test the statistical significance 
using Spearman’s Rank Correlation.  
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Figure 39 – Correlation of alginate G-residue frequency (F[G]) and level of pepsin inhibition with 
5mg/ml alginate. Pepsin activity is shown as a percentage of control pepsin activity. The error bars show 
the standard deviation of 6 replicates (n=6). The line of best fit indicates a negative correlation which is 
significant with a Spearman r value of -0.7789 and a p value of 0.0001.  
A significant negative correlation between pepsin inhibition and alginate F[G]  was 
found at both 5mg/ml and 2.5mg/ml (Figure 39 & Figure 40). No significant correlation 
was found at 1.25mg/ml (Figure 41). This indicates that at both 5 and 2.5mg/ml, an 
increasing proportion of mannuronic acid residues, and decreasing proportion of 
guluronic acid residues yielded higher levels of pepsin inhibition.  No significant 
outliers were observed and all eighteen samples generally followed this trend. 
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The significant negative correlation between alginate mediated pepsin inhibition and 
F[G] was also observed at 2.5mg/ml alginate, with a Spearman correlation coefficient of 
-0.4878 with a p-value of 0.04 (Figure 40). Levels of pepsin inhibition were 
significantly lower at 2.5mg/ml alginate than at 5mg/ml, with the highest level of pepsin 
inhibition at 2.5mg/ml being just a 31.4% ±10.03 reduction in pepsin activity and the 
correlation between structure and inhibition was not as strong as at the higher 
concentration, but still significant (p=0.040).  
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Figure 40– Correlation of alginate G-residue frequency (F[G]) and level of pepsin inhibition with 
2.5mg/ml alginate. Pepsin activity is shown as a percentage of control pepsin activity. The error bars 
show the standard deviation of 6 replicates (n=6). The line of best fit indicates a negative correlation 
which is significant with a Spearman r value of -0.4878 and a p value of 0.04.  
At a 1.25mg/ml concentration of alginate, pepsin activity levels varied from a 14.5% 
(±10.2%) inhibition of pepsin activity to a 5.3% (±6.8%) increase in activity as shown 
in Figure 41. Furthermore, no significant correlation was observed at 1.25mg/ml of 
alginate between frequency of G-residues and pepsin inhibition (Figure 41).  
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Figure 41 – Correlation of alginate G-residue frequency (F[G]) and level of pepsin inhibition with 
1.25mg/ml alginate. Pepsin activity is shown as a percentage of control pepsin activity. The error bars 
show the standard deviation of 6 replicates (n=6). The line of best fit indicates a non significant negative 
trend with a Spearman r value of -0.3604 and a p value of 0.1417.  
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Figure 42 shows the plot for the Frequency of mannuronic acid residues against levels 
of pepsin inhibition at 5mg/ml alginate. Mannuronic and guluronic acid frequencies are 
inversely related to each other; as one increases, the other necessarily decreases and visa 
versa. There is a significant positive correlation between inhibition of pepsin and 
alginate F[M]. 
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Figure 42 – Correlation of alginate M-residue frequency (F[M]) and level of pepsin inhibition with 
5mg/ml alginate. Pepsin activity is shown as a percentage of control pepsin activity. The error bars show 
the standard deviation of 6 replicates (n=6). The line of best fit indicates a positive correlation which is 
significant with a Spearman r value of 0.7862 and a p value of 0.0001.  
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The structure and biophysical properties of alginates are not just dictated by F[G] and 
F[M] frequency, but also by the arrangement of contiguous blocks of M and G residues 
as discussed in the introduction. The full characteristics of the alginates are shown in 
Table 9, Section 2.5. 
All alginates tested have been well-characterised using 
13
C-NMR and therefore other 
biophysical properties could be correlated with pepsin inhibition. Levels of pepsin 
inhibition were compared against the frequency of the structural patterns; F[M], F[GG], 
F[MM], F[GGG], F[MGM] and F[GM/MG] and also against n(g>1), the G-Block 
length. Similar significant relationships between structure and inhibition were observed, 
where higher levels of mannuronic acid brought about significantly higher levels of 
pepsin inhibition.  
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Figure 43 – Correlation of alginate G-residue frequency (F[GG]) and level of pepsin inhibition with 
5mg/ml alginate. Pepsin activity is shown as a percentage of control pepsin activity. The error bars show 
the standard deviation of 6 replicates (n=6). The line of best fit indicates a negative correlation which is 
significant with a Spearman r value of -0.7816 and a p value of 0.0001.  
Figure 43 shows the correlation between pepsin inhibition and the frequency of adjacent 
guluronic acid residues in a diad. As can be seen contiguous GG blocks are significantly 
associated with a reduced capacity to inhibit pepsin. This relationship holds true also for 
GGG-Blocks, that is three adjacent guluronic acid residues. Again there is a negative 
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correlation between the presence of GGG blocks and inhibition of pepsin, as shown in 
Figure 44. 
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Figure 44 – Correlation of alginate GGG-residue frequency (F[GGG]) and level of pepsin inhibition with 
5mg/ml alginate. Pepsin activity is shown as a percentage of control pepsin activity. The error bars show 
the standard deviation of 6 replicates (n=6). The line of best fit indicates a negative correlation which is 
significant with a Spearman r value of -0.7996 and a p value of 0.0001.  
 
In fact, across all samples as the G-block length increases, there is a significant 
reduction in the  inhibition of pepsin, showing a negative correlation between inhibition 
and n(g>1).  
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Figure 45 – Correlation of alginate N(G>1) and level of pepsin inhibition with 5mg/ml alginate. 
Pepsin activity is shown as a percentage of control pepsin activity. The error bars show the standard 
deviation of 6 replicates (n=6). The line of best fit indicates a negative correlation which is significant 
with a Spearman r value of -0.7709 and a p value of 0.0002.  
 
Levels of pepsin inhibition were inversely correlated with a frequency of guluronic acid 
residues, therefore as might be expected, the fraction of MM blocks was positively 
correlated with levels of pepsin inhibition.  
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Figure 46 – Correlation of alginate MM-block frequency (F[MM]) and level of pepsin inhibition with 
5mg/ml alginate. Pepsin activity is shown as a percentage of control pepsin activity. The error bars show 
the standard deviation of 6 replicates (n=6). The line of best fit indicates a negative correlation which is 
significant with a Spearman r value of 0.7917 and a p value of 0.0001.  
 
However, the relationship is not so simple as to say a high M:G ratio is the sole 
determinant of inhibition levels, as shown in Figure 47 there is a strong positive 
correlation between the frequency of MGM blocks and pepsin inhibition levels. There is 
also a strong correlation between the frequency of MG/GM blocks with pepsin 
inhibition as shown in Figure 48. 
However when (F[MGG/GMM]) was correlated against levels of pepsin inhibition there 
was still a significant positive correlation, however the correlation was weaker. This 
suggests that as well as depending on an increasing frequency of M-residues being 
associated with pepsin inhibition, the distribution of the M-residues is important and 
that their positioning in disrupting continuous G-Blocks may be important to the 
inhibitory effect. This shall be considered further in the discussion.   
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Figure 47 – Correlation of alginate MGM-Block frequency (F[MGM]) and level of pepsin 
inhibition with 5mg/ml alginate. Pepsin activity is shown as a percentage of control pepsin activity. The 
error bars show the standard deviation of 6 replicates (n=6). The line of best fit indicates a negative 
correlation which is significant with a Spearman r value of 0.8219 and a p value of 0.0001.  
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Figure 48 – Correlation of alginate GM/MG-block frequency (F[GM/MG]) and level of pepsin 
inhibition with 5mg/ml alginate. Pepsin activity is shown as a percentage of control pepsin activity. The 
error bars show the standard deviation of 6 replicates (n=6). The line of best fit indicates a negative 
correlation which is significant with a Spearman r value of 0.7240 and a p value of 0.0007.  
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Figure 49 – Correlation of alginate MGG/GMM-residue frequency (F[MGG/GMM]) and level of 
pepsin inhibition with 5mg/ml alginate. Pepsin activity is shown as a percentage of control pepsin 
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activity. The error bars show the standard deviation of 6 replicates (n=6). The line of best fit indicates a 
negative correlation which is significant with a Spearman r value of 0.59 and a p value of 0.01.  
Significant but weaker correlations were shown between alginate and certain structural 
characteristics of alginate at 2.5mg/ml as summarised in Table 11. None of the 
characteristics showed significant correlation with pepsin inhibition at 1.25mg/ml 
alginate.  
Structural 
Characteristic 
5mg/ml 2.5mg/ml 1.25mg/ml 
Spearmans 
value 
P-value Spearmans 
value 
P-value Spearmans 
value 
P-value 
F(G) -0.779 0.0001 -0.488 0.0400 -0.360 0.1417 
F(M) 0.786 0.0001 0.499 0.0350 0.360 0.1428 
F(GG) 
 
-0.782 0.0001 -0.494 0.0374 -0.334 0.1762 
F(MG/GM) 
 
0.724 0.0007 0.314 0.2047 0.191 0.4488 
F(MM) 
 
0.792 0.0001 0.561 0.0154 0.398 0.1020 
F(MGG/GGM) 
 
0.589 0.0102 0.0807 0.7502 -0.060 0.8130 
F(MGM) 
 
0.822 0.0001 0.481 0.0432 0.220 0.3805 
F(GGG) 
 
-0.800 0.0001 -0.482 0.0426 -0.320 0.1951 
N (G>1) 
 
-0.771 0.0002 -0.327 0.1851 -0.195 0.4380 
 
Table 11 Summary of Correlations between alginate structural characteristics and alginate 
inhibition at three concentrations 5mg/ml, 2.5mg/ml and 1.25mg/ml.  Significant Negative 
Correlation,  Significant Positive Correlation,  No Correlation.   
 
Molecular weight data was only available for the eight alginates supplied by 
Technostics Ltd. Alginates can vary greatly in molecular weight and the Technostics 
alginates used in this study ranged from 34,700 – 387,000 Da. However no significant 
correlation between molecular weight and pepsin inhibition could be demonstrated as 
shown in Figure 50. 
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Figure 50  - Correlation of alginate molecular weight (MW) and level of pepsin inhibition with 
5mg/ml alginate. Pepsin activity is shown as a percentage of control pepsin activity. The error bars show 
the standard deviation of 6 replicates (n=6). No significant correlation was found with a Spearman r value 
of 0.19 and a p value of 0.66.  Lamanaria alginates are represented as □  and Lessonia alginate as ■. 
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3.6.2 Enzyme kinetics 
As well as testing the absolute regulatory effects of biopolymers on pepsin, the kinetics 
of enzyme substrate reactions in the presence of dietary fibres were also analysed. 
Samples were tested using a modified version of the 96-well plate N-terminal protocol 
as described in the methodology section. All biopolymers were tested a minimum of 5 
times. Kinetic constants were calculated from GraphPad Prism 4 software using 
substrate-velocity data. 
Enzyme kinetics can help provide an understanding of enzyme catalysed reactions and 
can provide important insights into the mechanisms of enzyme inhibition. The kinetics 
of an enzyme-substrate interaction alters with substrate concentration (or ratio of 
substrate to enzyme) and how extrinsic compounds interfere with this can give insight 
into their mechanism of action. This can be graphically represented by a Michaelis-
Menten plot. Velocity of reaction, measured as percentage change in absorbance per 
minute is plotted on the y-axis against substrate concentration on the x-axis. 
This plot can also provide useful information about the kinetics of an enzyme catalysed 
reaction. The maximum velocity of the reaction (Vmax), is the theoretical concentration 
of substrate at which all enzyme active sites are saturated with substrate and functioning 
at a maximal rate. This value can be determined from where the Michaelis-Menten 
curve plateaus, this levelling of reaction rate occurs due to substrate saturation. 
 The constant Vmax can be used to calculate the Michaelis Constant (Km), which is the 
substrate concentration required for half of maximal enzyme activity. As such the Km 
provides an important measure of the affinity of an enzyme for its substrate. A low Km 
means that less substrate is required to reach Vmax/2, substrate/enzyme affinity must 
therefore be higher as less substrate is required to fill active sites. Inversely a higher Km 
would indicate a lower affinity. 
Km and Vmax are therefore important and useful measures of enzyme activity. 
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Figure 51 below shows a typical Michaelis Menten plot for alginate inhibition of 
pepsin. In the control digestion, from 0-2.5mg/ml substrate, reaction velocity increases 
in a linear fashion, however as substrate concentration increases beyond 2.5mg/ml the 
plot begins to plateaux as the enzyme active site becomes saturated. As can be seen in 
Figure 51, when the alginate ‘FMC2’ is added to the reaction, the velocity of the 
reaction is reduced at all substrate concentrations, and the addition of FMC2 alginate 
causes a similar plateauxing effect, but at a lower velocity.  
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Figure 51 Michaelis-Menten plot for alginate sample FMC2 at 5mg/ml ( ) as compared to a 
pepsin control ( ). Substrate concentration [s] is given in mg/ml and the velocity is given as the rate of 
change in percentage absorbance per minute. The error bars show the standard deviation of at least 5 
replicates (n=5) 
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The kinetic data from the Michaelis Menten plots was transformed in to the double 
reciprocal plot shown in Figure 52. From this data the Km and Vmax of a control pepsin 
digestion were calculated using Graphpad Prism 4.0, and the apparent Km and Vmax of 
all biopolymer samples were calculated.  
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Figure 52 - Lineweaver-Burk plot for alginate sample FMC2 at 5mg/ml ( ) as compared to a 
pepsin control ( ). Substrate concentration [s] is given in mg/ml and the velocity is given as the rate of 
change in percentage absorbance per minute. The error bars show the standard deviation of at least 5 
replicates (n=5) 
It is important to note that while the kinetic data was calculated using statistical 
software, lines of best fit were done using linear regression. 
With FMC2 alginate in the reaction mixture, pepsin has a Vmax of 3.267%/min, a Km of 
5.47mg/ml. This is compared to a control pepsin digestion where the Km is 4.67mg/ml 
and the Vmax is 4.55%/min. So as can be seen both the maximum velocity of reaction at 
a theoretical infinite substrate concentration and the apparent Km, the affinity of enzyme 
for substrate are reduced by the addition of FMC2 biopolymer to the reaction mixture.  
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The kinetic data for all alginate samples analysed is collated below in Table 12, 
biopolymers have been listed in descending order of potency of pepsin inhibition based 
on Ki. 
From the Vmax and Km the inhibition constant Ki was calculated. The kinetic constants 
Km and Vmax provide useful indicators of the type of inhibition or activation. Using Vmax 
and Km it is possible to calculate the Ki or inhibition constant using the formula below. 
The gradient of the line on the double-reciprocal Lineweaver Burk plot can be 
calculated as the Michaelis Constant ( ) divided by the Maximum Velocity ( ). 
The relationship between these two slopes is determined by the Inhibitor Concentration 
[I] and Inhibitor Constant  as shown below: 
 
 
 
 
 
 
 
 
 
 
Ki therefore describes the relationship between the uninhibited and inhibited enzyme. 
Biopolymer FMC2 shown in Table 12 was ranked as 13th most effective inhibitor 
according to Ki out of 18 alginate polymers.  
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Table 12  Kinetic data for alginate inhibition of Pepsin. 
This kinetic data was correlated against alginate F[G], and is plotted in the figures 
below. Figure 53 shows the correlation between F[G] and apparent Km. A significant 
negative correlation was observed. This correlation suggests that with a decreasing 
frequency of guluronate the enzyme substrate affinity of pepsin for succinyl albumin 
substrate is decreased and more substrate is required to reach half of the maximal 
velocity.  
Rank 
 
F [G] 
Vmax 
(%/min) 
Apparent  Km 
(mg/ml) 
Ki 
 PEPSIN 
 
4.547 4.677 
 
1 SF60 0.411 8.051 48.02 1.042 
2 FMC13 0.32 10.08 57.19 1.1072 
3 LF10L 0.45 3.847 12.85 2.2248 
4 H120L 0.45 8.335 27.53 2.2613 
5 FMC12 0.32 6.097 19.09 2.4462 
6 FMC10 0.41 7.195 22.25 2.4919 
7 LFR560 0.633 5.185 14.5 2.909 
8 FMC6 0.53 5.373 13.69 3.385 
9 FMC4 0.49 5.962 12.32 4.9555 
10 LF120L 0.424 4.151 7.813 6.025 
11 FMC9 0.42 3.396 6.032 6.879 
12 FMC2 0.65 3.267 5.474 7.9495 
13 FMC5 0.55 3.02 2.949 9.618 
14 FMC7 0.69 3.855 5.924 10.12 
15 FMC3 0.68 3.227 4.847 10.863 
16 SF120 0.664 4.605 6.247 15.681 
17 SFLF 0.66 4.68 6.132 18.259 
18 SF200 0.68 4.34 5.117 34.186 
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Figure 53 - Correlation between apparent Km of alginate samples and G-residue frequency (F[G]). 
Apparent Km was calculated with Michaelis-Menten Analysis. A negative correlation between apparent 
Km and F[G] was shown with a Spearmans r value of -0.7603 with a p-value of 0.0002.  
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A similar negative correlation was observed between F[G] and Vmax whereby the 
maximal reaction velocity of the reaction tended to increase in the presence of alginates 
with decreased guluronic acid residue frequency. A significant negative correlation 
between alginate F[G] and Vmax was seen.  
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Figure 54 - Correlation between apparent Vmax of alginate samples and G-residue frequency 
(F[G]). Vmax was calculated by Michaelis-Menten analysis. A negative correlation between Vmax and F[G] 
was shown with a Spearmans r value of -0.5940 with a p-value of 0.0093. 
The implication of this correlation is that an increasing frequency of mannuronate 
correlates with an increase in theoretical maximum velocity at an infinite substrate 
concentration. This is counter-intuitive considering that all the other data suggest 
alginates to have an inhibitory effect on the reaction. This will be considered further in 
the discussion.  
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The apparent kinetic constants Km and Vmax were used to calculate the inhibitor constant 
Ki. Ki, is the dissasociation constant of the enzyme-inhibitor complex and therefore the 
reciprocal of the enzyme-inhibitor binding affinity. In the case of uncompetitive and 
non-competetive inhibition, the Ki bears a strong relationship to the IC50 value, the 
amount of inhibitor required to cause 50% inhibition. This is not the case for 
competitive inhibition, however the Ki can be used to indicate how potent an inhibitor is 
[182]. 
This data reiterated the correlation between potency of inhibition and F[G] frequency 
with higher frequency of mannuronic acid and lower frequency of guluronic acid being 
associated with a lower Ki. This relationship was positive and statistically significant 
with Spearmans r value of 0.8130 with a p-value of 0.0001. 
One value has been starred ‘*’ in Figure 55 below as this appears as though it may be an 
outlier. However as can be seen from Figure 56, even with this possible outlier removed 
the correlation holds true with a p value of 0.003 and a Spearmans r value of 0.7951. 
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Figure 55 - Correlation between Ki of alginate samples and G-residue frequency (F[G]). Vmax was 
calculated by Michaelis-Menten analysis. A positive correlation between Ki and F[G] was shown with a 
Spearmans r value of 0.8130 with a p-value of 0.0001. 
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Figure 56 Correlation between Ki of alginate samples and G-residue frequency (F[G]). Vmax was 
calculated by Michaelis-Menten analysis. A positive correlation between Ki and F[G] was shown with a 
Spearmans r value of 0.7951 with a p-value of 0.003.  
* 
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Lineweaver Burk plots are a useful way of visualising types of enzyme inhibition, and 
four types of inhibition can be discerned from a Lineweaver Burk plot; competitive, 
non-competetive, uncompetitive and mixed inhibition. By comparing the derived 
apparent kinetic constants to the control substrate digestion, the biopolymer samples 
were fitted to different models of inhibition. The 95% Confidence intervals of the 
derived values were used and compared to the kinetic constraints of pepsin in an control 
reaction. 
The modelled data is shown in Table 13 below. The substrate control kinetic constants 
were compared to the apparent Km and Vmax values derived for each biopolymer. If these 
values lay without the 95% confidence interval, they were said to be different, and were 
fitted to an inhibition model.  
Sample 
 
Inhibition 
Model 
Apparent Kinetic 
Constants 
95% Confidence Intervals 
Vmax 
(%/min) 
Km 
(mg/ml) 
Vmax 
(%/min) 
Km 
(mg/ml) 
PEPSIN  4.547 4.677 4.233 to 4.862 3.811 to 5.543 
FMC 2 
Non-competitive 
reversible inhibition 
3.267 5.474 2.548 to 3.985 2.467 to 8.481 
FMC3 3.227 4.847 2.561 to 3.894 2.258 to 7.436 
FMC9 3.396 6.032 2.606 to 4.185 2.813 to 9.251 
FMC6 
Reversible 
competetive 
inhibition 
5.373 13.69 3.951 to 6.794 7.384 to 20.00 
FMC12 6.097 19.09 3.890 to 8.304 8.281 to 29.90 
FMC13 10.08 57.19 -2.921 to 23.09 -31.44 to 145.8 
LF10L 3.847 12.85 3.201 to 4.493 9.004 to 16.70 
H120L 8.335 27.53 3.946 to 12.72 7.165 to 47.89 
SF60 8.051 48.02 -0.002672 to 16.10 -11.44 to 107.5 
LFR560 5.185 14.5 4.406 to 5.964 10.79 to 18.20 
FMC10 
Does not fit to a 
model 
 
7.195 22.25 3.272 to 11.12 4.222 to 40.28 
LF120L 4.151 7.813 3.245 to 5.057 4.156 to 11.47 
SF120 4.605 6.247 3.964 to 5.245 4.180 to 8.313 
SF/LF 4.68 6.132 3.962 to 5.398 3.839 to 8.426 
SF200 4.34 5.117 3.970 to 4.709 3.968 to 6.266 
FMC4 5.962 12.32 3.245 to 8.679 2.026 to 22.62 
FMC7 3.855 5.924 3.287 to 4.422 3.908 to 7.939 
Table 13 Kinetic data of alginate inhibition of pepsin fitted to inhibition models at 5mg/ml. 
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Biopolymers FMC2, FMC 3 and FMC9 fit with the model of non competitive reversible 
inhibition. In Non-competitive reversible inhibition, the inhibitor binds the enzyme at a 
point other than the active site, either when the enzyme is free or in complex with the 
substrate. While the rate of enzyme-substrate formation and disassociation are affected 
by the inhibitor, association and disassociation are affected by the same amount, 
therefore the  remains unaltered and the x-intercept of the biopolymer sample will be 
the same as that of the control. Vmax is reduced as the presence of inhibitor blocks 
product formation. 
 
 
 
FMC 2 was shown previously in Figure 51 and Figure 52. The Michaelis Menten plot 
for FMC3 is shown in Figure 57 and the Lineweaver Burk plot in Figure 58. 
It is important to note that modelling was done on the basis of the 95% confidence 
intervals of apparent kinetic values and how they correlated to control values, rather 
than visually analysing the intercepts. So although in the Lineweaver burke plot for 
FMC 2, the x-intercepts may appear different, they were not significantly different 
based on the 95% confidence intervals.  
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Figure 57  Michaelis-Menten plot for alginate sample FMC3 at 5mg/ml ( ) as compared to a 
pepsin control ( ). Substrate concentration [s] is given in mg/ml and the velocity as the rate of change in 
percentage absorbance per minute. The error bars show the standard deviation of at least 5 replicates 
(n=5) 
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Figure 58  - Lineweaver-Burk plot for alginate sample FMC3 at 5mg/ml (  ) as compared to a 
pepsin control (  ). Substrate concentration [s] is given in mg/ml and the velocity as the rate of change in 
percentage absorbance per minute. The error bars show the standard deviation of at least 5 replicates 
(n=5) 
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A number of biopolymers fit with a model of competitive inhibition, these were; FMC6, 
FMC12, FMC13, LF10L, H120L, SF60, LFR560. Competitive Inhibition occurs when 
an inhibitor [I] directly competes for the active site and combines with the enzyme, 
blocking substrate binding to the active site. This causes an increase in Km, but as the 
competition can be overcome by increasing substrate concentration, the Vmax remains 
unaffected. As Vmax remains unaffected, the Y-intercept which is equal to 1/Vmax for the 
biopolymer will be the same as that of the control. This is why this method of inhibition 
is referred to as competitive, and as the binding is reversible, the inhibitor will 
dissociate from the enzyme, and all substrate will eventually be converted. 
 
 
 
FMC12 is shown in Figure 59 and Figure 60 as a typical example of competitive 
inhibition. As can be seen the Y-intercepts of both regression lines intersect as the Vmax 
is unaffected, but the Km is increased so the X-intercepts differ.  
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Figure 59 - Michaelis-Menten plot for alginate sample FMC12 at 5mg/ml ( ) as compared to a 
pepsin control ( ). Substrate concentration [s] is given in mg/ml and the velocity as the rate of change in 
percentage absorbance per minute. The error bars show the standard deviation of at least 5 replicates 
(n=5) 
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Figure 60 - Lineweaver-Burk plot for alginate sample FMC12 at 5mg/ml ( ) as compared to a 
pepsin control ( ). Substrate concentration [s] is given in mg/ml and the velocity as the rate of change in 
percentage absorbance per minute. The error bars show the standard deviation of at least 5 replicates 
(n=5) 
 
Alginates FMC10, LF120L, SF120, SF/LF, SF200, FMC4 and FMC7 could not be 
fitted to any of the inhibition models. While these inhibitory effects do not fit exactly to 
a model of inhibition, Table 14 below shows the closest-fit models of inhibition based 
on their lineweaver burke plots.  
The michaelis-menten and Lineweaver Burke plots for LF120L are shown in Figure 61 
and Figure 62, and as can be seen from Table 14, LF120L is closest to the model of 
competitive inhibition. As seen in Figure 62, the Y-intercept is unaltered in the presence 
of the inhibitor, showing that the Vmax is not affected, however the X-intercept is 
affected by the presence of inhibitor suggesting that the binding affinity (Km) is 
reduced.  
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Sample 
 
Closest fit Inhibition 
Model 
Apparent Kinetic 
Constants 
95% Confidence Intervals 
Vmax 
(%/min) 
Km 
(mg/ml) 
Vmax 
(%/min) 
Km 
(mg/ml) 
PEPSIN 
 
4.547 4.677 
4.233 to 
4.862 
3.811 to 
5.543 
FMC10 
Non-competetive 
reversible inhibition 
7.195 22.25 
3.272 to 
11.12 
4.222 to 
40.28 
LF120L 
Reversible Competetive 
Inhibition 
4.151 7.813 
3.245 to 
5.057 
4.156 to 
11.47 
SF120 
Reversible Competetive 
Inhibition 
4.605 6.247 
3.964 to 
5.245 
4.180 to 
8.313 
SF/LF Mixed Inhibition 4.68 6.132 
3.962 to 
5.398 
3.839 to 
8.426 
SF200 
Reversible 
Competetive/Mixed 
Inhibition 
4.34 5.117 
3.970 to 
4.709 
3.968 to 
6.266 
FMC4 Mixed Inhibition 5.962 12.32 
3.245 to 
8.679 
2.026 to 
22.62 
FMC7 
Non-competetive 
reversible inhibition 
3.855 5.924 
3.287 to 
4.422 
3.908 to 
7.939 
 
Table 14 Closest fit inhibition models for remaining alginate samples at 5mg/ml. 
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Figure 61 - Michaelis-Menten plot for alginate sample LF120L  at 5mg/ml ( ) as compared to a 
pepsin control ( ). Substrate concentration [s] is given in mg/ml and the velocity is given as the rate of 
change in percentage absorbance per minute. The error bars show the standard deviation of at least 5 
replicates (n=5) 
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Figure 62 - Lineweaver-Burk plot for alginate sample LF120L at 5mg/ml ( ) as compared to a 
pepsin control (  ). Substrate concentration [s] is given in mg/ml and the velocity is given as the rate of 
change in percentage absorbance per minute. The error bars show the standard deviation of at least 5 
replicates (n=5) 
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3.7 Discussion 
 
A modified N-Terminal (TNBS) assay of proteolytic activity was used to quantify 
inhibition with alginates. Trinitrophenylated protein turns yellow-orange in colour and 
can be measured at the wavelength 340nm, the increase in absorbance is directly 
proportional to the number of N-terminals formed (i.e. peptide bonds cleaved) during 
proteolysis. This method was used to quantify the modulatory effects of alginates on 
pepsin activity.  
Some modifications had to be made to the original methodology. Alginates are acidic 
molecules with pKa’s ranging from 3.38 to 3.65 and in aqueous solution will have a pH 
ranging from 5.75 to 7.25 at 4mg/ml [169]. It was observed that during the testing of  
aqueous alginates as described by the method of Strugala et al 2005, the pH of the 
reaction mixture is raised by 0.2 units of pH from 2.2 to 2.4 [7]. While only a small 
change in pH, this shift away from the optimum pH was shown to have a significant 
effect on the activity of pepsin. The methodology was therefore adapted such that all 
components of the assay were made up in 0.05M phosphate buffer at pH2.2, to ensure 
that any inhibitory effects observed were not due merely to a pH effect.  
Buffering of the system did result in reduced levels of inhibition detected, this suggests 
that at least some of the inhibition of pepsin observed by Strugala et al was the result of 
an alginate induced shift in pH away from the optimum of pepsin. However with all 
alginates that were tested, significant levels of inhibition were still detected with the 
buffered system.  
The methodology was further adapted by scaling down the assay to run on a 96-well 
microplate. This was done in order to increase the throughput capability of the assay 
and reduce any error which may have arisen due to delayed pippeting between wells. 
The original Lin et al 1969, method could not be done using a multi-pipette and 
required individual spectrophotometric measurements, this introduced slight but 
potentially significant time delays between samples [168]. Modification of the 
methodology to a 96 well microplate allowed spectrophotometric measurements to be 
done in one reading and a multipipette coud be used for adition of substrates.  
Each of the catalogue of eighteen alginates was tested in this assay and compared to a 
Pepsin control which contained buffer only instead of sample, but was in every other 
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way identical. All alginates tested showed the ability to inhibit pepsin at 5mg/ml 
(1.36mg/ml in reaction mixture). The strongest inhibitor at 5mg/ml was the High-M 
alginate H120L. 
Using the original Lin et al methodology, Strugala et al had shown that there was a link 
between alginate structural composition and levels of inhibition [7, 168]. Alginates high 
in mannuronic acid residues were shown to inhibit pepsin activity more strongly than 
those high in G-residues. The data presented herein supports this conclusion.  
Not all alginates inhibit pepsin activity to the same degree, and as shown in Figure 37 
alginates from the Lessonia species of brown seaweed inhibited pepsin activity more 
potently than Lamanaria alginates. Alginates from Lessonia are high in M-residues with 
F[M] ranging from 0.411 to 0.45 and Lamanaria alginates are high in G-residues, with 
F[M] ranging from 0.322 to 0.367. The four alginates from Lessonia seaweed caused 
significantly higher levels of inhibition than those derived from Lamanaria. This 
suggested a correlation between alginate structure and inhibition, however to ensure that 
this was not a species-effect, further alginates across the range of F[G] were tested.  
A catalogue of eighteen alginates with a range of structural characteristics from high 
F[G] to high F[M] were tested in the modified N-terminal assay. The results showed a 
strong positive correlation between alginate F[M] and levels of pepsin inhibition with 
alginate at 5mg/ml. These results support the conclusion of Strugala et al 2005 that 
levels of pepsin inhibition are associated with alginates high in M-residues [7].  
As the frequency of M-residues increases, the frequency of G-residues decreases and 
visa-versa. Therefore increasing levels of G-residues correlate with decreased levels of 
pepsin inhibition. The same pattern of correlation persists with F[GG] and F[GGG]. The 
frequency of contiguous guluronic-acid diads and triads was negatively correlated with 
Pepsin inhibition. Furthermore the average length of G-Blocks [n(g>1)] was also 
negatively correlated with pepsin inhibition. This suggests that an increasing proportion 
of contiguous G-Blocks is disruptive to the inhibitory effect of the alginates.  
The hypothesis that increasing M-residues increases the potency of pepsin inhinition is 
supported by the data, however the relationship may not be as simple as to say levels of 
pepsin inhibition are solely determined by the M:G ratio. Patterns of structure-function 
relationship were apparent when looking at further structural characteristics of the 
alginates.  
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While the frequency M residues and contiguous M-Residue diads correlated with 
inhibition of pepsin, so too did mixed blocks of M and G. Increased F[GM/MG], 
F[MGM] and F[MGG/GGM] were positively correlated with increased levels of pepsin 
inhibition. It is therefore possible that while F[M] correlates with increased levels of 
pepsin inhibition is due to the disruption of gel forming contiguous G-Blocks. 
Heteropolymeric regions form flexible gels, are not as stable as G-rich gels. The 
potential importance of flexible gel structure to pepsin inhibition will be discussed 
further. 
From selected kinetic analysis, alginates FMC6, FMC12, FMC13, LF10L, H120L, 
SF60 and LFR560 fit with a model of competitive inhibition. Competitive inhibition 
occurs when an inhibitor [I] directly competes for the active site and combines with the 
enzyme, blocking substrate binding to the active site.  
By looking at other competitive inhibitors of pepsin activity, it is possible to get an idea 
of how alginate may competitively inhibit pepsin activity by binding to the active site. 
Pepstatin is a linear peptide inhibitor of aspartic proteases including pepsin [183]. It is a 
competitive pepsin inhibitor which blocks the active site by forming a network of 
hydrogen bonds and charge-charge interactions with active-site residues. The potential 
hydrogen bonding between pepsin and the inhibitor pepstatin are shown in Figure 63 
below, and a number of charge-charge interactions are formed between the sidechains 
of the pepstatin residues and the pepsin molecule. The strongly bound inhibitor 
complexes with the enzyme and prevents substrate binding [184].  
 
Figure 63  Stylized representation of potential hydrogen bonding between pepsin and pepstatin. 
Taken from Fujinaga et al 1995 [184]. 
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Alginates are composed of mannuronic and guluronic acid residues rich in hydroxyl 
groups which would be capable of forming hydrogen bond interactions with these same 
active site residues. Furthermore the C=O group of the carboxyl group of the alginate 
residue is polarised; the oxygen attracts electrons more strongly than the carbon, making 
it δ- and the carbon δ+. This polarisation means that the C=O of the carboxyl group is 
able to participate in hydrogen bonding, and to a lesser extent form charge-charge 
interactions with positively charged amino acids of the pepsin molecule.   
Similarly to pepstatin, alginate may affect pepsin activity by occupying the active site 
and forming a network of charge-charge interactions and hydrogen bonds to stabilise the 
interaction and therefore block substrate binding. This may also provide an explanation 
as to why High-M alginates tend to inhibit to a higher degree than High-G alginates. 
The increased chain flexibility with High-M alginates will cause the polymer chain to 
be more supple and able to adapt its shape to fit the active site of pepsin. The freer 
movement around the glycosydic bonds may therefore mean that High-M alginates are 
more capable of mirroring the structure of the protein molecules and forming a more 
stable interaction by bonding throughout the active site, whereas the rigidity of High-G 
alginates prevents them from doing so.  
Other pepsin inhibitors operate by different mechanisms. As discussed, the assay system 
was validated using pentosan polysulphate (SP54) as a positive inhibition control. 
Pentosan polysulphate is a highly sulphated oligosaccharide shown to inhibit pepsin 
activity [179, 181] Sulphated polysaccharides have been shown to have anti-peptic 
effects, inhibiting the activity of pepsin in vitro and reducing peptic ulceration in vivo in 
rats and guinea-pigs [179, 185, 186]. The maximum inhibition with pentosan 
polysulphate at 5mg/ml was 75.1%.  
Interactions between proteins and carbohydrates are common in biology, and are also 
widely reported in vitro, as reviewed in Dickinson et al 1998 [56]. SP54 and other 
highly sulphated polysaccharides such as heparin are known to inhibit pepsin activity 
[179, 180]. Heparin sulphate is a ubiquitous glygosaminoglycan well known for 
regulating proteolytic enzymes. Heparin is composed of repeating disaccharide 
subunits; composed of either D-glucuronic acid or L-iduronic acid, and D-glucosamine 
with N- and 6-O-sulphates and N-acetyl substitutions [187]. It is known to bind a wide 
range of proteins and is implicated as a regulator in hemostasis, inflammation, 
angiogenesism, cell adhesion and other biological processes. Furthermore heparin is 
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known to regulate the activity of proteolytic enzymes, both inhibitory and activatory 
effects have been observed [188, 189].  Heparin is an essential activator for several 
zymogens involved in the coagulation cascade [190]. It has been suggested that 
glycosaminoglycans exert their affect on proteolytic enzymes by inducing 
conformational changes to effect substrate binding, change catalytic activity, protect 
from pH inactivation or by exposing or masking the active site [191-193].  
As well as enzyme-binding, carbohydrates have also been observed to be capable of a 
more general protein binding, raising the possibility of inhibitor-substrate interactions 
being involved in enzyme inhibition. Interactions between casein and carrageenans have 
been observed. This interaction is due to electrostatic interactions forming between the 
sulphate groups of the carrageenan and positively charged regions of the casein polymer 
[194, 195]. Hatzmann et al describe how as the pH is lowered and a protein is taken 
below its iso-electric point, it results in a loss of negative charges and formation of 
positive charges. The positively charged protein can then form interactions with 
negative charges on the carbohydrate and carbohydrate-protein complexes form, leading 
to gelation [196].  
Likewise, alginate is a negatively charged polymer, and as such would be capable of 
forming electrostatic interactions with proteins that have become positively charged 
after being taken below their pKa [197]. Alginate may associate with protein through 
hydrogen bonding at hydroxyl groups; charge-charge interactions with δ- carboxyl 
groups, and the negatively charged COO- group of the alginate, although this group 
would become protonated at low pH.  As with the carrageenan-casein interactions, these 
reactions would be sensitive to structure, pH, concentration and levels of counterions. 
This also provides a clue as to why high-M alginates tend to be better inhibitors of 
pepsin activity than high-G alginates.  
The characteristics of the alginate are dictated by the frequency and arrangement of 
blocks of guluronic and mannuronic acid. These residues can form G-rich, M rich, or 
MG rich blocks which determine the gelling properties of alginate in solution. G-rich 
blocks form relatively stiff blocks as there is limited rotation around the glycosidic 
bond. The presence of mannuronic acid residues increases chain flexibility with M 
blocks and MG blocks forming relatively flexible chains because of freer rotation 
around the glycosidic bonds. As discussed in the introduction, alginates form ionic gels 
by binding cations and by the formation of interchain associations between fibres. 
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Homopolymeric regions (M or G blocks) better support the formation of junction zones 
between adjacent polmers and therefore increase viscosity in solution, with G-Blocks 
forming the most stable gels.  The affinity of an alginate for cations increases with G 
content as G-blocks have a greatly increased selectivity for divalent cations. Alternating 
blocks (MG blocks) increase the flexibility of the polysaccharide chain and therefore 
decrease alginate gel viscosity. 
High-G alginates form stiff gels with rigid polymer chains at low pH and strongly bind 
divalent cations. Cations are strongly bound between adjacent alginate chains in the 
folded-ribbon “egg-box model” as described in the introduction, forming strong 
interchain associations. High-M alginates on the other hand form much weaker gels, 
with more flexible alginate chains. The binding of cations would compete for negatively 
charged COO- groups on the alginate chain, and the stronger these interactions are, the 
less likely these COO- groups will be free to interact with free protein substrate. 
Furthermore with stronger  alginate interchain associations, a strong gel will be formed 
of tightly bound alginate which will not be free to interact with protein substrate. 
Increased chain flexibility with High-M alginates will also allow the polymer chain to 
be more supple and have freer movement around its glycosydic bonds, and therefore be 
more capable of mirroring the structure of the protein molecules it is interacting with. 
Sunderland had suggested a link between molecular weight and levels of Pepsin 
inhibition [57]. The results of Strugala et al did not support this finding, and could not 
show any correlation between MW and levels of inhibition [7]. While data on molecular 
weight was only available for eight of the eighteen alginates tested, no correlation 
between molecular weight and inhibition was shown in this study.  
The eighteen alginates tested in the higher-throughput micro-plate assays were tested 
again using a kinetic assay of pepsin activity. The kinetic assay used was a modification 
of the pepsin N-terminal assay. Alginate at 4mg/ml was tested against pepsin at a range 
of substrate concentrations (0-15mg/ml). The purpose of enzyme kinetics is to 
determine the point at which enzyme activity becomes independent of substrate 
concentration in order to determine enzyme-substrate affinity and the maximum 
reaction velocity. All tested samples were compared to a pepsin control. 
The alginates causing inhibition of pepsin were fitted to theoretical models of pepsin 
inhibition which were, competitive, non-competitive, uncompetitive or mixed 
inhibition. Those that could fitted statistically to a model of inhibition fell in to two 
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categories; Non-competitive inhibition and competitive inhibition (Table 13). Seven of 
the sample alginates could not be fitted to a model, but were compared to the closest 
model of inhibition in Table 14. 
Alginates FMC6, FMC12, FMC13, LF10L, H120L, SF60 and LFR560 fit with a model 
of competitive inhibition, and competitive inhibition was the closest fit model for 
LF120L and SF120. Three of the tested alginates fitted a model of non-competetive 
inhibition; FMC2, FMC3 and FMC9 and it was the closest fit model for FMC7 and 
FMC10. Mixed inhibition was the closest fit model for SF/LF, SF200 and FMC4.  
As has been discussed already, there are a number of possible inhibition mechanisms by 
which alginate may reduce pepsin activity, these include; a competitive alginate-pepsin 
interaction where alginate competes with substrate for the active site; a non-competetive 
alginate-pepsin interaction where alginate binds to the enzyme somewhere other than 
the active site and modifies enzyme activity; or by a direct substrate binding. The fact 
that all of the alginates did not fit to one single model of inhibition suggests that more 
than one of these single mechanisms of inhibition may be acting in concert to produce 
the inhibition effects.  
Competitive Inhibition occurs when an inhibitor [I] directly competes for the active site 
and combines with the enzyme, blocking substrate binding to the active site as is the 
mechanism with Pepstatin. As discussed, alginate may function in a similar way and 
occupy the binding site, stabilised by hydrogen bonding and charge-charge interactions. 
However, this is not the only scenario which could produce an inhibition profile for that 
of competitive binding. If alginate were directly binding the protein substrate, similar to 
the manner seen with carrageenan and milk-protein, then an inhibition profile would be 
produced where the Vmax remained unaltered, but the enzyme-substrate affinity 
appeared to be reduced. By binding to protein substrate and removing it from the 
reaction solution, the reaction velocity at low substrate concentration would be reduced. 
This would occur because although there is an apparent net concentration of substrate in 
the reaction solution, a certain proportion of this substrate is bound to alginate and 
therefore not free to interact with the enzyme. However with increasing substrate 
concentrations, this effect is overcome and as the concentration tends towards an 
‘infinite’ concentration, the binding effect will therefore be diluted into insignificance 
and the normal maximum velocity will be reached.  
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Not all of the alginates however fitted the model of competitive inhibition. FMC2, 
FMC3 and FMC9 fit the model of non-competitive reversible inhibition, and this model 
was the closest fit model for FMC7 and FMC10. Non-Competitive Reversible inhibition 
occurs when the inhibitor binds the enzyme at a point other than the active site, either 
when the enzyme is free or in complex and does not affect substrate binding. As 
substrate binding and dissociation is unaffected the  will be unaltered as [ES] 
complex formation and dissociation will be unhindered. The inhibitor causes its effect 
by impeding or blocking substrate formation and   will therefore be reduced. 
The mechanism of non-competitive reversible inhibition may be similar to what can be 
seen with certain types of heparin sulphate inhibition whereby binding of inhibitor 
causes conformational changes to the enzyme which impedes or blocks product 
formation. With non-competitive reversible inhibition, the Km is unchanged, as ES 
association and disassociation are affected in equal proportions, Vmax however is 
reduced, because the inhibitory effect cannot be out competed by increasing substrate 
concentration.  
The idea of a direct inhibitory interaction between alginate and pepsin was also argued 
by Sunderland et al who showed in an alginate-pepsin centrifugation experiment that 
pepsin was pulled out of the supernatent by alginate upon centrifugation [57]. This 
suggested direct binding of pepsin as a possible mechanism of inhibition.  
The inhibition of lipase with pectin provides an example of how alginate may inhibit 
pepsin activity directly. Carboxyl groups have been shown to be important in enzyme 
inhibition, as in the case of pectin and lipase. The carboxyl groups of pectin are believed 
to be involved in the protanation of active site serine residue of the lipase enzyme. The 
catalytic mechanism of lipase is based on a charge relay system between the residues of 
the catalytic serine-histidine-apartic-acid triad, and protonation of the hydroxyl group of 
serine blocks the initiation of this charge relay system, thereby inactivating the enzyme 
[5]. The importance of carboxyl groups to pectin inhibition of lipase has been shown as 
increasing levels of methyl esterification are correlated with reduced lipase inhibition. 
As it is the carboxyl group that becomes esterified, an increase in methyl esterification 
necessarily means a decrease in the number of carboxyl groups.  
Similar to pectins, alginates are rich in carboxylic acid groups. As seen in Figure 6, each 
monosaccharide residue of alginate contains a carboxyl groups which would become 
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protonated at low pH forming carboxylic acid. These carboxylic acid groups are 
involved in the hydrogen bonding network which forms as alginate interact to form an 
acid gel at low pH. It is therefore possible that a similar interaction occurs between the 
carboxylic acid groups of alginate and active site residues of pepsin as occurs with 
pectin and lipase. It is possible that similar interactions may form with the active site 
Asp32 residue of pepsin, disrupting the acid-base pair of Asp32-Asp215, and thereby 
preventing nucleophilic attack on the peptide bond. As the pH is taken below the pKa of 
the alginate, COO- groups will become increasingly protonated, however there will still 
be a mix of COO- and COOH groups, with the proportion of COOH increasing at lower 
pH. The COOH groups may participate in hydrogen bonding with the negatively 
charged active site Asp residues. Aalternatively the COO- groups would disrupt the 
charge relay system of the catalytic mechanism by the presence of a large negative 
charge which could disrupt nucleophilic attack by attracting the nucleophillic H+, or 
attracting H2O preventing regeneration of the catalytic nucleophile.  
While direct interactions between alginate and pepsin may be a possible mechanism of 
inhibition, data presented in the next chapter supports the theory that there is a more 
general protein binding interaction which may affect enzyme activity through substrate 
binding as well binding directly to the enzyme. 
The interaction of these two mechanisms; substrate binding and enzyme binding, may 
explain why the kinetic data fit to more than one model of inhibition, and that in some 
cases, mixed inhibition was the closest model.  
A significant negative correlation between Km and alginate F[G] was observed. This 
correlation suggests that with an increasing frequency of Mannuronate the enzyme 
substrate affinity of pepsin for succinyl albumin substrate is decreased and more 
substrate is required to reach half of the maximal velocity than with the uninhibited 
enzyme. 
 A similar negative correlation was observed between F[G] and Vmax whereby the 
maximal reaction velocity of the reaction tended to increase the presence of alginates 
with increased mannuronic acid residue frequency. 
This may seem counter intuitive, that the trend is for the better inhibitors to be 
associated with a higher Vmax. However a possible explanation for this is that there are 
two mechanisms at work, firstly an inhibitory mechanism that reduces enzyme activity 
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at lower substrate concentrations which can be overcome by increasing substrate 
concentration.  At higher substrate concentrations, the inhibitor is out competed and 
does not inhibit enzyme activity. This provides an explanation of how the inhibitory 
effect is lost at high substrate concentrations, but there is necessarily a second 
mechanism resulting in an increase in Vmax at high substrate concentrations. This could 
be a number of mechanisms including the presence of alginate reducing the volume of 
the reaction mixture causing it to occur at a faster rate.  
The apparent kinetic constants Km and Vmax were used to calculate the inhibitor constant 
Ki. Ki, the inhibition constant is the amount of inhibitor theoretically required to halve 
the Vmax and therefore indicates how potent an inhibitor is. Despite this unexpected 
relationship between the structural characteristics and Vmax, there was astill a strong 
positive correlation between alginate F[M] and Ki. Reiterating the correlation between 
potency of inhibition and the presence of mannuronic acid residues.  
The current data confirmed the observations of Strugala et al that lengths of G-Blocks 
(F[G], F[GG], F[GGG] and ]N(G>1)]) were associated with reduced inhibition. Higher 
mannuronic acid F[M], and  alternating alginate structure F[GM/MG] and F[MGM] 
were all positively correlated with pepsin inhibition. Strugala et al suggested that the 
increased inhibition levels observed with these alginates may either be due to a specific 
interaction between alternating sequences of alginate and pepsin, or due to the physical 
properties of these alginates favouring acid solubility. It was shown by Smidsrod and 
Draget that alternating seguences of M and G residues conferred on alginates good acid 
solubility and chain flexibility [198]. It was suggested by Strugala et al that these 
physical properties may lead to a prolonged exposure of pepsin to these alginates and 
increase the probability of inhibitory interactions occurring.  
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Chapter 4 
Modulation of Trypsin Activity 
4.1 Introduction 
After gastric digestion, the digesta is passed into the small intestine. In the duodenum 
the acidic chyme is neutralised upon mixing with the pancreatic juices which are rich in 
bicarbonate (secreted by duct cells). The pancreas secretes a range of proteolytic, 
amylolytic and lipolytic digestive enzymes as shown in Table 3 in Section 1.7. 
Although digestion is well underway by the time food reaches the small intestine, the 
majority of food is digested by pancreatic enzymes which are secreted into the 
pancreatic duct by acinar cells of the exocrine pancreas [85].  Before the pancreatic 
juices are released into the duodenum through the sphincter of Oddi, they are mixed 
with bile in the ampulla of Vater, where the pancreatic duct and common bile duct 
merge [86].   
As discussed in Section 1.7.3, protein digestion is completed in the small intestine in 
three phases; 1) luminal protein digestion 2) brush border membrane digestion and 3) 
Cytoplasmic assimilation of polypeptides. Proteolytic enzymes (Table 15) are secreted 
from the pancreas into the small intestine as zymogens and activated during the 
proteolytic enzyme cascade which also causes the activation of pancreatic lipase and 
colipase.  
4.2 Pancreatic Proteolysis 
A reported 2% of the human genome codes for proteolytic enzymes or protease 
inhibitors. This fraction of the genome is collectively referred to as the degradome and 
is comprised of ‘561 protease and protease-related genes and more than 156 protease 
inhibitor genes’ [199].   
The pancreatic proteases can be divided into two groups; the endopeptidases and the 
exopeptidases (Table 15). The endopeptidases trypsin, elastase and chymotrypsin are 
serine proteases that cleave interior peptide bonds. The carboxypeptidases are zinc-
containing metallopeptidases with exopeptidase activity and cleave single amino acids 
from the carboxyl terminal of polypeptides [200]. 
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Proteases are a broad category of enzymes which cleave peptides via a range of 
mechanisms by which they are categorised; proteases are classified as aspartic-, 
cysteine-, serine-, threonine-proteases and metallo-proteases [199]. Of these, serine 
proteases are the most abundant, making up over one third of all known proteases [200, 
201] 
Enzyme Family Enzyme Favoured Site of Activity 
Serine proteases 
(endopeptidases) 
Trypsin 
cleaves on the carboxyl side of basic 
amino acids (Arg, Lys) 
chymotrypsin 
aromatic carbonyl group  (Tyr, Phe, 
Trp) 
Elastase 
aliphatic carboxyl group (Ala, Leu, 
Gly, Val, Ile) 
Zinc-containing 
metallopeptidases 
(exopeptidases) 
Carboxypeptidases A 
and B 
single amino acids from the carboxy 
terminal ends of 
proteins and oligopeptides 
Table 15 The pancreatic proteases, taken from Erickson et al 1990 [201]. 
 
4.2.1 Trypsin Activation and the Proteolytic Enzyme Cascade 
 
The proteolytic zymogens trypsinogen, proelastase, chymotrypsinogen, the 
procarboxypeptidases and kallikreinogen are secreted from the pancreas in response to a 
meal. This array of proteolytic enzymes are secreted into the small intestine from the 
pancreas as zymogens which are activated during the proteolytic enzyme cascade 
(Error! Reference source not found.) which also causes the activation of pancreatic 
lipase and colipase.  
The mucosal enzyme enterokinase catalyses the activation of trypsinogen to trypsin. 
Enterokinase is a 316kDa glycosylated protein synthesised by small intestinal 
enterocytes. While trypsinogen is capable of autocatalytic activation, activation by 
enterokinase is reported to be 2000 times more efficient [202]. Activated trypsin then 
mediates the activation of pancreatic zymogens to their active forms.  
4.3 Serine Proteases 
Trypsin is part of the serine protease family of proteolytic enzymes. Serine proteases 
make up over a third of the known proteases and are named as such due to the catlytic 
mechanism depending upon a nuclephillic serine residue at the active site [200, 203]. 
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Serine proteases are usually endopeptidases and preferentially cleave within the 
poplypeptide chain.  
Commonly the serine residue is as part of the Asp-His-Ser catalytic triad by which 
Serine proteases were first thought to be characterised. However a range of serine 
dependent catalytic mechanisms have been identified in other families of serine 
proteases as described in Table 16. 
 
Table 16 General properties of serine proteases. Taken from De Cera et al 2009 [200] 
Serine proteases are found in prokaryotes, eukaryotes, archae and viruses. In the human 
they are critical to a range of physiological processes including immune response, blood 
coagulation, reproduction, signal transduction, and as discussed herein digestion [204]. 
4.4 Trypsin 
In humans, trypsin is synthesised as the proenzyme trypsinogen by acinar cells of the 
pancreas and stored in secretory granules for release in response to a meal and 
subsequent activation by enterokinase [205].  As well as its importance as a digestive 
protease, trypsin is also key for its role in downstream activation of other zymogens in 
to their active forms.  
Trypsin has a strong preference for cleavage after Arg or Lys residues at P1, with 
relative values of catalytic efficiency 10
5 
times higher for basic amino acids than others 
[205]. The pH optimum of trypsin is generally reported at pH 7-9, although this varies 
with species [206]. Trypsin is inactive at low pH, although can remain stable in solution 
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down to pH3 [205]. It was after the discovery of pancreatic trypsin that the German 
physiologist Willhelm Kuhne fist coined the term enzyme [207].  
4.4.1 Categorisation 
Trypsin is part of the serine protease family of enzymes (EC 3.4.21.4) and belongs to 
the PA clan of serine proteases which depend upon the His, Asp, Ser catalytic triad. 
Trypsin is the major proteolytic enzyme of the small intestine, and along with the other 
small intestinal proteases is responsible for completing the digestion of dietary protein 
after passage from the stomach to small-intestine. Trypsin is an endopeptidase which 
prefererentially cleaves on the carboxyl side of lysine and arginine.  
Duodenal trypsin digestion is thought to be important in breaking down large proteins 
for further digestion by the small-intestinal proteases.  
4.4.2 Structure of Trypsin 
Active trypsin has a reported molecular weight of roughly 25kDa, Leon et al report the 
MW as specifically 23,800 daltons [205, 208]. Trypsin shares a tertiary structure which 
is highly conserved throughout the serine protease family. The 3d structure of bovine 
trypsin was first solved in 1974, trypsin has become the proteotypic structural model for 
serine proteases [209].  
Trypsin is a globular protein molecule whose tertiary structure is comprised primarily of 
β-sheet. In terms of primary structure, active trypsin is composed of a single 
polypeptide chain. Trypsin has a two domain structure with the active site domain 
contained in between the two β –Barrel containing domains.  
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Figure 64  Crystal structure of Bovine Trypsin. Taken from Leiros et al 2004 [210]. 
Trypsin has a calcium binding site formed by a loop from Glu70-Glu80. Calcium 
binding is known to be important to trypsin structure and function and autodegredation 
of trypsin is shown to occur in its absence [209, 211]. 
4.4.3 Activation of Trypsin 
All trypsins are synthesised as pro-enzymes. An N-terminal propeptide which varies 
between species normally contains hexapeptide consensus sequence of (Asp)4–Lys-
Ile16-Val17-Gly-18Gly19 for cleavage by enteropeptidase with clevage occurring 
between the Lys and Ile16 residues.  
Cleavage of the N-terminal propeptide disrupts a His40, Asp194 hydrogen bond which 
allows a rotation of Asp194 so it is able to interact with the new Ile16 N-terminal.This 
rotation allows formation of the catalytically critical Oxyanion Hole comprised of the 
amide groups of Gly193 and Ser195. This new conformation is stabilised by 
hydrophobic interactions of the Ile16 sidechain [205].  
4.4.4 Substrate Binding 
Active trypsin binds substrate by forming an anti-parallel beta-sheet across the protein 
binding site. Asp189 has been shown to be critical to substrate specificity, substitution 
with Ser results in a 10
5
 fold decrease in catalytic efficiency for substrates with Arg and 
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Lys at P1 position [212]. A direct interaction between Asp189 and the guanidinium side 
chain of Arg has been shown. In the case of Lys, a water molecule is required to 
mediate the Asp189-Lys interaction [213]. 
4.4.5 Catalytic Mechanism 
Serine proteases are characterised by the nucleophillic serine residue which is part of 
the catalytic triad of Asp-His-Ser [205, 214]. The residues of the catalytic triad are 
spread across the active site cleft. With Ser195 on one side and Asp102 and His57 on 
the other [214].  
The proximity of Asp102 and His57 is important to the reaction mechanism. The 
carboxylate group of Asp102 forms hydrogen bonds with the imidizole functional group 
of His57 and polarises it to enhance its function as a proton shuttle [215].  Another 
important structural feature of the serine protease is the oxyanion hole formed by the 
amine groups of Gly193 and Ser195 which form a positively charged pocket that is 
important for stabilising the negatively charged intermediary of the reaction which shall 
be discussed later [203].  
4.4.6 Reaction Mechanism 
With the substrate co-ordinated in place, the electronegatively charged base His57 can 
act to accept the hydrogen from the hydroxyl group of Ser195. This allows Ser195 to 
act as a nucleophile, attacking the carbonyl carbon of the peptide bond, forming an acyl-
enzyme intermediate with the substrate [204]. The carbonyl carbon is δ+ as a dipole is 
formed over the C=O bond with the electrons pulled towards the electronegative 
oxygen, leaving the carbon susceptible to nucleophillic attack from serine.  
In the newly formed tetrahedral acyl-enzyme intermediate, the carbonyl carbon is bound 
to the serine oxygen, the carbonyl oxygen, the scissile amino group as well as being 
bound to the α-carbon of it’s own amino acid. Each of these bonds is a single bond, and 
the electron from C=O double bond moves to the carbonyl oxygen which becomes 
negatively ionised. The positively charged pocket of the previously described oxyanion 
hole is important for stabilising this negatively charged intermediate [214].  
The His57 bound hydrogen is then donated to the scissile nitrogen and the peptide bond 
is broken as the double bond is reformed between the carbonyl carbon and the carbonyl 
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oxygen [204]. The formation of the NH group releases the N-terminal product from the 
active site and leaves His57 electronegatively charged. With release of product,  a water 
molecule can enter and attack the electron dense nitrogen (δ-) of His57 with a hydrogen 
and the carbonyl carbon with the resulting hydroxyl group thus deacylating the acyl-
enzyme intermediate and freeing the carboxyl component of the substrate from Ser195 
[203]. The hydrogen newly bound to the His57 nitrogen then moves across to Ser195 to 
reform a hydroxyl group and regenerate the active site (Figure 65).  
 
Figure 65  The generally accepted mechanism for serine proteases. Taken from Hedstrom 
et al 2002 [203]. 
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4.4.7 pH optima and inactivation 
Ph optimum of trypsin is generally reported at pH 7-9, although this varies with species. 
Trypsin activity rapidly decreases below pH7 and is relatively inactive at low pH, 
although can remain stable in solution down to pH3 . Trypsin activity is highest at pH7 
and above, however, pH inactivation is also most rapid at above neutral pH [206]. 
Figure 66 shows the inactivation profile of trypsin after 15 minutes at 0°C and 24 hours 
at 30°C. As can be seen, at 0°C after 15 minutes, trypsin is stable at pH 1-12, at a pH 
higher than 12, trypsin is rapidly inactivated. After 24 hours at 30°C trypsin is 
denatured at low pH and will precipitate, at pH~2.5 the enzyme is stable but inactive, at 
pH approaching neutral, trypsin becomes active and therefore will autocatalytically 
digest over the course of 24 hours (Figure 66) [216].  
 
Figure 66  Loss of trypsin activity after 15 minutes at 0°C and 24 hours at 30°C Taken from 
Kunitz et al 1934 [216] 
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4.5 Aims 
Previous literature, and the data generated in Chapter 3 showed that alginates are 
capable of inhibiting the action of pepsin, and that the levels of inhibition are related to 
structure.  
Protein digestion occurs throughout the upper digestive tract through the combined 
physical, chemical processes of digestion and the actions of proteolytic enzymes.  The 
aim of this chapter therefore was to investigate the effects of bioactive alginates on the 
action of the enzyme trypsin. A library of bioactive alginates was tested in high 
throughput assays to screen for regulatory effects, and structure-function relationships 
were investigated. Selected enzyme kinetics were carried out to attempt to elucidate the 
nature of any regulatory effects.  
Selected viscometric and rheological investigations were carried out to look at the way 
in which alginates interact with protein substrates. 
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4.5.1 Introduction to gel rheology 
Rheology is the study of the flow and deformation of materials - liquids and soft-solids - 
under external stresses.  
When alginate gels, it forms a polymeric gel composed of a network of cross-linked 
biopolymers and as such can have properties like that of a visco-elastic solid [217].  The 
properties of a polymeric gel are determined by the structure of the polymer, the 
composition of the surrounding liquid (the sol), and the manner in which the polymers 
interact. Strong gels may form when polymers are chemically cross linked which if 
broken will not reform. Weak gels form from the formation of cross-links between 
polymers and these may break and reform under stress. Pseudo gels may also form, 
these are entangled polymer systems that mimic some of the properties of gels [217].  
Polymeric interactions between proteins and polysaccharides have been shown 
previously. In solution proteins and polysaccharides may attract and complex, or repel 
and segregate [218]. A segregation and phase separation occurs when the gain of 
entropy which would occur on mixing is outweighed by the thermodynamic energy 
disadvantage, meaning it is energetically favourable to resist mixing. If polymer mixing 
is energetically favourable a heteropolymeric mixture will occur and lead to polymeric 
interactions. Such interactions give rise to synergistic changes in rheological properties 
which are greater than that expected from the individual components.  
Alginates form viscoelastic gels which has previously been shown to interact with other 
biopolymers, including proteins and mucins. Such interactions are likely to modify the 
rheological properties of the alginate gel 
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4.6 Plate-Plate Rheology 
In plate-plate rheology, the test sample is held between two parallel plates at a fixed 
distance apart (h) (Figure 67). The bottom plate is fixed in place, and the top plate 
(moved plate) with a surface area A (m
2
) is rotated by a force F [N=kgm/s
2
] at a speed v 
[m/s] and the test material is displaced by distance (s) with a deformation angle (α). 
From this, the shear reate, shear stress, viscosity and strain can be calculated using the 
formulae shown in Figure 67 below.  
 
 
Figure 67  Diagram of Plate-Plate rheometer and formulas for calculating shear rate, 
shear stress, viscosity and strain. Taken from Rheotec: Introduction to Rheology [219] 
 
Plate-plate oscillatory rheology is based on applying a rotational stress to a material and 
measuring the induced strain. This rotation of the upper plate applies a shear stress to 
the sample. The shear stress τ is the force (F) applied over the given area (A). Strain is 
the resulting displacement of particles within the sample, it is a dimensionless unit 
which can be calculated from the deformation angle (α) and distance of displacement 
(s). 
 
Moved Plate 
Fixed Plate 
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Pure solids can be referred to as Hookean, as they are non-yielding and follow Hookes 
law that the force required to produce a displacement is directly proportional to the 
displacement. This linear-elasticity means that the stress and strain waves are in perfect 
phase and maximum strain occurs at the point of maximum stress. Hookean solids 
therefore have a phase angle of 0°. 
Hookean Solid: 
 
  
 
In a newtonian fluid, stress and strain are 90° out of phase as the maximum strain occurs 
at the point of maximum change in the rate of stress and at the point of maximum stress 
the strain is zero. However, many materials are neither perfect Hookean solids or 
perfect Newtonian liquids and therefore under stress the stress-strain wave phase angle 
will lie somewhere between 0 and 90°. 
90 180 270 360 
Stress and Strain Waves 
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Newtonian Fluid: 
 
 
 
 
Materials with a phase angle of 0- 45° exhibit more solid-like behaviour and are 
considered gels. Materials with a phase angle of 45-90° exhibit more fluid-like 
behaviour and are considered liquid. The solid like behaviour with a phase angle of 0-
45° corresponds to a higher elastic modulus (G’) than viscous modulus (G”). In liquid 
like behaviour with a phase angle of 45-90° the viscous modulus is higher than the 
elastic modulous and G” >G’. 
Solid-like Viscoelasctic Fluid 
 
 
 
Liquid-like Behaviour:  
 
 
 
 
The viscous and elastic moduli are derived from the Shear Modulus, which is a measure 
of the stress/strain ratio.  
 
90 180 270 360 
Stress and Strain Waves 
90 180 270 360 
Stress Wave 
Strain Wave 
Stress Wave 
Strain Wave 
90 180 270 360 
Stress Wave 
Strain Wave 
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The elastic modulus (G’) and viscous modulus (G”) are derived using the formulae 
below. The elastic phase is the component of the shear modulus which is in-phase with 
the deformation, and the viscous component the part which is out-of-phase [217].  
Elastic modulus G’ =G*Cosδ 
Viscous modulus G”=G*Sinδ 
 
Oscillatory frequency testing provides an important tool for understanding the 
rheological properties of a material. The way a material responds to deformation gives 
information about its physical properties. After a deformation, the material will relax 
through Brownian motion to its energetically favourable state. At low frequencies both 
viscoelastic gels and viscoelastic liquids can dissipate energy and return to an 
energetically favourable state. However as relaxation time is proportionate to molecular 
weight, gel network relaxation times can increase with the size of the network to an 
infinite value, at which point they will never relax to their original state. As the 
frequency of oscillation increases, the polymers do not have time to rearrange and the 
way in which the polymers are entangled will contribute to the response of the material 
to stress [217].   
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4.7 Experimental Section 
 
4.7.1 Materials 
 
All dietary fibre samples were supplied by FMC Biopolymer and Technostics (Hull, 
UK). Bovine serum albumin was purchased from VWR Jencons. Unless otherwise 
stated, all other chemicals and reagents were purchased from Sigma Aldrich (Poole, 
UK). 
4.7.2 Equipment 
 
A Biotek 96 well plate reader set at 340nm was used for spectrophotometric 
measurements (Elx808 Biotek, Bedfordshire, UK). An Autoblot microhybridization 
oven was used for temperature incubations at 37°C and 55°C (Bellco Glass Inc, 
Vineland, NJ). A Martini Mi150 pH meter was used for all pH measurements. 
(Milwaukee Instruments, Inc. NC, 96-Well Plate N-Terminal Method U.S.A.). 
 
4.7.3 Devlopment of High Throughput Trypsin N-Terminal Assay 
The trypsin N-terminal assay works on the same basis as the pepsin N-terminal assay as 
both assays use the generation of new N-terminals during peptide cleavage as a direct 
measure of proteolysis. The trypsin assay requires a modification of the methodology as 
trypsin has a pH optimum of around pH7. A 0.066 M Sorensens Phosphate pH 6.85 was 
used to buffer the alginate samples, as can be seen from Figure 68. 
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Figure 68 pH variation of reaction solution with addition of alginates made up in 0.066 M 
Sorensen’s phosphate buffer,   0.25mg/ml  1mg/ml,  4mg/ml. 
4.8 Preperation of Solutions 
Figure 69 shows the assay tested at a range of trypsin and TNBS concentrations in order 
to work out optimum reaction conditions.  
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Figure 69 Colour development with Trypsin N-Terminal assay at varying trypsin and TNBS 
concentrations.  
 
 
Concentration 
of TNBS 
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For high-throughput analysis, biopolymer samples were prepared at 10mg/ml in 0.066
•
 
M Sorenren’s Phosphate buffer. It was decided that Tri-nitro benzo sulfonic acid 
(TNBS) would be prepared at 2µl/ml in deionised water and trypsin at 5µg/ml. 
In order to raise the pH for trinitrophenylation, only 4% w/v Sodium Bicarbonate was 
required.  
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4.9 Method 
 
30ul alginate sample was pre-incubated with 50µl succinyl albumin substrate for 30 
minutes on shaker. At T0 30µl of trypsin solution or buffer blank was added as 
appropriate and the plate was incubated for 30min at 37˚C. After 30 minutes, 50µl 
sodium bicarbonate and 50µl TNBS were added and the plate was incubated for 15 
minutes in the Autoblot Microhybridisation oven at 55˚C. At T45, 50µl SDS and 50µl 
1M Hydrochloric Acid were added and the plate was left to stant until all wells had 
stopped effervescing, and samples were read at 340nm. 
To calculate percentage pepsin inhibition the following formula was used: 
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4.9.1 Plating 
4.9.2 Plating – HTP Assay 
 
Figure 70  Plating layout for the trypsin N-Terminal microplate assay.  
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4.9.3 Kinetic assay of Trypsin Activity 
 
The kinetics of dietary fibre interactions with trypsin were measured, as with pepsin 
using a modification of the 96 well-plate N-Terminal method previously described. 
Substrate dilutions were prepared from a stock of 25mg/ml succinyl albumin and plated 
out as below, including a control and blank lane both at 10mg/ml succinyl albumin. 
200µl was plated into each well so that there would be sufficient substrate for 3 plates to 
be run in triplicate. 
Table 17 Substrate dilutions for Trypsin N-Terminal Kinetic assay. 
 
In sample plates 30µl of DF sample (4mg/ml) was pre-incubated with 30µl trypsin 
(5μg/ml) for 15 minutes at 37˚C to give sample concentrations of 2mg/ml and 5µg/ml 
respectively. At T0 50µl of of substrate was added into the appropriate wells and 
incubated for 30 minutes. After 30 minutes 50µl NaHCO3 and 50µl of TNBS was added 
and the temperature raised to 55°C for colour development. After 15 minutes at 55˚C.  
50µl SDS and 50µl HCl was then added and the plate was left to stand until 
effervescence had stopped. Samples were then read at 340nm.  
 
Blank 
Lane 
Control 
Lane 
Substrate Dilutions (mg/ml) 
10 10 25 20 15 10 5 2.5 1.25 0.625 0.3125 0 
10 10 25 20 15 10 5 2.5 1.25 0.625 0.3125 0 
10 10 25 20 15 10 5 2.5 1.25 0.625 0.3125 0 
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4.9.4 Plating Kinetic assay 
Figure 71  Substrate dilutions for the trypsin N-Terminal Kinetic assay. 
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4.9.5 pH dependent alginate-protein Viscosity interactions 
Alginates were made up at 2.5mg/ml with casein or BSA at 10mg/ml in deionised 
water. Aliquots of 5ml were taken and titrated across the pH range using HCl and 
NaOH to pH 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8 and 9. Samples were incubated at room 
temperature for 30min and then left to stand for a further 30min to allow any precipitate 
to settle. 2ml of the sample supernatent was pipetted off the top of the sample and 
viscosity was measured.  
Sample viscosity was measured using a cup and bob viscometer (Contraves, 
Switzerland) which plots percentage deflection against shear rate. All samples were 
tested in triplicate and specific viscosity and relative viscosity were calculated from 
percentage deflection, as recorded, using equations 1 and 2.  
Equation 1: Relative Viscosity 
 
 
Equation 1: Relative Viscosity 
 
 
4.9.6 Rheology Methodology 
Rheological measurements were taken with a Kinexus pro+ rotational rheometer 
(Malvern Instruments Ltd., Malvern, UK) with controlled shear strain, with a parallel 
plate geometry (CP1/60 60mm diameter with a 1mm gap). All measurements were 
carried out at 22°C. Data was analysed using rSpace software. 
The linear visco-elastic region (LVER) of all samples was determined by carrying out 
an amplitude sweep at 1 Hz. A value which represented this range was calculated using 
rSpace software and an oscillation frequency sweep was conducted over a frequency 
range 0.1-100Hz from which rheological data including G*,G’,G” and phase angle 
δ(deg) was collected.  
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All rheological data is typical data from a single sample. 
4.10 Results 
Trypsin activity in the presence of dietary biopolymers was measured using a 96 well 
microplate adaptation of the N-terminal proteolysis assay as described in the 
experimental section.  
As with the pepsin activity assay, succinylated bovine serum albumin was used as the 
substrate. 
As with the pepsin analysis, colour development was measured in the presence of 
dietary bioplolymers and trypsin inhibition was calculated as a percentage change in 
optical density as compared to uninhibited trypsin. The assay system was validated 
using three known serine-dependent protease inhibitors; Soya bean trypsin inhibitor, 
benzamidine hydrochloride and α-amino-n-caproic acid as positive inhibition controls.  
Soya bean trypsin inhibitor (SBTI) is a monomeric protein with a molecular weight of 
21,500 which binds to and inhibits trypsin by blocking the active site [220, 221]. SBTI 
is a potent inhibitor of trypsin activity with a Ki reported in the range 10
-9
-10
-14
. SBTI 
inhibits trypsin activity by strongly binding across the active site and blocking substrate 
binding as is shown in Figure 72 [222]. SBTI binding is thought to mimic the binding 
seen in a normal productive peptide hydrolysis reaction. Arg63’-Ile64’ mimics the 
‘scissile’ peptide bond which occupies the active site with the positively charged 
Arg63’ occupying the primary specificity pocket of trypsin. An equilibrium is reached 
between SBTI and the cleaved form held in place by covalent interactions between 
SBTI and Trypsin.  
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Figure 72   Residues 61’-65’ of the Soybean Trypsin Inhibitor, and the residues of the trypsin molecule 
involved in binding. Atoms of the Trypsin molecule are clear, and of the inhibitor are shaded.Taken from Blow 
et al 1974 [222]. 
 
The concentration dependent inhibition of trypsin with SBTI is shown in Figure 73. SBTI 
was found to be the more potent than the other two inhibitors tested (Figure 75-Benzamidine 
HCl, and Figure 76-α-amino-n-caproic acid). With SBTI there was a near complete inhibition 
of the activity of 5µg/ml of trypsin at a concentration of 12.5µg/ml SBTI; trypsin activity was 
reduced to 1.4±3.1% of normal. A clear dose effect can be seen with 52%±16.4% inhibition 
at 1.56µg/mlmg/ml SBTI. At concentrations of SBTI higher than 12.5µg/ml, no trypsin 
activity was observed.  
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Figure 73 - Concentration dependent inhibition of trypsin (5µg/ml) in the presence of Soya Bean Trypsin 
Inhibitor. Activity is shown as a percentage of normal pepsin activity at a range of concentrations (0-0.1 mg/ml). 
All samples were tested in triplicate (n=3) with error bars showing standard deviation. 
The concentration dependent inhibition of trypsin with Benzamidine Hydrochlride is shown 
in Figure 75. Benzamidine Hydrochloride is an amine derivative of benzene known to 
competitively inhibit trypsin, it does this by occupying the substrate binding cleft of trypsin, 
competing for substrate binding (See Figure 74) [223, 224]. At 5 and 10mg/ml benzamidine 
hydrochloride, activity of 5µg/ml trypsin was reduced to 1.7±2.1% and -1.36±2.4% of normal 
activity respectively. As can be seen benzamidine hydrochloride completely abolished trypsin 
activity at 5mg/ml compared to SBTI which completely inhibited activity at 12.5µg/ml, 
meaning SBTI is approximately 400 times more effective at inhibition.  
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Figure 74 Structural view of Benzamidine occupying the substrate binding cleft of Human Brain 
Trypsin. Critical substrate binding and catalytic residues are also shown. However in human pancreatic trypsin 
Arg193 is substituted with Gly193. Taken from Katona et al 2002 [224] 
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Figure 75 - Concentration dependent inhibition of trypsin in the presence of benzamidine Hydrochloride. 
Activity is shown as a percentage of normal pepsin activity at a range of concentrations (0-10 mg/ml). All 
samples were tested in triplicate (n=3) with error bars showing standard deviation. 
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Figure 76- Concentration dependent inhibition of trypsin in the presence of α-amino-n-caproic acid. Activity is 
shown as a percentage of normal pepsin activity at a range of concentrations (0-10mg/ml). All samples were 
tested in triplicate (n=3) with error bars showing standard deviation. 
α-amino-n-caproic acid, a known protease inhibitor was also tested [225]. As shown in Figure 
76, trypsin inhibition was shown to be limited and variable, with a statistically significant 
correlation between α-amino-n-caproic acid concentration and trypsin inhibition with an r2 
value of 0.7505 and a p-value of 0.0025. 
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Again, the catalogue of eighteen alginates provided by Technostics Ltd and FMC 
biopolymer were tested in the trypsin activity assay. All alginate samples were tested at 
three concentrations; 5, 2.5 and 1.25mg/ml. This gave concentrations in the reaction 
mixture of 1.36, 0.68 and 0.34mg/ml respectively. These results are shown in Figure 
77. 
Figure 77 shows the complete catalogue of alginates across the entire range of M:G 
structural composition. Control trypsin activity is represented by the dotted line running 
horizontally at 100%, as can be seen there is little deviation from this control trypsin 
activity with the addition of any of the alginates. 
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Figure 77 - Concentration dependent regulation of trypsin in the presence of sample alginates. Activity is shown as a percentage of control pepsin activity at three 
concentrations of alginate,   1.25mg/ml  2.5mg/ml,   5mg/ml.. All samples were tested in triplicate (n=3) with error bars showing standard deviation.  
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While the vast majority of alginate samples had no significant effect on trypsin activity. 
a small number of biopolymers were observed to have had a statistically significant 
effect. These are shown in Figure 78, the significant effects have been indicated.  
FMC 5 was the only alginate sample to show a significant inhibition of trypsin activity 
at all three concentrations. 10.4±2% at 5mg/ml, 7.5±2.5% at 2.5 mg/ml and 7.9±2.7% 
at 1.25mg/ml. FMC3 and FMC4 showed a decrease of 7.8±1.5% and 7.7±2.6% 
respectively at 2.5mg/ml. However neither alginate showed a significant effect at the 
other concentrations tested. FMC 7 showed significant inhibition at 5 and 2.5mg/ml of 
7.3±2.9% and 5.6±0.8% respectively, however showed no significant affect at 
1.25mg/ml. 
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Figure 78 - Concentration dependent regulation of trypsin in the presence of sample alginates. Activity is shown 
as a percentage of normal pepsin activity at three concentrations of alginate, ,   1.25mg/ml  2.5mg/ml,   
5mg/ml. All samples were tested in triplicate (n=3) with error bars showing standard deviation. Samples which 
were shown to be significantly different to control are shown with (*) (p=0.05). 
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Given the limited effects seen in the high throughput assays, all samples were further 
tested using kinetic methods to see if inhibitory effects varied as the enzyme:substrate 
ratio was changed.  
The kinetics of an enzyme-substrate interaction alters with substrate concentration (or 
ratio of substrate to enzyme) and extrinsic compounds may have effects at across this 
range that were not observed in the high throughput assays at a fixed enzyme:substrate 
ratio.  
The kinetics of enzyme substrate reactions in the presence of dietary fibres were 
analysed using an adapted 96 well microplate assay as described in the methods 
section. All biopolymers were tested a minimum of 5 times. Kinetic constants were 
calculated from GraphPad Prism 4 software using substrate-velocity data. Velocity of 
reaction, measured as percentage change in absorbance per minute is plotted on the y-
axis against substrate concentration on the x-axis.  
Figure 79 below shows a Michaelis Menten plot for a control trypsin digestion of 
succinylated BSA. The control digestion begins to reach enzyme saturation at the 
higher substrate concentration and the plot begins to plateaux.  
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Figure 79  Michaelis-Menten plot for control digestion of trypsin. Substrate concentration [s] is given in mg/ml 
and the velocity is given as the rate of change in percentage absorbance per minute. The error bars show the 
standard deviation of 5 replicates (n=5) 
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Across most of the samples, no effects were seen, confirming what was seen in the 
highthroughput microplate assays. Some small but statistically significant effects were 
observed. Interpolated kinetic constants were compared to those of the trypsin control and 
where there were statistically significant differences to normals, these have been highlighted 
in Table 18. LF10L, FMC3 and FMC 4 had a significantly different Vmax, and FMC3 and 
FMC7 were statistically different for both Vmax and Km. 
 
Table 18 Showing alginate samples where kinetic data was significantly different from control values 
for trypsin.   Represents where no significant difference was observed. FMC5 has been included in 
the table, as significant inhibition was shown in microplate assays (Figure 78).  
 
Figure 80 shows the Michaelis-Menten plot for FMC2, as a representation of the alginate 
samples that caused a significantly different Vmax to normals. With FMC3 a significant 
change in both Vmax and Km to be reported.While these effects are statistically significant, 
with FMC2 and FMC3 the sample lines deviate only slightly from the control line. While 
statistically significant, the changes in the kinetics of the reaction are marginal and suggest 
that alginates do not inhibit trypsin activity.  
 
 
 
P-Values of Kinetic Data which are 
significantly different from control  
 
Vmax Km   Conclusion 
LF10L 0.04   Reject null hypothesis 
FMC3 0.04 P<0.0001 Reject null hypothesis 
FMC2 P<0.0001 
 
Reject null hypothesis 
FMC4 0.04 
 
Reject null hypothesis 
FMC7 0.0004 0.002 Reject null hypothesis 
FMC5 0.12 0.17 
Do not reject null 
hypothesis 
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Figure 80  Michaelis-Menten plot for alginate FMC2 at 5mg/ml as compared to a trypsin 
control . Substrate concentration [s] is given in mg/ml and the velocity is given as the rate of 
change in percentage absorbance per minute. The error bars show the standard deviation of 5 
replicates (n=5). 
 
4.10.1 pH dependent alginate-protein Viscosity interactions 
Only marginal changes in trypsin activity with a small number of alginates were observed in 
microplate high-throughput and kinetic assays. These results contrast with the strong 
inhibitory effects of alginate on pepsin shown  in Chapter 3.  
In order to investigate the different inhibition profiles of pepsin and trypsin, the pH 
dependency of alginate-protein interactions were investigated. As pH dependent gels, the 
behaviour and bioactivity of alginates can vary dramatically across the pH range, including 
the way alginate interacts with other molecules and polymers.  
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In the control alginate solution the samples showed behaviour typical of a pH dependent gel 
with specific viscosity increasing at lower pH’s as an acid gel is formed. Addition of BSA or 
Casein to the mixture caused a visible precipitate to form in samples titrated to acidic pH, but 
not in samples at neutral pH. After the precipitate had been allowed to settle for 30 minutes, 
the viscosity of the remaining supernatant was measured. As can be seen from the pH 
dependent specific viscosity plot of H120L and BSA/Casein in Figure 81 below, at a pH 
around neutral there is little or no difference in viscosity of supernatant with the addition of 
BSA or casein. However as the pH is lowered, the specific viscosity of the H120L alginate 
control increases as an acid gel is formed. However in the samples with BSA and Casein 
present, at lower pHs the viscosity of the supernatant approaches  zero as a precipitate has 
formed between alginate and the protein which has settled to the bottom of the tube, bringing 
the viscous alginate component out of solution.  
Four alginates were tested in this way H120L; (Figure 81), SF120 (Figure 82), LFR560 
(Figure 83) and SF200 (Figure 84). As can be seen from Figure 83, LFR560 has a maximum 
specific viscosity of between 3-4 as compared to the other alginates with maximum specific 
viscosities in the range 15-45. This is due to LFR560 being a low molecular weight alginate 
(34,700Da) as compared to alginates H120L, SF120 and SF200 with molecular weights up to 
an order of magnitude larger (195,000- 397,000). These larger alginates have higher specific 
viscosities as predicted by the Mark-Houwink equation which describes the positive 
relationship between molecular weight and viscosity – although it is important to note that 
this relationship is affected by many other factors including structure, pH, and ion chelation.  
In all samples the same formation of precipitate and lower supernatant viscosity was seen. In 
the case of SF200, at neutral pH the addition of BSA and Casein to the mixture caused an 
approximate doubling of supernatant viscosity suggesting a synergistic interaction between 
alginate SF200 and protein at neutral pH. The interaction between SF200 and BSA/Casein at 
lower pH was consistent with the other tested samples, with a precipitate forming and 
lowering the viscosity of the supernatant.  
LFR560 was the only sample in which some viscosity remained at low pH after the addition 
of BSA, this suggests that there is an interaction by which some alginate remains able to form 
a gel. This result may indicate a size-dependent interaction between BSA and alginate, 
although LFR560 was the only  low molecular weight available for testing.  
160 
 
0 1 2 3 4 5 6 7 8 9 10 11
-5
0
5
10
15
20
25
30
35
40
45
50
55
H120L H120L and BSA H120L and casein
pH
S
p
e
c
if
ic
 V
is
c
o
s
it
y
 
Figure 81– pH dependent viscosity interaction of alginate H120L (2.5mg/ml) with BSA (10mg/ml) and casein 
(10mg/ml) across the pH range (n=3). H120L molecular weight = 397,000. 
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Figure 82 – pH dependent viscosity interaction of alginate SF120 (2.5mg/ml) with BSA (10mg/ml) and casein 
(10mg/ml) across the pH range (n=3). SF120 molecular weight = 195,000. 
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Figure 83– pH dependent viscosity interaction of alginate LFR560 (2.5mg/ml) with BSA (10mg/ml) and Casein 
(10mg/ml) across the pH range (n=3). LFR560 molecular weight = 34,700 
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Figure 84 – pH dependent viscosity interaction of alginate SF200 (2.5mg/ml) with BSA (10mg/ml) and casein 
(10mg/ml) across the pH range (n=3). SF200 molecular weight = 387,000.  
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The formation of pH dependent precipitate between alginate and protein suggests a possible 
mechanism by which alginate may prevent the action of pepsin without affecting trypsin in a 
similar way. Having said this, complex interactions between alginate gels and other polymers 
such as proteins cannot properly be characterised by viscometry. Viscosity is a fluid property 
and a measure of how liquids flow and respond to stress. Alginates at low pH are not true 
liquids, but viscoelastic gels and therefore must be characterised using rheology.  
The interaction of alginate samples with BSA, casein and milk protein were compared 
rheologically nder controlled stress conditions at pH 2 and pH 7 to simulate the pH 
conditions at which pepsin and trypsin would be active. Casein refers to a group of 
phosphoproteins which constitute approximately 80% of the total protein in bovine milk 
including α-s1 Casein, α-s2 Casein, β-Casein, and κ-Casein. Milk powder on the other hand 
refers to commercially available dried skimmed milk powder, containing all of the other 
components of dried milk powder, including lactose, fats, and minerals.  
Alginate samples and alginate-protein mixes were all subjected to an initial amplitude sweep 
to determine the linear viscoelastic region: this is the region where the viscoelastic properties 
are independent of the deformation force. Frequency sweeps were then conducted over the 
range 0.1-40Hz using the determined LVER values for controlled stress measurements. G*, 
G’, G” and phase angle were monitored throughout.  
 
In Figure 85 the complex modulus G*, which gives a measure of rigidity and stiffness, of the 
alginate H120L is compared at pH2 and pH7. As can be seen, at lower frequencies the 
dynamic modulus in the pH2 acid alginate gel is higher than pH7 H120L alginate by an order 
of magnitude, indicating a much greater gel strength and stiffness at pH2 [226]. In both the 
pH2 and pH7 samples the alginate shows frequency dependence typical of a viscoelastic gel.  
 
As can be seen from Figure 85, at frequencies above 10Hz, the gradient of the complex 
modulus curve increases rapidly as the frequency increases. This occurs with H120L alginate 
at both pH2 and pH7, and is expected due to the way biopolymer gels arre known to respond 
to deformation. At low frequencies there are longer relaxation times, and the polymer 
network can respond to stress without rupturing. However, at higher frequencies a process 
called strain-hardening occurs, whereby the frequency does not allow for a relaxation of the 
polymer network, and the material cannot accommodate any more stretching or deformation. 
163 
 
This causes an increasing stiffness as the polymer network resists any further deformation, 
until the junction points cannot accommodate any more stretching and the network ruptures. 
It would be expected that after the polymer has been taken through the strain-hardening phase 
and the rupture point has been passed, the polymer would display flow behaviour [227].  
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Figure 85 - Typical plot of complex  modulus (G*) of alginate H120L at pH2 (O) and pH7 (*) 
across frequency range 0.1-40Hz. (n=1). G* .   
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At pH2, alginate H120L shows gel-dominated solid-like behaviour. Comparing the elastic 
modulus G’ at pH2 and pH7 in Figure 86, it can be seen that elastic modulus is an order of 
magnitude larger in the pH2 alginate gel than the pH7 alginate solution at lower frequencies, 
as you would expect when comparing a gel to a viscous liquid. Again a frequency 
dependence is shown with the moduli increasing at higher frequencies such that in both pH2 
and pH7 alginate solutions at high frequencies the solid like properties are increased. 
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Figure 86 Typical plot of a frequency sweep of elastic modulus (G’) of H120L at pH2 (ο) and pH7 (*). 
(n=1) Across frequency range 0.1-40Hz 
Again the phenomenom of strain-hardening can be seen at higher frequencies, as the 
biopolymer network cannot accommodate further deformation. At both pH7 and pH2, the 
elastic modulus of the alginate solution approaches the same value, as the strain-hardening 
becomes the dominant factor, above pH and gelling effects.  
From Figure 87 it can be seen that the viscous modulus is similar between the pH2 and pH7 
solutions, although slightly lower in the pH2 solution, again strain-hardening is apparent at 
higher frequencies.  
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Figure 87 Typical plot of a fFrequency sweep of viscous modulus (G”) of H120L at pH2 and pH7. (n=1) 
Across frequency range 0.1-40Hz 
 
From Figure 88 it can be seen that there is a marked difference in phase angles at frequencies 
0.1-10Hz, with pH2-H120L showing strong solid-like behaviour δ=0-45 and pH7 showing 
viscous, liquid like properties δ=45-90.  
0.1 1 10 100
0
10
20
30
40
50
60
70
80
90
100
f(Hz)
P
h
a
s
e
 A
n
g
le
 
Figure 88 Typical plot of a frequency sweep of phase angle (α) of H120L at pH2 and pH7. (n=1) Across 
frequency range 0.1-40Hz 
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At frequencies above 10Hz the readings for phase angle become varable, this tallies with the 
region of increased G*, G’ and G”. The relationship between phase angle and the elastic and 
viscous moduli can be explained by the equation - tan(δ) = G''/G'. Therefore at pH2, as the 
viscous modulus increases at higher frequencies, while the elastic modulus stays relatively 
constant, the phase angle will increase. This corresponds with the polymer network passing 
through a rupture point and demonstrating more flow like behaviour, although the data in 
Figure 88 above 10Hz is somewhat variable.  
Alginate samples FMC3, FMC13 and SF60 were also compared at pH2 and pH7. Similar pH 
dependent alginate gel formation at pH2 was shown with all alginate samples as would be 
expected.  
Alginate-protein mixtures were made with alginate at 2.5mg/ml and either BSA, Casein or 
Milk Protein at 5mg/ml. With the addition of protein to the alginate solution the rheological 
properties were changed at both pH2 and pH7.  
The rheological properties of alginate sample H120L at pH2, with the addition of BSA, 
Casein and Milk Powder are shown in Figure 89.  
From Figure 89a it can be seen that with the addition of protein, the Dynamic Modulus of the 
mixture was decreased as compared to H120L alginate to varying degrees. These results 
indicate that there is an interaction between H120L alginate and each of the proteins BSA, 
Casein and Milk Protein. This interaction is such that the alginate gel is disrupted and the gel 
strength decreases and becomes less rigid. With H120L, Milk Powder causes the largest 
decrease in G*, followed by BSA, and casein has the weakest effect. As shown in Figure 89b, 
at pH2 the addition of the protein substrate results in a lowered G’ elastic modulus suggesting 
the gel strength is weakening with the addition of each of the three protein substrates, these 
effects again had the same order of magnitude milk powder > BSA > casein. The G” viscous 
modulus is also lowered at low frequency by the addition of the three proteins in the same 
order Figure 89c suggesting that the viscous portion of the solutions are too getting weaker. 
Figure 89d shows that the addition of protein to the H120L sample results in an increased 
phase angle. Although with the addition of each protein, at all frequencies the phase angle 
remains less than 45° and gel-like behaviour still dominates, the addition of protein causes an 
increase in phase angle in all cases and a shift towards more liquid like behaviour. 
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Figure 89 - Typical plots of rheological properties of H120L at pH2 in the presence of BSA, Casein and 
Milk Protein. (a) Complex modulus - G*, (b) Elastic Modulus - G’, (c) Viscous modulus - G” (d) Phase angle – 
α. Control H120L is shown as – ο, with 2.5mg/ml BSA as -*-, with 2.5mg/ml Casein as - -, and with 2.5mg/ml 
Milk Powder as - . 
 
(a) (b) 
(c) (d) 
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At pH7 there are less pronounced disruptions to the rheological behaviour of H120L as can 
be seen in Figure 90a-d, although some frequency dependent variation is apparent. There is a 
lowering of G* of H120L at pH7 with the addition of BSA and casein, with the addition of 
milk powder there is a slight increase Figure 90a. With the addition of BSA and Casein there 
is a decrease in both the elastic modulus G’ and viscous modulus G” of H120L, indicating a 
weakening of the polymer interactions Figure 90b&c.  With the addition of BSA and Casein 
the phase angle remains relatively similar Figure 90d.  
However, with the case of milk powder there is an increase in the dynamic modulus and 
elastic modulus, a decrease in viscous modulus and a pronounced lowering of the phase 
angle. This suggests that the addition of milk powder is interacting with the alginate to form a 
heteropolymeric gel. The increase in G* and G’ shows that the gel is formed by the addition 
of milk protein and the shift in phase angle from liquid-dominant behaviour (45-90°) to solid-
dominant-behaviour (0-45°) shows the stabilising effect milk protein has at pH7. 
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Figure 90   Typical plots of rheological properties of H120L at pH7 in the presence of BSA, Casein and 
Milk Protein. (a) Shear modulus - G*, (b) Elastic Modulus - G’, (c) Viscous modulus - G” (d) Phase angle – α. 
Control H120L is shown as – ο, with 2.5mg/ml BSA as -*-, with 2.5mg/ml Casein as - -, and with 2.5mg/ml 
Milk Powder as - . 
 
 
The change in rheological properties of alginate H120L with the addition of protein substrate 
suggests alginate-protein interactions.  The fact that changes in rheological properties occur 
with casein, BSA and milk protein suggests that these interactions are non-specific protein-
alginate interaction, but that the nature of the interaction is both alginate and protein 
dependent as shall be discussed.  
(a) (b) 
(c) (d) 
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Although changes in rheological properties were apparent at both pH2 and pH7, it is evident 
from Figure 91 that in absolute terms, the change in properties is much more apparent at pH2. 
The addition of BSA to H120L alginate has been used as an example, as bovine serum 
albumin was the substrate used in the pepsin and trypsin activity assays. At pH2 there is a 
91% decrease in G* with the addition of BSA, compared to a 49% reduction respectively at 
pH7. 
  
Figure 91 Dynamic modulus of H120L at 1Hz frequency with and without the addition of BSA at pH2 
and pH7 
 
4.10.2 FMC3  
FMC3 shows the behaviour of a classic weak viscoelastic gel system as defined by JD Ferry 
[228]. The interactions between alginate and protein appear to be dependent upon both the 
type of proteins and alginate involved. With alginate FMC3 at pH2 the rheological properties 
change with the addition of protein, and the magnitude of the change in rheological properties 
is different for each of the three protein substrates. When protein was added to H120L 
alginate solution at pH2, the gel structure was disrupted and the alginate gel weakened. 
However with the addition of protein to FMC3 alginate there is an increase in dynamic 
modulus, elastic modulus and viscous modulus Figure 92a-c. There is however no change in 
phase angles at lower frequencies (Figure 92d), so the addition of protein to FMC3 alginate 
gel acts to stabilise the alginate gel and biopolymer interactions but does not affect phase 
angle and cause the solution to become more solid-like or more liquid like, although with a 
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phase angle already under 10, the solution is displaying very strong solid-dominant 
behaviour. FMC3 alginate does not show the same frequency dependence across the range 
0.1-10Hz that was seen with H120L. Following the model of JD Ferry the increase in G” and 
increased tanδ indicate that the proteins seem to be acting as filler between the gum network. 
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Figure 92 Typical plots of rheological properties of FMC3 at pH2 in the presence of BSA, casein and milk 
powder with change in frequency across the range 1-10Hz. (a) Shear modulus - G*, (b) Elastic Modulus - G’, 
(c) Viscous modulus - G” (d) Phase angle – α. Control H120L is shown as – ο, with 2.5mg/ml BSA as -*-, with 
2.5mg/ml casein as - -, and with 2.5mg/ml milk powder as - .  
The rheological properties of alginate FMC3 are largely unaffected with the addition of 
protein substrate at pH7 (Figure 93a-d), suggesting no interaction between the two polymers. 
Across all frequencies, G*,G’ and G” remain largely similar to control FMC3. Although there 
is more variation with phase angle at lower frequencies, the alginate-protein mixtures display 
largely the same behaviour to FMC3 alone at pH7.  
(a) (b) 
(c) (d) 
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Figure 93  Typical plots of rheological properties of FMC3 at pH7 in the presence of BSA, casein and 
milk powderwith change in frequency across the range 1-10Hz. (a) Shear modulus - G*, (b) Elastic Modulus - 
G’, (c) Viscous modulus - G” (d) Phase angle – α. Control H120L is shown as – ο, with 2.5mg/ml BSA as -*-, 
with 2.5mg/ml Casein as - -, and with 2.5mg/ml Milk Powder as - .  
(a) (b) 
(c) (d) 
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4.10.3 SF60 
Alginates SF60 (Figure 94a-d & Figure 95a-d) and FMC13 (Figure 96a-d & Figure 97a-d) 
were also tested for pH dependent rheological interactions with protein substrates.  
At pH7, SF60 alginate behaved like a viscous liquid across most of the frequency range 
tested, as is indicated by the phase angle, which for most of the frequency range is between 
δ=80-90. However, at frequencies above 1Hz, there is a shear hardening effect, as both the 
elastic and viscous components of the complex modulus plateaux, but the phase angle rapidly 
drops. This indicates that the molecular interactions are strengthening as the frequency is 
increasing and resisting the deformation, and as the phase angle indicates, the polymer 
network becomes more solid-like. This phenomenom carries on as the frequency increases up 
to a point where the polymer network ruptures, and while the gel strength continues to 
increase, the phase angle returns to the range 80-90 as the polymer behaves like a viscous 
liquid again. At this pH, with SF60 there was no significant change in this rheological 
behaviour at with the addition of BSA, casein or milk powder (Figure 95a-d).  
However at pH2, BSA and Casein acted to change the rheological properties of the alginate 
gel, causing a decrease in both the dynamic and elastic modulus Figure 94a&b. The viscous 
modulus at pH2 was also decreased by the addition of BSA and Casein, although the phase 
angle was relatively unaffected Figure 94c&d. The fact that both the viscous and elastic 
components of the complex module increase with the addition of all three proteins suggests 
that interactions between the polymer network are strengthened by the inclusion of protein. 
There is little change in the phase angle with the inclusion of protein, indicating that the flow 
properties of the material are not greatly changed. This suggests that the interactions of the 
alginate polymer chains are strengthened  with the inclusion of protein, but that under 
deformation they can be broken and reformed such that the flow properties are not changed.  
With FMC13, BSA and Casein addition acted to stabilise the polymeric interactions and 
cause an increase in gel strength. Complex modulus, elastic modulus and viscous modulus of 
FMC13 at pH2 were all increased by the addition of BSA and Casein, without causing 
significant change to the phase angle Figure 96a-d.  
Milk powder had no significant rheological affects on either SF60 or FMC13. This is unusual 
as casein forms a major constituent of milk powder, it would therefore be expected that if 
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casein alone interacts with alginate, that the casein component of milk powder would also 
interact with alginate. As discussed previously, milk powder also contains the other 
components of dried milk powder, including lactose, fats, and minerals, which may interact 
with either the alginate or casein, to disrupt interactions, although further investigations 
would be required in order to determine this.  
The low-G alginate FMC13 is a weaker system at pH2 than was seen with the high G FMC3, 
the tanδ value is 10 times higher and with the G’ and G” tending to close tofether there is a 
more liquid like behaviour. This suggests theat as with FMC3 there is a weak viscoelastic gel 
system, but with liss interactions between the polmer chains. At pH7 FMC13 shows the 
behaviour of a frequency dependent liquid system rather than a network. In the case of pH2, 
the addition of BSA to this system appears to produce an interactive structure approximately 
three orders of magnitude stronger in terms of G’ and G” and is indicative of cooperative 
interaction between the polymers as opposed to infill.  
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Figure 94  Typical plots of rheological properties of SF60 at pH2 in the presence of BSA, casein and 
milk powder. (a) Shear modulus - G*, (b) Elastic Modulus - G’, (c) Viscous modulus - G” (d) Phase angle – α. 
Control SF60 is shown as – ο, with 2.5mg/ml BSA as -*-, with 2.5mg/ml Casein as - -, and with 2.5mg/ml 
Milk Powder as - .  
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Figure 95 Typical plots of rheological properties of SF60 at pH7 in the presence of BSA, casein and 
milk powder. (a) Shear modulus - G*, (b) Elastic Modulus - G’, (c) Viscous modulus - G” (d) Phase angle – α. 
Control SF60 is shown as – ο, with 2.5mg/ml BSA as -*-, with 2.5mg/ml Casein as - -, and with 2.5mg/ml 
Milk Powder as - .  
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Figure 96 Typical plots of rheological properties of FMC13 at pH2 in the presence of BSA, casein and 
milk powder. (a) Shear modulus - G*, (b) Elastic Modulus - G’, (c) Viscous modulus - G” (d) Phase angle – α. 
Control FMC13 is shown as – ο, with 2.5mg/ml BSA as -*-, with 2.5mg/ml Casein as - -, and with 2.5mg/ml 
Milk Powder as - .  
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Figure 97 Typical plots of rheological properties of FMC13 at pH7 in the presence of BSA, casein and 
milk powder. (a) Shear modulus - G*, (b) Elastic Modulus - G’, (c) Viscous modulus - G” (d) Phase angle – α. 
Control FMC13 is shown as – ο, with 2.5mg/ml BSA as -*-, with 2.5mg/ml Casein as - -, and with 2.5mg/ml 
Milk Powder as - .  
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4.11 Discussion 
 
As with the pepsin methodology, the trypsin N-terminal assay was scaled down to a 96 well 
microplate in order to increase the throughput capability of the assay and reduce error. While 
alginates are basic molecules and so were unlikely to have a profound effect on pH, all 
samples and reagents were buffered in a Sorensen’s Phosphate buffer. As shown from Figure 
68, the 0.066
•
M Sorensens phosphate buffer was effective at buffering the alginates so that 
there was no significant variation in pH.  
The assay system was validated using three known serine protease inhibitors; Soya bean 
trypsin inhibitor, benzamidine hydrochloride and α-amino-n-caproic acid as positive 
inhibition controls. SBTI was the most potent of the three inhibitors, completely inhibiting 
the activity of 5µg/ml of trypsin at 0.0125mg/ml SBTI. Benzamidine Hydrochloride at 
5mg/ml reduced 5µg/ml trypsin to 1.72±2.14% of normal activity. Inhibition of trypsin with 
α-amino-n-caproic acid was shown to be limited and variable. 
The same catalogue of eighteen alginates provided by Technostics Ltd and FMC biopolymer 
were tested in the trypsin activity assay. The vast majority of alginate samples had no 
significant effect on trypsin activity, however a small number of biopolymers were observed 
to have had a statistically significant effect. Despite these few examples of statistically 
significant inhibition, the effects are inconsistent between alginates, do not show a dose 
response and the levels of inhibition were not to the same extent as was observed with 
alginates and pepsin. Given these limited effects in the high throughput assays, the samples 
were further tested using kinetic methods to see if inhibitory effects varied as the 
enzyme:substrate ratio was changed.  
Again, as with the higher-throughput assays, across most of the samples no significant effects 
were seen, however, some small but statistically significant effects were observed. Again, 
while statistically significant, the changes in the kinetics of the reactions were marginal, and 
not of as great a magnitude as those observed with alginate inhibition of pepsin. These data 
therefore suggests that alginates do not inhibit trypsin activity.  
In the previous chapter a number of potential mechanisms of alginate inhibition of pepsin 
were discussed, including both alginate interaction with substrate and alginate interaction 
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with enzyme. It must therefore be considered what mechanism of enzyme inhibition would 
allow for the observations that alginate can inhibit activity of pepsin at acidic pH, but have no 
effect on the activity of trypsin at neutral pH.  
It was discussed in Chapter 3 that Lipase is inhibited by pectin. The mechanism for this 
inhibition is that the carboxyl group of pectin protonates key active site residues, disrupting 
the charge relay mechanism of the catalytic triad thereby blocking enzyme activity [229]. It 
was discussed how a similar mechanism may be responsible for the inhibition of pepsin by 
alginate, with the carboxyl groups of alginate protonating key active site residues and 
inactivating the enzyme, for example protonation of the active site Asp32 of the acid-base 
pair would prevent nucleophillic attack on the scissile peptide bond.  
At the assay pH which was used for the experiments described herein, and at the 
physiological pH at which trypsin is active, the carboxyl groups of alginate would not be 
protonated, and therefore would be unable to act as proton donors. It is therefore unlikely that 
a similar mechanism of inhibition is possible with trypsin, whereby the carboxylic acid 
groups of alginate would interact with catalytic residues of trypsin.  
However, as was shown in Figure 72-Figure 74, trypsin activity can be inhibited by a range 
of serine-dependent protease inhibitors. SBTI inhibits trypsin activity by strongly binding 
across the active site and blocking substrate binding. As discussed previously, SBTI binding 
mimics a normal productive peptide hydrolysis reaction with Arg63'-Ile64' of SBTI 
mimicking the scissile peptide bond which occupies the active site with the positively 
charged Arg63' occupying the primary specificity pocket of trypsin [222]. Evidently, as a 
polysaccharide, an alginate molecule would not be able to mimic binding of a protein 
substrate in.  
Substrate binding by trypsin has been shown to be highly specific, with the Asp189 residue 
being critical to protein substrate binding and a strong preference for cleaving on the carboxyl 
side of basic amino acids (Arg, Lys). Active trypsin binds to protein substrate by forming an 
anti-parallel beta-sheet across the protein binding site. Not only therefore is trypsin highly 
specific to the binding of protein, but also shows strong preference for cleavage sites, it is 
therefore unlikely that an alginate molecule could form a stable interaction and mimic 
substrate binding in the same way that SBTI does. Furthermore the active site of trypsin is 
enclosed within the centre of the two domains of the globular trypsin protein, which would 
further reduce alginate accessibility to those key active site residues [224].  
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Likewise, benzamidine hydrochloride is a small molecule serine-dependent protease inhibitor 
known to completely inhibit trypsin by occupying the substrate binding cleft of trypsin and 
competing for substrate binding (See Figure 74) [223, 224]. Benzamidine hydrochloride is 
held in place in the substrate binding pocket by electrostatic interactions. All trypsin enzymes 
have a negatively charged substrate binding pocket, and as alginates are large negatively 
charged polymers, they would be repelled from the trypsin substrate binding site due to 
charge:charge repulsion and have poor accessibility to the active site binding pocket due to 
size  [224].  
Due to the distinctly different inhibition profiles for pepsin and trypsin, the manner in which 
alginates and protein substrates interact across the pH range was investigated. Pepsin is an 
acid protease with a pH optima of 2.2; this is the pH that was used for analysis of pepsin 
inhibition in Chapter 3. Trypsin on the other hand is a serine protease and has a pH optimum 
of 7-9. A pH as high as 9 will not be reached in the small intestine, and the pH of the 
duodenum is in the range of 6-.65, therefore the current experiments were undertaken at at 
pH 6.85 so as to be more physiologically relevant to the small intestine.  
As pH dependent gels, the behaviour and bioactivity of alginates can vary dramatically across 
the pH range, including the way alginate interacts with other molecules and polymers [230-
232]. A series of alginate-protein binding experiments were carried out across the pH range 
where an alginate-protein solution was made and any precipitate formed from molecular 
interactions was allowed to settle. The viscosity of the remaining supernatant was then 
measured as a means of comparing and quantifying the interactions of alginate and protein at 
the different pH values.  
With all alginates, there was typical pH dependent acid gel behaviour, with specific viscosity 
increasing at lower pH’s as an acid gel is formed. With all of the alginate samples tested, at 
the lower end of the pH range there was a visible precipitate formed when BSA or Casein 
was added to the mixture. After 30 minutes the precipitate was allowed to settle and there 
was a measurable drop in the viscosity of the remaining supernatant. This precipitation and 
interaction between alginate and protein was not however evident at higher pH values at and 
above neutral.  
The observation of a pH dependent interaction between alginate and protein suggests a 
possible mechanism by which alginate may prevent the action of pepsin without affecting 
trypsin in a similar way. By binding to protein and pulling it out of solution by the formation 
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of a precipitate the alginate may make the protein substrate unavailable to pepsin. However, 
this precipitation interaction did not occur at higher pH’s and substrate remains available for 
trypsin digestion. As was discussed in Chapter 3, carbohydrates have been shown to be 
capable of a general protein binding, and it was discussed that the mechanism of inhibition of 
pepsin may be due to a direct inhibitor-substrate interaction.  
At low pH interactions occur between positively charged protein molecules and negative 
charges on carbohydrate polymers leading to the formation of carbohydrate-protein 
complexes and gelation [196]. Electrostatic interactions have also been demonstrated to form 
between negatively charged sulphate groups of carrageenan and positively charged regions of 
casein [194, 195]. However the formation of positive charge on the protein only occurs as it 
the pH is lowered and the protein is taken below its iso-electric point. At the pH at which 
trypsin is active, both in the current experiments, and physiologically, protein would be above 
its iso-electric point and carry negative charges therefore making it unable to interact with 
carbohydrate polymers.  
The interaction of alginate samples with BSA, Casein and Milk Protein were therefore 
compared rheologically at pH2 and pH7 to simulate the pH conditions at which pepsin and 
trypsin would be active. 
In general, across all samples, changes in rheological preoperties were observed with the 
addition of protein to alginate solutions, as would be expected with the combination of any 
two polymer solutions. The nature of the change in rheological properties was shown to vary 
with the type of protein, type of alginate, and the pH. In some cases addition of protein to the 
alginate solution caused an increase in gel strength, and in some cases a weakening of the gel. 
But in all cases the synergistic effects were more pronounced at pH2, suggesting that 
interactions between alginate and protein are pH dependent, and occur more strongly at low 
pH.  
With alginate H120L at pH2, the addition of all three protein types (BSA, Casein and MP) 
caused a weakening of gel strength with the both the viscous and elastic component of the 
dynamic modulus decreasing, and an increase in phase angle indicating a shift to more liquid 
like behaviour. At pH7, the addition of protein also caused changes to rheological properties, 
although as is demonstrated in Figure 91, in terms of the magnitude, the effects are much 
greater on the alginate gel at pH2, than at pH7. G*, G’ and G” the dynamic, elastic and 
viscous moduli are directly related to gel strength, and as can be seen alginate forms a much 
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stronger gel at low pH, with the dynamic modulus of H120L alginate at pH2 being 
approximately an order of magnitude larger than at pH7 (~1Pa at pH7, ~ 10Pa at pH2). So the 
addition of protein has a more disruptive effect on the physical properties of alginate at a 
lower pH in terms of magnitude.    
Similarly with alginate SF60, there was a weakening of gel strength at pH2 with the addition 
of BSA and Casein, with a decrease in both viscous and elastic modulus. There was however 
no change with the addition of milk powder, and no interactions were observed at pH7 
between SF60 and any of the proteins.  With FMC3 and FMC13 alginates, at pH2 the 
addition of protein to the mixture served to strengthen the gel, causing an increase in both the 
viscous and elastic component of the dynamic modulus, without changing the phase angle.  
In each of the alginates tested, at pH2 the elastic modulus G’ is higher than the viscous 
modulus G”, this indicates that elastic solid-like properties dominate and the material has 
formed a strongly cross-linked gel as opposed to a physically entangled gel network. This 
occurs because in a physically entangled network, upon relaxation the material can untangle 
and reform, behaving like a viscous liquid, but in a cross-linked gel network interactions 
between polymers are broken at high frequency and do not have time to reform.  
This oscillation profile is indicative of a gel that is formed by both molecular entanglement 
and hydrogen bonds forming between polymers. Alginate by itself is known to form strongly 
cross-linked gels, the data presented here shows that alginate will non-specifically interact 
with proteins to form a heteroplolymeric cross-linked gel and that this synergism can either 
have a strengthening or weakening effect on gel strength as compared to alginate by itself, 
but in both cases the effect is caused by the crosslinking of alginate-protein molecules and 
not just by physical entanglement [233].  
Furthermore, the pH sensitivity of the synergism indicates that ionisation plays a role in the 
formation of electrostatic interactions. This further supports the argument that at low pH, 
interactions occur between positively charged protein molecules and negative charges on 
carbohydrate polymers leading to the formation of non-specific carbohydrate-protein 
complexes and gelation [196]. This would explain why interactions between alginate and 
protein are much stronger at low pH, as the formation of positive charge on the protein occurs 
as the protein is taken below its iso-electric point.  
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There is evidence in vivo of interactions between carbohydrates and protein affecting the 
digestion kinetics of protein. It was shown by Lambers et al 2013, that casein forms a protein 
network in the acidic gastric environment which caused casein coagulation and elevated 
viscosity, and with whey protein, a precipitate has been shown to form that causes a lowering 
of solute viscosity [175]. Lambers et al suggested that these intramolecular interactions 
slowed the digestion kinetics of casein as compared to whey protein which did not coagulate 
in the same way. It was shown that by mixing casein with low molecular weight 
carbohydrates such as lactose and dextran the intramolecular casein network could be 
disrupted and reaction kinetics enhanced. What has been observed in the previous chapter is 
that when interacting with the high molecular weight polysaccharide alginate, inter-molecular 
interactions occur which increase coagulation and elevate the viscosity profile beyond what is 
seen with casein alone and further slow the kinetics of casein digested. This coagulation was 
also observed when alginate was mixed with whey protein and milk powder, suggesting 
alginate would be an effective additive to attenuate and retard the digestion kinetics of these 
and perhaps other proteins such as BSA in the acid environment of the stomach. It further 
raises the prospect that carefully chosen carbohydrate additives can be used to modulate and 
manipulate the digestion kinetics of protein in the acid environment of the stomach as 
desired.  
The speed at which protein digestion occurs and the rate of amino acid absorption from the 
gut has been shown to affect whole body post prandial protein synthesis and anabolism [174]. 
Dangin et al 2001 argue that ‘slow and fast’ protein digestion can be important in health and 
disease, with slow digested proteins having applications in cases of protein-energy 
malnutrition and slow digested proteins in cases such as renal diseases where high protein 
intakes have to be avoided. Carefully selected carbohydrates which interact with proteins 
may present a way of modulating protein digestion. 
Alginates are used in the treatment of gastro-oesophogeal reflux. The major mechanism of 
protection is the raft of acid-gel which forms when alginate enters the stomach which creates 
a protective barrier to reflux. It is well established that non-acid components of refluxate 
cause damage to the oesophagus in reflux, it had been thought that a possible mechanism of 
the protective effect of alginate could be inhibition of pepsin. The data presented here 
suggests that the major mechanism of alginate inhibition of pepsin is through binding and 
making substrate unavailable. However these results do not conflict with the findings of 
Sunderland et al that alginate directly binds to pepsin; alginate likely non-specifically binds 
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to gastric pepsin and removes it from solution [57, 172]. Inhibition of pepsin activity may 
occur by two mechanisms; direct enzyme binding, and substrate binding. Furthermore, the in 
vivo gastric environment is not buffered as in the in vitro assays, therefore alginate will also 
affect the activity of pepsin also by raising the pH of the gastric environment.  
Alginate protein interactions have previously been utilised in cold gelling matrices. Alginate-
protein microbeads have been used as a gastric resistant delivery system to protect nutrients 
such as retinol and riboflavin through the stomach for release in the small intestine, where 
they are absorbed [234]. These delivery methods work by keeping the protein separate from 
the enzyme and therefore protecting it from proteolytic degredation. 
The observations that alginates are capable of inhibiting pepsin digestion of a protein 
environment in the stomach, but not capable of inhibiting trypsin digestion in a pH neutral 
environment such as the small intestine suggests that alginates may not affect total protein 
digestion, but alter the kinetics and timecourse of protein digestion. Alginate may retard 
protein digestion in the stomach, with little effect in the small intenstine to the rate and 
kinetics of protein digestion. However, the gastric phase of digestion is important for the 
breakdown of large polypeptides into smaller oligopeptides and some amino acids, therefore 
a lower level of gastric protein digestion means that protein passed from the stomach will 
reach the small intestine at a slower rate or in a more complex form. This will mean that 
while the total yield of protein digestion may remain unaltered, the release and absorption of 
amino acids from protein will be slowed.  
Furthermore it has been shown that exocrine pancreatic secretion of trypsin and chymotrypsin 
in to the duodenum is upregulated in response to proteinase inhibition in the small intestine 
[235].  These feedback mechanisms may overcome small intestinal trypsin inhibition, 
therefore inhibition in the gastric phase may be a better therapeutic target, and be less 
susceptible to treatment resistance.   
While distinctly different profiles of alginate interaction with pepsin and trypsin were shown 
in in vitro microplate assays, the way in which alginate may interact with gastro-intestinal 
and dietary components in a physiologically relevant system is much more complex. In 
Chapter 6 the way in which alginate interacts with proteins in a model gut system is studied.  
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Chapter 5 
Modulation of α-amylase Activity 
 
5.1 Amylase 
5.1.1 Categorisation 
The α-amylases belong to glycosyl-hydrolase family 13. Glycosyl hydrolases are the super-
family of enzymes that catalyse the cleavage of glycosidic bonds between sugar residues. 
This family also includes pullulunases, glucanotransferase, cyclomaltodextrinase, trehalose-
6-phosphate hydrolase, malto-oligosyltrehalose trehalohydrolase [110]  
The α-amylases are a class of glycosyl hydrolases that catalyse the cleavage of α-(1-4) 
glycosidic bonds in polysaccharides, α-amylase will cleave at multiple sites in linear 
polysaccharides to generate primarily maltose and maltotriose product. Enzymes  which 
cleave α-D-(1-4) glycosidic bonds are also referred to as amylolytic enzymes or α-glucanases 
[236]. Of these α-glucanases, α-amylases are the pre-eminent starch hydrolysing enzymes in 
humans. The α-amylases are endohydrolytic α-glucanases, cleaving within the polysaccharide 
chain. 
5.2 Structure of α-amylase 
α-amylase is monomeric, consisting of a single polypeptide chain. The molecular weights of 
microbial α-amylases have been reported to vary from between 10,000 and 139,000 Da but 
are usually between 50 and 60,000 Da [237]. Porcine pancreatic amylase is reported as 45-
50,000 Da in molecular weight and in man between 55,000 and 65,000 Da [85]. The porcine 
pancreatic α-amylase enzyme consists of approximately 470 amino acids [238]. 
All mammalian and bacterial α-amylases have been shown to have three domains, A,B and C 
as can be seen from (Figure 98) and contain an alpha-beta barrel structure (αβ)8 in the B 
domain. Domain A is composed mainly of an eight stranded β-barrel structrure which 
contains the active site [239]. Domain A constitutes residues 1-99 and 169-404, containing 
residues involved in the active site and a Cl
-
 binding site. The binding of a Cl
-
 ion has been 
shown to activate α-amylase [240]. All a-amylases bind an essential Ca+ ion which is 
required for structure and catalytic activity, this Ca+ binding site is located in Domain B. 
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Domain C is the N-terminal portion of the enzyme, and is thought not to be important to the 
catalytic mechanism [240].  
 
Figure 98  Schematic representation of the polypeptide chain fold of human pancreatic α-
amylase and the positionings of the three structural domains (Domain A, residues 1-99, 169-404; Domain B, 
residues 100-168;  Domain C, residues 405-496) Calcium and chloride binding sites, N- and C-terminal ends of 
the polypeptide chain have also been shown. Taken from Brayer et al 1995 [239] 
5.3 Catalytic Mechanism 
The active site is contained within Domain A and contains three perfectly conserved residues 
throughout the α-amylase family, corresponding to Asp180, Glu205, and Asp291 in barley 
and Asp176, Glu208, and Asp269 in Bacillus subtilis α-amylase. Mutation of these results in 
total loss of activity [240-242]. 
The α-amylase active site can hold five sugar residues and holds the substrate between the 
conserved catalytic residues. Amylase will cleave the polysaccharide chain at the glycosidic 
bond between residues 3 and 4 (Figure 99).  
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Figure 99  Active site centre of α-amylase. Cleavage occurs between residues 3 and 4. Taken 
from Butterworth et al 2011 [240]. 
 
Glycosyl hydrolases cleave in different ways and at different sites, but operate with the same 
essential mechanism which depends on two residues; a catalytic proton donor (glutamate) and 
a nucleophile/base (aspartate) [110]. The cleavage can result in either a ‘retention or an 
inversion, of the anomeric configuration’ which depends upon the distance between the 
proton donor and nuceophilic base [243]. α-amylase is a retaining glycosyl hydrolase and so 
the sugar residue conserves it’s anomeric configuration after cleavage [244, 245].  
In stereochemical retention, the reaction mechanism is two-step; first the acid/base catalysis, 
then nucleophillic attack. Both are mediated by carboxylic acid groups on the conserved 
active site residues. The first step is proton donation; the glycosydic oxygen at C6 is 
protonated by the acid-catalyst residue. i.e. the hydrogen of the carboxyl OH group forms a 
hydrogen bond with the glycosidic oxygen. Secondly, the nucleophilic base attacks the δ+ C6 
of the sugar residue, releasing the glycosidic product from the active site and forming a 
glycosyl-enzyme intermediate. Release of substrate from the glycosyl-enzyme intermediate 
requires nucleophillic attack by a water molecule; the water molecule is split into H+ which 
attacks the negatively charged acid/base residue, regenerating the acid/base hydroxyl group 
and the remaining OH- group of the water molecule attacks the C6 carbon of the sugar 
residue, releasing it from the enzyme and reforming the nucleophillic O- group. 
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Figure 100  Glycosidic bond hydrolysis, 2 mechanisms: (a) The retaining mechanism (b) The 
inverting mechanism . Taken from Davies and Henrisatt 1995 [243] 
The diference in stereochemical inversion is that the catalytic bases are further apart and 
protanation and nucleophilic attack are believed to occur simultaneously. The distance of the 
nucleophilic base from the aglycon C6, results in an inversion of stereochemistry [243]. 
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5.4 Amylase pH optimum and activity 
Porcine pancreatic α-amylase has been shown to have a substrate dependent pH-optimum. 
With starch and amylose substrates, the pH optimum of α-amylase is 6.9. However with p-
nitrophenyl, α-D-maltoside, ϒ-cyclodextyrin and maltopentitol (low molecular weight 
oligosaccharides), the pH optimum was shifted down to 5.2.  
Ishikawa et al showed this substrate dependent shift in pH optimum to be dependent on the 
occupation of subsite 5 of the enzyme active site.  With subsite 5 occupied in the case of 
saccharides of 5 residues or more in length the pH optimum is 6.9. When subsite 5 is not 
productively occupied, the pH optimum is shifted down to pH5.2 (Figure 101). 
 
 
Figure 101     Active site of  porcine pancreatic amylase binding substrates. The  catalytic  residue  
is  located between subsites 3  and  4.  Taken from Ishikawa et al 1990 [246]. 
This substrate dependent pH optimum has been shown to occur in human pancreatic α-
amylase as well as in porcine α-amylase [246]. 
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5.5 Dietary Fibre and Amylase Activity  
As discussed in the introduction, the α-glucosidase inhibitor acarbose (Figure 3) has been 
shown to significantly attenuate development of Type 2 Diabetes in patients with glucose 
intolerance and promote a return to normal glucose tolerance [31]. Acarbose is a pseudo-
oligosaccharide and is similar in structure to the substrate maltotetraose (Figure 3). Acarbose 
can be effectively transported through the maltose-maltodextrin transport system, but is a 
poor substrate for α-glucosidases and can not be metabolised and therefore occupies and 
blocks α-glucosidase capacity [33]. By slowing carbohydrate digestion, acarbose reduces the 
glycaemic-hit of a meal and reduces post-prandial insulin secretion. [32]. In  the 2002 STOP-
NIDDM randomised control trial, 682 patients with impaired glucose tolerance were treated 
with acarbose and 686 with placebo, there was a significant reduction in diabetes 
development in the treatment group, with 32% of patients on acarbose developing diabetes 
compared to 42% in the control group [31]. In a 5-year study of nearly 2000 individuals with 
Type II diabetes, 4.7% showed adverse effects believed to be linked to acarbose. Side effects 
included; flatulance, diarrhoea, nausea, abdominal pain, loss of appetite and heart burn [35].  
Dietary fibres have also been investigated as potential treatments of diabetes and metabolic 
disease. The dietary fibre guar gum was shown to have anti-hyperlipidaemic and anti-
hyperglycaemic effects when given as a dietary supplement to diabetic rats [139]. Guar gum 
is composed of 80-85% galactomannan, with 1.5-2.0 mannose residues for every galactose. It 
is structurally composed of a (1-4) β-D-mannopyranosyl backbone with single β-D-
galactopyranosyl branching residues and can form thick gels [247]. Forty two male rats with 
Streptozotocin induced diabetes were split in to groups and were fed diets with 0%, 5%, 10% 
and 20% guar gum. Blood and glucose levels were measured at 0, 7, 14 and 28 days. It was 
shown that after 28 days there was a significant hypoglycaemic effect in the rats that had 
been fed 20% glucose with a 52% decrease in blood glucose. It was also shown that rats fed 
5, 10 and 20% guar gum had significantly lower circulating cholesterol and triglyceride 
levels.  
Partially Hydrolysed Guar Gum (PGHH) has been investigated as a human intervention in a 
randomised clinical trialo. 63 patients with type-2 diabetes were split into a control group and 
an intervention group fed 5g PHGG twice a day for 6 weeks. The PHGG diet was shown to 
have beneficial effects towards markers of metabolic syndrome with a significant reduction in 
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waist circumferance in the intervention group (average 1.2cm) and a significant 
hypoglycaemic affect. The PGHH was shown to blunt the post-prandial increases in blood 
glucose and insulin [140].  
Dietary fibre including pectin, alginate, xantham gum and guar gum have been shown to 
attenuate post-prandial blood glucose response and to be an effective treatment of diabetes 
[141, 248-251]. It has been argued that this is due to the soluble dietary fibres increasing the 
viscosity of the meal which slows digestion and delays gastric emptying. Alginate has been 
investigated as a dietary additive to be used in diabetes management. Seven patients with 
type 2 diabetes were fed test meals with control or 5g alginate added and blood glucose and 
gastric emptying were compared. Addition of alginate to the meal resulted in reduced post-
prandial blood glucuse (31% lower) and serum insulin (42% lower). Radiolabelled chromium 
was used to monitor the rate of gastric emptying, at 75 minutes after feeding 29% less of the 
meal was emptied with alginate supplementation and by 105 minutes 19% less had emptied. 
Furthermore the reduced blood glucose rise correlated with slowed gastric emptying. This 
study suggests that like other soluble dietary fibres, alginate may be a potential treatment for 
diabetes and that through delayed gastric emptying can reduce the glycaeminc hit of a meal 
and attenuate the ensuing glucose and insulin response.   
Kimura et al 1996 looked at the effects of alginates supplementation in rats groups of 5-6 rats 
were fed a range of alginates and it was found that two low molecular weight alginates 
attenuated glucose response 30min and 60min after feeding [252].  
The importance of viscosity in blunting the glycaemic response was shown by Jenkins et al. 
Six types of dietary fibre were compared for their ability to reduce post-prandial blood 
glucose. Guar, pectin, tragacanth gum, methylcellulose, wheat bran and cholestyramine were 
compared and Guar Gum was shown to be most effective at flattening the glucose response, 
however when hydrolysed non-viscous guar gum was administered, the effect was abolished. 
This adds weight to the argument that it is the viscosity of guar and other fibres which is 
important to the blunting of post-prandial hyperglycaemia [249].  
Interest in bioactive compounds and carbohydrate digestion has not just been on garstric 
emptying and GI transit time, but also into direct effects exogenous compounds may have on 
amyolytic enzymes. Research into fibres as inhibitors of digestive enzymes began in the late 
70s and early 80s. Rats fed a high fibre diet containing 20% cellulose have shown a 
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significant decrease in intestinal proteolytic, lipolytic and amylolytic enzyme activity upon 
analysis of intestinal contents [50]. Dilution of stomach contents with DF has been suggested 
as a possible factor during in vivo studies of enzyme activity [50]. However, the same 
investigators were also able to demonstrate in vitro inhibiton of pancreatic enzymes in 
samples of human pancreatic juice. Activity of lipase, amylase, trypsin and chymotrypsin was 
compared in samples of human pancreatic juice incubated with or without a range of DFs. 
With the exception of pectin, the fibres examined (alfalfa fibre, oat bran, hemicellulose, 
wheat bran and cellulose)  all brought about a reduction in activity of trypsin, chymotrypsin, 
lipase and α-amylase, with cellulose and hemicellulose producing the largest effect. 
However, incubation with pectin was shown to bring about a 48% increase in α-amylase 
activity and a 23% increasse in lipase activity [51].  
In the 1980s starch blockers became a popular area of research in the treatment of obesity and 
other ‘carbohydrate-dependent’ diseases such as diabetes and insulin resistance as researchers 
sought to find ways of inhibitting α-amylase in order to block carbohydrate digestion. 
Although starch blocker tablets are still widely marketed, their efficacy is the subject of 
dispute [24-26]. The active agents in starch blockers are proteins extracted from a number of 
plants; Phaseolus vulgaris (Common bean) extract [27], Triticum aestivum (wheat flour) 
extract [28] and Ttype 1 α-amylase Iinhibitor (α-AI) from Amaranthus hypochondriacus 
seeds [29]. It is thought that these natural amylase inhibitors evolved as a defense mechanism 
to protect the plant against predation [30]. Relatively recent work has again supported the use 
of Phaseolus vulgaris extract. In a small human trial weight-loss with Phaseolus vulgaris 
extract was shown to be higher than placebo when 25 healthy individuals were fed Phaseolus 
vulgaris extract or placebo with meals [25]. 
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5.6 Methods 
5.6.1 Dinitrosalycylic assay of a-amylase activity 
 
The DNSA α-amylase assay, first developed by Sumner in 1921, works on the principle of 
measuring the amount of reducing sugar produced by α-amylase cleavage of substrate starch 
[253].  
 
Reducing sugars are generated by the α-amylase cleavage of the starch substrate. When 3,5-
dinitrosalycylic acid is heated to 100°C in the presence of reducing sugars, a red colour is 
formed proportionate to the amount of reducing sugar. At  100°C these reducing sugars 
reduce 3,5-Dinitrosalycylic acid to 3-amino, 5-nitrosalycylic acid and the aldehyde group of 
the sugar is oxidised to carbonyl. Change in absorption can be detected at 550nm in a 96-well 
plate spectrophotometer. 
5.6.2 Scaling Down to 96 well microplate 
 
30µl of amylase solution was incubated with 30µl of biopolymer sample and incubated for 30 
minutes. At T0 60µ of starch substrate was added and incubated at 37°C for 30 minutes. At 
T30 120µl of DNS reagent solution was added to all wells and the plate was heated to 100°C 
for 15 minutes. Colour absorption was then measured at 550nm. 
 
As with the N-terminal assay, in an unbuffered system there is a large degree of pH variation 
in the reaction solution with the addition of alginate, as can be seen in Figure 102. 
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Figure 102  pH variation of Dinitrosalycylic acid reaction solution with the addition of alginate  . 
0.25mg/ml,  1mg/ml,  4mg/ml. 
 
The assay was therefore set up to run in a 30mM Sorensen’s phosphate buffer. As can be seen 
from Figure 103 this effectively buffers the alginates, and keeps the reaction pH consistent.  
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Figure 103  pH variation of Dinitrosalycylic acid reaction solution with the addition of alginates 
buffered in 30mM sorensen’s phosphate.. 0.25mg/ml,  1mg/ml,  4mg/ml. 
 
   
195 
 
A range of starch and amylase concentrations were tested. As can be seen from Figure 104 at 
0.5 and 1mg/ml amylase there was a non-linear relationship between colour development and 
substrate concentration. At 0.25mg/ml the relation between substrate concentration and 
activity was linear as shown in Figure 104. 
Iit was therefore decided that dietary fibre activity would be tested against 0.25mg/ml 
amylase with 5mg/ml Starch substrate concentration.  
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Figure 104  Colour development in DNS assay with varying starch and α-amylase concentrations.  
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5.7 α-Amylase HTP Assay  
5.7.1 96-Well Plate N-Terminal Method 
5.7.2 Preperation of Solutions 
For high-throughput analysis, biopolymer samples were prepared at 10mg/ml in 30mM 
Sorensen’s Phosphate buffer. Starch substrate was prepared by heating 5mg/ml potato starch 
to 80°C while stirring and then left to cool and kept at 27°C. α-amylase was prepared at 
0.25mg/ml in buffer.  
The dinitrosalycylic acid reagent was prepared by dissolving 0.25g DNS in 5ml 2N NaOH 
and making up to 12ml. 7.5g Sodium Tartrate was then added and the solution was made up 
to 25ml.  
A 0.2% (w/v) Maltose Standard was also prepared in buffer.  
5.7.3 Method 
30µl Fibre Sample was pre-incubated with 30µl α-amylase for 30 minutes on a shaker. At T0 
60µl of Starch substrate solution or buffer blank was added as appropriate and the plate was 
incubated for 30min at 37˚C. 
After 30 minutes, 120µl of DNS reagent was added and mixed and the plate was incubated 
for 15 minutes in an Autoblot Microhybridisation oven at 100˚C. 
At T45, the plate was removed from the microhybridisation oven and left to cool to room 
temperature and read at 550nm. 
For each dietary fibre sample an adjacent control sample was run on the opposite side of the 
plate. This was to ensure that any affect on the rate of the dinitrosalyclic acid reaction due to 
uneven heating of the plate as the temperature is raised to 100°C was controlled for.
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5.7.4 Plating 
Figure 105  Plating layout for the α-amylase microplate assay.  
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5.7.5 Kinetic Analysis 
 
As with the high-throughput assay α-amylase was made up at 0.25mg/ml in 30mM Sorensens 
Phosphate. All biopolymer samples were made up at 4 mg/ml in 30mM Sorensen’s Phospate 
buffer. 
Substrate starch solution was prepared by heating 5% (w/v) sigma starch from potato in 
30mM Sorensen’s Phosphate to 80°C while stirring.  
DNSA colour reagent was prepared by dissolving 0.25g DNSA in 5ml 2N NaOH. This was 
then made up to 12ml with water and 7.5g of sodium tartrate was added. The final solution 
was then made up to 25ml.  
A 0.2% (w/v) Maltose Standard was also prepared in buffer.  
5.7.6 Procedure 
On Plate 1 a range of dilutions of substrate starch was prepared in three lanes ranging from 
5% w/v to 0.6125% w/v. These values represent the highest concentration that will go into 
solution, and the lowest concentration that produces a reliable result. 
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5.7.1 Plating Kinetic assay 
 
Figure 106  Plating layout for the α-amylase kinetic microplate assay. 
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On one plate, substrate dilutions were prepared at appropriate concentrations. On a second 
plate 30µl of biopolymer at 4mg/ml was added to all wells in the three test rows. 30µl of 
buffer was added to all wells in the control lane and 30µl of 0.025mg/ml α-amylase was 
added to all wells in the two test lanes. The plate was then pre-incubated for 30 minutes at 
37°C.  
At T0, 60µl of substrate from plate 1 was added to the relevant column on plate 2 and pre-
incubated for 30 minutes. At T30, 120µl of DNS reagent was added to all wells and heated at 
100°C until T50. After the plate has cooled for 30 minutes samples were read at OD540. 
All results were done in duplicate on the plate and standardised to the control. Each plate was 
run in triplicate with fresh solutions.  
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5.8 Alginate and Amylase 
5.8.1 Microplate Screening  
Amylase activity in the presence of dietary biopolymers was measured using a 96-well 
microplate adaptation of the DNSA α-amylase assay, first developed by Sumner in 1921, as 
described in the experimental section. The assay system was validated using EDTA, a known 
α-amylase inhibitor as a positive inhibition control. EDTA is a calcium chelator thought to 
inhibit amylase activity by chelating the tightly bound calcium of α-amylase [254]. 
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Figure 107 – Amylase Inhibition with EDTA. Amylase activity is plotted against EDTA concentration in mM as 
a positive inhibition control. (n=3). Uninhibited α-amylase control activity is represented by 100%.  
Maximum inhibition with sodium EDTA was achieved at a concentration of 5mg/ml, there is 
a clear dose response effect, as shown in Figure 107. The strongest inhibition of α-amylase 
was at 5mg/ml, reducing activity to 0.15±0.13% of normal amylase activity. 
Again the catalogue of 18 well characterised alginates was tested for their modulatory 
activity towards α-amylase. All alginate samples were tested at three concentrations; 10, 2.5 
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and 0.625mg/ml. This gave reaction concentrations of 2.5, 0.625 and 0.156mg/ml, 
respectively.  
In Figure 108 the results for the catalogue of eighteen alginates have been collated. Taken 
together there is a clear dose effect as can be seen in Figure 108. At a 2.5mg/ml concentration 
of alginate, there is an average increase in amylase activity of 18.45±6.1%. At a 0.625mg/ml 
concentration of alginate, there is an average increase in amylase activity of 11.0±4.4%. At a 
0.1625mg/ml concentration of alginate, there is an average increase in amylase activity of 
5.5±3.3%. 
 
 
 
 
 
 
 
 
 
 
 
Figure 108 - Concentration dependent activation of amylase in the presence of sample alginates. Activity 
is shown as a percentage increase from normal amylase activity at three concentrations.  0.156mg/ml,  
0.625mg/ml,   2.5mg/ml. All samples were tested in triplicate (n=3) with error bars showing standard 
deviation. 
The complete data for alginate regulation of α-amylase is shown in Figure 109. Tthe highest 
concentration of 2.5g/ml all alginates bring about an increase in amylase activity. However 
there is a large degree of variation in the magnitude of activation from alginate to alginate. 
This variation was investigated in relation to alginate structure. 
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Figure 109 - Concentration dependent activation of amylase in the presence of alginates. Activity is shown as a percentage of normal amylase activity at three concentrations 
of alginate,  0.156mg/ml,  0.625mg/ml,   2.5mg/ml. All samples were tested in triplicate (n=3) with error bars showing standard deviation. 
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Figure 108 demonstrates that alginates per se can activate α-amylase activity and increase the 
rate of activity in a dose dependent way. In order to investigate links between this activation 
and alginate structure, the levels of activation were correlated against alginate F:G content. 
As previously stated, the 8 brown seaweed alginates provided by Technostics Ltd were 
extracted from two separate species; High-G Lamanaria, and High-M Lessonia. These have 
been compared in the Box-Plots in Figure 110. No statistically significant difference could be 
shown between these two groupings using an unpaired T-Test (P=0.24), and therefore no 
species effect was demonstrated.  
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Figure 110 – Comparison of amylase activation levels between high-G Lamanaria alginate and high-M Lessonia 
Alginate.  The boxplots show four High-G alginate samples from Lamanaria and four High-M from lessonia. 
All samples were done with 6 repeats. The plot shows no significant difference in activation between the two 
species, P=0.2379 with an unpaired T-Test.  
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The catalogue of 18 alginates tested cover a full range of structural F[G] content, as shown in 
Figure 111 it was therefore possible to correlate percentage activation of amylase activity 
against alginate F[G] and test the statistical significance using Spearman’s Rank Correlation.  
No significant correlation was found between alginate F[G] and percentage pepsin activation 
at 2.5mg/ml, 0.625mg/ml or 0.156mg/ml. That is therefore to say that no significant link 
could be demonstrated between manuronic/guluronic acid residue content and levels of 
pepsin activation.  
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Figure 111 - Correlation of alginate G-residue frequency (F[G]) and level of amylase activation with 2.5mg/ml 
alginate. Amylase activation is shown as a percentage of normal amylase activity. The error bars show the 
standard deviation of 3 replicates (n=3). No statistically significant correlation could be shown with a Spearman 
r value of -0.085 and a p value of 0.74.  
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At 12.5mg/ml the Spearman rank correlation coefficient, as shown in Figure 111 was -0.085 
and a p value of 0.74, showing no statistically significant correlation between α-amylase 
activation at 10mg/ml and alginate F[G] content. At 0.625mg/ml the Spearman rank 
correlation coefficient, as shown in Figure 112 was -0.36 and a p value of 0.14, showing no 
statistically significant correlation between amylase activation at 2.5mg/ml and alginate F[G] 
content. At 0.156mg/ml the Spearman rank correlation coefficient, as shown in Figure 113 
was -0.33 and a p value of 0.18, showing no statistically significant correlation between 
amylase activation F[G] content.  
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Figure 112- Correlation of alginate G-residue frequency (F[G]) and level of amylase activation with 0.625mg/ml 
alginate. Amylase activation is shown as a percentage of normal amylase activity. The error bars show the 
standard deviation of 3 replicates (n=3). No statistically significant correlation could be shown with a Spearman 
r value of -0.36 and a p value of 0.14.  
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Figure 113 - Correlation of alginate G-residue frequency (F[G]) and level of amylase activation with 
0.156mg/ml alginate. Amylase activation is shown as a percentage of normal amylase activity. The error bars 
show the standard deviation of 3 replicates (n=3). No statistically significant correlation could be shown with a 
Spearman r value of -0.33 and a p value of 0.18. 
208 
 
 
The fact that no correlations could be shown with alginate F[G] at any of the tested 
correlations suggest that the activation effect observed with alginates is a nonspecific 
activation caused by any alginate and not affected by alginate composition. However, while 
no correlation was demonstrated between alginate F[G] and amylase activation levels, the 
structure and biophysical properties of alginates are not just dictated by F[G] frequency, but 
also by the arrangement of contiguous blocks of M and G residues as was discussed in the 
introduction. Levels of amylase activation were correlated against the other structural data 
available for the well characterised alginates (Table 19). No statistically significant 
correlations could be shown between levels of α-amylase and activation and any of the 
structural characteristics of the well characterised alginate samples.  
 
Structural 
Characteristic 
2.5mg/ml 0.625mg/ml 0.156mg/ml 
Spearman
s value 
P-value 
Spearman
s value 
P-value 
Spearman
s value 
P-value 
F[G] -0.085 0.7376 -0.360 0.1417 -0.329 0.1820 
F[M] 0.049 0.8483 0.365 0.1368 0.347 0.1582 
F[GG] 
 
-0.096 0.7047 -0.353 0.1506 -0.324 0.1893 
F[MG/GM] 
 
0.032 0.8994 0.249 0.3199 0.350 0.1544 
F[MM] 
 
-0.023 0.9286 0.346 0.1593 0.356 0.1476 
F[MGG/GGM] 
 
0.349 0.1562 0.233 0.3526 0.321 0.1944 
F[MGM] 
 
-0.046 0.8547 0.207 0.4110 0.366 0.1358 
F[GGG] 
 
-0.129 0.6096 -0.314 0.2044 -0.286 0.2497 
N [G>1] 
 
-0.127 0.6157 -0.329 0.1822 -0.352 0.1521 
 
Table 19 Correlation between levels of α-amylase activity and structural characteristics of alginate.  
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Molecular weight data was only available for the eight alginates supplied by Technostics Ltd. 
Levels of amylase activation were correlated against these eight alginate with molecular 
weights ranging from 34,700 – 387,000 Da. However no significant correlations could be 
shown between molecular weight and amylase activity as shown at substrate contractions of 
either 2.5mg/ml, 0.625mg/ml or 0.156mg/ml as shown in Figure 114, Figure 115 and Figure 
116 respectively. 
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Figure 114 - Correlation of alginate Molecular Weight (MW) and level of amylase activation 
with 2.5mg/ml alginate. Amylase activation is shown as a percentage of normal amylase 
activity. The error bars show the standard deviation of at least 3 replicates (n=3). No 
statistically significant correlation could be shown with a Spearman r value of -0.07143 and a 
p value of 0.9063. 
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Figure 115 - Correlation of alginate Molecular Weight (MW) and level of amylase activation 
with 0.625mg/ml alginate. Amylase activation is shown as a percentage of normal amylase 
activity. The error bars show the standard deviation of at least 3 replicates (n=3). No 
statistically significant correlation could be shown with a Spearman r value of 0.2143and a p 
value of 0.6615. 
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Figure 116 - Correlation of alginate Molecular Weight (MW) and level of amylase activation 
with 0.156mg/ml alginate. Amylase activation is shown as a percentage of normal amylase 
activity. The error bars show the standard deviation of at least 3 replicates (n=3). No 
statistically significant correlation could be shown with a Spearman r value of 0.5357 and a p 
value of 0.2357. 
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5.9 Alginate-amylase enzyme kinetics  
Selected kinetic analysis was carried out on all well characterised alginate samples using a 
modified version of the 96 well microplate DNS Acid Assay as described in the methods 
section. All biopolymer samples were tested a minimum of 5 times and kinetic data was 
calculated using Graphpad Prism 4 software.  
Enzyme kinetics is primarily used for the study of enzyme inhibition, but the principles may 
also be applied to enzyme activation. Enzyme activation may occur through an increase in the 
affinity of the enzyme for the substrate. This would cause an increased rate of reaction at low 
substrate concentrations, but would be saturated out at higher substrate concentrations and 
therefore the Km would be lowered, but the  would remain unchanged. 
Alternatively the enzyme becomes more active towards the substrate via a mechanism other 
than increased enzyme-substrate affinity and the maximum velocity of the reaction is 
increased, but as there is no change in enzyme-substrate affinity the Km remains the same.  
Figure 117 below shows a typical kinetic plot for alginate activation of α-amylase. In the 
control digestion the velocity of the reaction increases more or less proportionally with the 
concentration of the substrate from 0-0.5mg/ml of substrate, after which the reaction velocity 
begins to plateaux as the enzyme active site becomes saturated. As can be seen from Figure 
117 below, when the alginate FMC13 is added to the reaction mixture at 1.25mg/ml the 
velocity of the reaction is increased at all concentrations, with the increase in reaction 
velocity slowing and beginning to plateaux at substrate concentrations higher than 1mg/ml.  
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Figure 117- Michaelis-Menten plot for alginate sample FMC13 at 1.25mg/ml ( ) as 
compared to a normal α-amylase control (■). Substrate concentration [s] is given in mg/ml 
and the velocity is given as the rate of change in percentage absorbance per minute. The error 
bars show the standard deviation of at least 5 replicates (n=5) 
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Figure 118- Lineweaver-Burk plot for alginate sample FMC13 at 1.25mg/ml ( ) as compared to a normal α-
amylase control (■). Substrate concentration [s] is given in mg/ml and the velocity is given as the rate of change 
in percentage absorbance per minute. The error bars show the standard deviation of 5 replicates (n=5). 
The kinetic data from the Michaelis Menten plot was transformed into the double reciprocal 
Lineweaver Burke plots shown in Figure 118. From these data the kinetic constants Vmax and 
Km were calculated for a normal α-amylase control and for each of the alginate samples 
tested.  
In a normal α-amylase digestion of potato starch substrate the Vmax is 6.024 %/min and the 
Km is 0.51. In the case of FMC13 shown above in Figure 118, the addition of FMC13 
alginate to the reaction mixture resulted in an increase of Vmax to 18.33, and a Km increased to 
1.29. However, while the Vmax was significantly different, the Km was not as the control value 
lay within the 95% confidence interval of the test sample FMC13.
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Although no statistically significant relationships between alginate structure and levels of 
activation in the high-throughput microplate analysis, the kinetic data was assesed to 
investigate any correlations, this data is included in Table 20.  
Structural 
Characteristic 
Vmax Km KA 
Spearman
s value 
P-value 
Spearma
ns value 
P-value 
Spearman
s value 
P-value 
F(G) -0.601 0.0084 0.000 1.0000 -0.024 0.9252 
F(M) 0.599 0.0086 0.030 0.9061 0.020 0.9384 
F(GG) 
 
-0.638 0.0044 -0.049 0.8484 -0.030 0.9061 
F(MG/GM) 
 
0.377 0.1230 -0.073 0.7750 0.016 0.9512 
F(MM) 
 
0.520 0.0270 -0.003 0.9903 -0.007 0.9773 
F(MGG/GGM) 
 
0.283 0.2561 -0.383 0.1169 0.099 0.6950 
F(MGM) 
 
0.174 0.4912 -0.172 0.4939 -0.050 0.8452 
F(GGG) 
 
-0.569 0.0137 0.054 0.8323 -0.018 0.9449 
N (G>1) 
 
-0.474 0.0471 0.133 0.5985 -0.042 0.8676 
 
Table 20 Kinetic date for alginate activation of α-amylase.  
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There is a significant negative correlation between levels of guluronic acid in alginate and the 
maximum reaction velocity (Figure 119). Therefore increasing levels of guluronic acid tends 
towards a lower level of α-amylase. Conversely increasing levels of mannuronic acid F[M] 
correlates with an increased level of α-amylase activation as would be expected with a 
spearmans coefficient of 0.60 and a p-value of 0.008. 
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Figure 119- Correlation between apparent Vmax of α-amylase in the presence of alginate samples (1.25g/ml) 
and alginate G-residue frequency (F[G]). A significant negative correlation was shown between Vmax and F[G] 
with a spearmans r value of -0.60 and a p-value of 0.008.  
 
As can be seen in Figure 119 there is one starred value which represents alginate sample 
FMC10 that stands apart from the rest of the data-set. In Figure 120 this outlier has been 
excluded from the data set, and the correlation still remains significant with a spearman value 
of -0.5584 and a p-value of 0.0198 between alginate F[G] and Vmax. Likewise the correlation 
between F[M] and Vmax also remains significant with the outlier removed with a spearmans 
value of 0.5567 and a p-value of 0.0203. 
* 
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Figure 120- Correlation between apparent Vmax of α-amylase in the presence of alginate (1.25g/ml) samples 
and alginate G-residue frequency (F[G]). A significant negative correlation was shown between Vmax and F[G] 
with FMC10 data removed, with a spearmans r value of -0.56and a p-value of 0.020.  
 
Significant negative correlations between structural characteristics of alginate and Vmax were 
also present when comparing F(GG), F(GGG) and N (G>1). A significant positive correlation 
between Vmax and F(MM) was also shown.  
As with overall G-residue frequency (Figure 120), decreasing frequency of GG-block 
frequency (Figure 121), GGG-block frequency (Figure 122) and overall G-block length 
(Figure 123) are all associated with increasing levels of apparent Vmax.   
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The correlation in Figure 121 between alginate F[GG] and apparent Vmax is significant and 
negative with a spearman value of -0.6381 and a p-value of 0.0044. This correlation remained 
significant with the starred outlier shown in Figure 122 excluded with a spearman value of -
0.5800 and a p-value of 0.0147. In Figure 122 there is also a significant negative correlation 
between F[GGG] and apparent Vmax, with a spearman value of -0.5692 and a p-value of 
0.0137. Again, this correlation remained significant with the starred outlier excluded with a 
spearman value of -0.5129 and a p-value of 0.0353.  
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Figure 121- Correlation between apparent Vmax of α-amylase in the presence of alginate samples and alginate 
G-residue frequency (F[GG]). A significant negative correlation was shown between Vmax and F[G] with a 
spearmans r value of -0.6381 and a p-value of 0.0044.  
* 
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Figure 122- Correlation between apparent Vmax of α-amylase in the presence of alginate 
samples and alginate G-residue frequency (F[GGG]). A significant negative correlation was 
shown between Vmax and F[G] with a spearmans r value of -0.5692 and a p-value of 0.0137.  
 
* 
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There is also a negative correlation between apparent Vmax of α-amylase in the presence of 
alginate and the overall size of G-blocks in alginate. As shown in Figure 123 the trend is that 
the larger the G-Block length, the lower the increase in Vmax. The spearman r value is -
0.4737, with a p-value of 0.0471. However when the starred outlier is removed the 
correlation between Vmax and [N(G>1)] is no longer significant and the outlier  may be giving 
the data a false correlation.  
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Figure 123- Correlation between apparent Vmax of α-amylase in the presence of alginate 
samples and alginate G-residue frequency [N(G>1)]. A significant negative correlation was 
shown between Vmax and F[G] with a spearmans r value of -0.4737 and a p-value of 0.0471.  
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Figure 124 shows the positive correlation between alginate F[MM] and apparent Vmax. As 
would be expected from the negative correlation with G-residue frequency, there is a positive 
correlation between apparent Vmax and frequency of GG blocks. The spearman r value is 
0.5199 with a p-value of 0.0270. When the starred outlier is removed, the relationship 
remains significant.  
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Figure 124- Correlation between apparent Vmax of α-amylase in the presence of alginate samples and alginate 
G-residue frequency (F[MM]). A significant negative correlation was shown between Vmax and F[G] with a 
spearmans r value of -0.5199 and a p-value of 0.0270.  
* 
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Apparent Vmax was also compared against F(MG/GM), F(MGG/GGM) and F(MGM), 
however no significant correlations were shown between these structural characteristics. The 
kinetic constants Km and Ki were also compared against the structural characteristics of 
alginate and no significant correlations were shown.  
5.9.1 FMC10 
 
The alginate sample FMC10 has been described as an outlier as it causes much higher 
increases in Vmax than all of the other alginates. This tallies with the results of the higher 
throughput microplate assays which showed FMC10 to be the most potent activator of α-
amylase. Figure 125 shows the microplate HTP assay results for FMC10 as compared to the 
overall average of all alginate samples. As can be seen at each of the three tested alginate 
concentrations, FMC10 is considerably more potent than both the average level of alginate 
activation and LF120L, which is the next most potent activator of α-amylase after FMC10 
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Figure 125 - Comparison of α-amylase inhibition with FMC10 and the next most potent activator LF120L and 
the average level of α-amylase activation with alginates.  
As can be seen from Figure 109 the apparent Vmax of α-amylase in the presence of FMC10 is 
significantly higher than the rest of the alginates. However the other two kinetic constants Km 
and KA are not dissimilar to those of other alginates.  
2.5mg/ml    0.625mg/ml   0.156mg/ml 
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When looking at the structural characteristics of FMC10 it does not differ remarkably from 
the range of the catalogue of well characterised alginates, and the structurally similar alginate 
SF60 does not show such a level of activation (Full characteristic for all alginates are 
included in Appendix 8.1).  
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Figure 126 Vmax of α-amylase in the presence of all alginate samples.
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From the kinetic analysis, two different modes of activation were seen. The more 
common case was where the maximum velocity of the reaction was increased, but 
enzyme-substrate affinity was unaffected, this gave a significantly higher apparent Vmax, 
but apparent Km remained unchanged. This was the case with SF200, LF10L, FMC13, 
FMC9, LFR560, SF/LF, FMC12, SF120, SF60, FMC10, H120L and FMC2. The 
Michaelis Menten plot for FMC12 have been included as an example of this kind of 
activation Figure 127.  
In the presence of alginate FMC12, the velocity of the reaction is increased at all 
substrate concentrations and the maximum reaction velocity is over 3-fold higher in the 
presence of alginate FMC12 than control. However the Km of α-amylase is not 
significantly different in the presence of FMC12 than in control suggesting that the 
activation of α-amylase occurs without a significant change in enzyme-substrate 
affinity.  
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Figure 127- Michaelis-Menten plot for alginate sample FMC12 at 1.25mg/ml ( ) as compared to a 
normal α-amylase control (■). Substrate concentration [s] is given in mg/ml and the velocity is given as 
the rate of change in percentage absorbance per minute. The error bars show the standard deviation of 5 
replicates (n=5). Represents Km and represents the upper and lower 95% confidence limits of 
Km.  
The samples FMC3, FMC4, FMC5, FMC6 and FMC7 all brought about significant 
changes to both Vmax and Km. The Michaelis Menten plot for FMC5 is included below, 
and as can be seen there is an increase in both the apparent Km and apparent Vmax of α-
amylase with the addition of alginate sample FMC5 (Figure 128). This suggests that for 
these samples that a change in substrate-enzyme affinity may be involved in the 
activation.  
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Figure 128- Michaelis-Menten plot for alginate sample FMC5 at 1.25mg/ml ( ) as compared to a 
normal α-amylase control (■). Substrate concentration [s] is given in mg/ml and the velocity is given as 
the rate of change in percentage absorbance per minute. The error bars show the standard deviation of 5 
replicates (n=5). Represents Km and represents the upper and lower 95% confidence limits of 
Km. 
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LF120L was the only alginate sample which did not cause a statistically significant 
change in either Vmax or Km.  
 
5.10 Alginate starch interactions 
Figure 129 shows the viscosity of an alginate solution (H120L, 2.5mg/ml, pH7) both 
alone and with the addition of three starch substrates (5mg/ml; corn, wheat or potato 
starch). As can be seen from Figure 129, the addition of each of these starches causes a 
loss of viscosity as compared to alginate by itself. The current experiment was 
underataken at room temperature, and provides evidence ofstarch disrupting the 
interactions etween alginate molecules and a possible interaction between starch and 
alginate.  
 
Figure 129  Viscosity vs Shear stress of alginate and starch solutions at pH7. H120L alginate ( ), 
H120L alginate and corn starch ( ), H120L and Wheat Starch ( ), H120L and potato starch ( ) 
2.5mg/ml aqueous alginate was ade up with 10mg/ml starch and incubated for  30 minutes before 
viscosity measurement. 
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5.11 Discussion 
Activity of α-amylase was quantified using an adapted version of the Sumner et al Di-
nitro salicylic acid assay. The DNSA assay works by detecting the reduction of 3,5-
Dinitrosalycylic acid to 3-amino, 5-nitrosalycylic acid in the presence of reducing 
sugars above 100°C. Reducing sugars are  produced by α-amylase cleavage of substrate 
starch  and therefore, quantification of the coloured product is measurable 
spectrophotometrically at 550nm proportionate to the amount of reducing sugar. 
 
Certain modifications had to be made to the original methodology. All solutions and 
reagents in the reaction mixture were buffered with Sorensen’s phosphate bufferand the 
volume was scaled down to a 96 well microplate. The assay system was validated using 
the known α-amylase inhibitor EDTA as a positive inhibition control. Dose response 
inhibition was shown with EDTA. 
The catalogue of eighteen well characterised alginates was tested for modulatory 
activity against α-amylase. Alginates increased α-amylase activity by an average of 
18.35±6.05% at the highest tested concentration. Significant activation of α-amylase 
was also shown at lower alginate levels. 
There was a large degree of variation in the magnitude of the activation, and this 
variation was investigated in relation to alginate structure. 
The effect was shown not to be species dependent, with no significant difference 
between the four High-G lamanaria alginates and the four High-M lessonia alginates. 
Furthermore, across the full catalogue of alginate samples tested in the high throughput 
microplate assays, no significant correlation was found between alginate F[G] and 
percentage α-amylase activation.  
The observation that there is no correlation between alginate F[G] and levels of alginate 
activation suggests that there is a nonspecific activation of α-amylase which does not 
relate to the alginate composition. This was further demonstrated by the fact that no 
statistically significant correlations could be shown between levels of α-amylase and 
activation and any of the structural characteristics of the well characterised alginate 
samples; F(G), F(M), F(GG), F(MG/GM), F(MM), F(MGG/GGM), F(MGM), F(GGG) 
or N (G>1). 
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Furthermore, for the eight alginates with characterised molecular weights, no correlation 
could be shown between alginate size and levels of inhibition.  
As no structural correlations could be shown in the high throughput assays, selected 
kinetic assays were carried out on all well characterised alginate samples in order to 
investigate the mechanisms of the alginate-enzyme interactions, and see if any structural 
correlations could be shown with kinetic data. While enzyme kinetics is primarily used 
for the study of enzyme inhibition, the principles may also be applied to enzyme 
activation. 
Although the high-throughput microplate analysis had shown no statistically significant 
relationships between alginate structure and levels of activation, significant negative 
correlation was shown between levels of guluronic acid in alginate and the maximumun 
reaction velocity (Vmax). That is to say that alginates higher in mannuronic acid residues 
tended to be better activators of α-amylase.  
Significant negative correlations between structural characteristics of alginate and Vmax 
were also present when comparing F(GG), F(GGG) and N (G>1). A significant positive 
correlation between Vmax and F(MM) was also shown. The kinetic constants Km and KA 
were also compared against the structural characteristics of alginate and no significant 
correlations were shown. 
FMC10 was the strongest activator of α-amylase of the tested alginates. As can be seen 
in Figure 125, after FMC10, the next strongest activator of α-amylase was LF120, 
which increased amylase activity by 22.5±2.3%. This was close to the average level of 
alginate activation  of 18.4±8.5%. The activation levels of FMC10 were greatly in 
excess  of that seen with any of the other alginate samples. However no extraordinary 
structural properties could be identified when comparing the characteristics of FMC10 
to other alginates to try identify any stand-out properties which may explain the 
different activity profile. 
While the guluronic and mannuronic acid composition for FMC10 was available, the 
molecular weight for FMC10 was not charachterised in this current study. It is therefore 
possible that the molecular weight of FMC10, or some other structural charachteristic is 
responsible for the elevated activation profile. It must be considered that there is another 
factor at work, such as contamination of the sample or a fault in the production process.  
230 
 
Enzyme activation can be described as essential or non-essential. Essential activation 
occurs when the presence of the activator is required for the reaction to take place. With 
α-amylase activity, binding of a calcium ion is essential to enzyme activity, and the 
binding of monovalent cations is known to increase enzyme activity, with Chloride 
being the most potent anionic activator. Non-essential activation occurs when the 
reaction would take place without the presence of the activator, although at a slower 
rate, as α-amylase is capable of catalysing the breakdown of starch in the absence of 
Chloride, but is more potent in its presence.   
All α-amylases bind an essential Ca++ ion which is required for structure and catalytic 
activity, this Ca++ binding site is located in Domain B of the enzyme. The α-amylase 
inhibitor EDTA stops amylase activity by chelating the calcium of α-amylase which is 
necessary for activity [254]. 
Alginates are also known to chelate divalent cations such as calcium, and it is possible 
that there is some kind of alginate interaction with the α-amylase enzyme that occurs 
through this known calcium binding site [255]. However, clearly alginate does not 
remove the calcium ion from α-amylase otherwise there would be a decrease in α-
amylase activity. It is possible that by attempting to chelate this calcium ion that 
alginate associates with the enzyme and in doing so stabilise the binding of the calcium 
cation at the enzyme binding site and helps to present Ca++ to the α-amylase enzyme. 
However, as was seen with protein and alginate, it is possible that there is also an 
alginate-substrate interaction which affects the activity of the enzyme. Interactions 
between alginate and starch have been previously reported. When investigating the way 
alginate affects starch pasting, Richardson et al showed that potato starch in an alginate 
solution had a much lower viscosity than potato starch in water suspension at high 
temperatures (at 80–85 °C).  While this is a higher temperature than was used in the 
assays described in this chapter, the data presented by Richardson et al shows that under 
the right circumstances, alginate will interact with starch in such a way to disrupt 
gellation [256].  
However as can be seen in Figure 129, the addition of corn, wheat and potato starch to 
an H120L alginate solution greatly reduced alginate viscosity. This experiment was 
undertaken at room temperature and provides evidence of an interaction between 
alginate and starch. It may be therefore that a mechanism by which alginate increases 
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the activity of α-amylase is by disrupting the gel network of starch, increasing the 
surface area of starch substrate that is available for α-amylase to act upon.  
The results discussed herein are interesting in that they somewhat go against what has 
been shown in the literature regarding dietary fibres and their protective affects against 
diabetes. Dietary fibres have been shown to have anti-hyper-glycaemic effects and high 
long term intake of dietary fibre is associated with decreased risk of diabetes [44]. There 
is a well established link between fibre defficient diets and metabolic disease including 
diabetes. It is therefore somewhat counterintuitive that alginates actually increase α-
amylase activity. However, these results are in a pH controlled single-enzyme 
environment; how alginate affects carbohydrate digestion in a physiologically relevant 
system will be discussed in Chapter 6.  
Guar gum reduced post-prandial hyperglycaemia in diabetic rats [139]. Partially 
Hydrolysed Guar Gum (PGHH) has been shown to have beneficial effects towards 
markers of metabolic syndrome with a significant reduction in waist circumferance in 
and a significant hypoglycaemic affect when fed 5g PHGG twice a day for 6 weeks.  
Kimura et al 1996, showed that alginate feeding could attenuate the post-prandial blood 
glucose response in rats. Furthermore post-prandial blood glucose and serum insulin 
were lowered in a group of seven patients who were fed test meals with alginate [252]. 
These results contrast with the data presented in this chapter that alginates cause an 
increase in the activity of α-amylase. It would be expected that an increase in α-amylase 
activity would be associated with faster carbohydrate digestion kinetics and elevated 
post-prandial hyperglycaemia and hyperinsulaemia. However the studies cited above 
have suggested that the opposite is the case.  
In the Torsdottir et al 1991 study, rates of gastic emptying were measured in the seven 
test subjects [257]. Radiolabelled chromium was used to monitor gastric emptying, and 
it was shown that alginate supplementation significantly slowed the rate of gastric 
emptying, and that this reduced blood glucose rise correlated with slowed gastric 
emptying. As was discussed in the introduction, the breakdown of starch into maltose, 
maltotriose and α-limit dextrin is thought to occur very rapidly and within 10 minutes of 
transit into the duodenum [258]. This rapid digestion of carbohydrate offers an 
explanation of how despite alginates having been shown to be activators of α-amylase 
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in vitro, that they have proven to have anti-hyperglycaemic effects in vivo. Because the 
duodenal digestion of carbohydrate is so rapid, an increase in amylolytic activty will 
have a marginal effect on the speed of carbohydrate digestion. Gastric emptying 
however will present a rate limiting step. As carbohydrate predominantly occurs in the 
duodenum, the reate at which carbohydrates are delivered to the duodenum will 
therefore be the determining factor in the rate of carbohydrate digestion.  
In the Torsdottir et al 1991 study, Radiolabelled chromium was used to monitor the rate 
of gastric emptying, and 75 minutes after feeding, 29% less of the meal was emptied 
with alginate supplementation and by 105 minutes 19% less had emptied. This is likely 
to be the determining factor which resulted in the anti hyper-glycaemic effect, as 
reduced blood glucose rise correlated with slowed gastric emptying [257].  
This theory is further supported by the observations of Jenkins et al 1978 that in human 
volunteers undergoing glucose tolerance tests after consuming 50g of glucose and a 
dietary fibre, that the reduction in blood glucose rise correlated with the viscosity of the 
fibre [249]. The more viscous fibres were more effective at delaying mouth to caecum 
transit time and attenuating the blood glucose response.  
In the study of alginate supplementation in rats, Kimura et al 1996 advanced another 
theory as to why alginate reduces glucose uptake in the small intestine [252]. Alginate 
has been shown to increase Na+ excretion during digestion, as alginate inhibits sodium 
absorption in the small intestine [259]. Sodium is essential for intestinal absorption of 
glucose, as glucose uptake occurs through the sodium glucose co-transporter [260]. 
Reduced glucose uptake and the hypoglycaemic effect of alginates may be due to in part 
to alginate making sodium unavailable to the NaGluc Cotransporter.  
Kimura et al 1996, suggest that the net hypoglycaemic effect of alginate 
supplementation may be due to a combination of alginate gelling in the stomach and 
delaying gastric emptying, and reduced sodium uptake in the small intestine inhibiting 
the action of the sodium-glucose co-transporter [252].  
A further mechanism suggested by V Dall’Alba et al 2013, in the case of Guar Gum 
inhibition of carbohydrate digestion, which would also be applicable to alginates, is that 
the increased viscosity of the gut lumen contents caused by the viscous fibre reduces the 
accessibility of amylase to it’s substrate, and reduces the rate of glucose diffusion 
through the lumen for uptake [140].  
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Chapter 6 
Model Gut Analysis 
 
6.1 Introduction 
6.1.1 Overview 
A physiologically relevant in vitro Model Gut System (MGS) has been developed 
which simulates the digestive processes of the gastrointestinal tract from mouth to 
terminal small intestine. This model can be used to study the chemical and enzymatic 
digestion of the macronutrients; fat, protein and carbohydrate, and to analyse the effects 
of exogenous compounds on their digestion.  
The efficacy of the MGS has been validated by the role it has played in building a case 
for the novel lipase inhibitor alginate as a weight loss treatment [Unpublished Data]. 
The digestion and absorption of macronutrients (fat, protein and carbohydrate) is a 
major factor in health and in metabolic diseases such as obesity and diabetes. For 
absorption across the intestinal epithelia, dietary macronutrients must be mechanically, 
chemically and enzymatically broken down as they pass through the upper GI tract. 
Modulating macronutrient digestion with food additives and pharmaceuticals has been 
shown to be an effective approach in the management and treatment of health and 
disease, for example the treatment of obesity with Orlistat and diabetes with Acarbose 
[4, 261]  
Model gut systems provide a physiological simulation of normal human digestion, as 
such they provide an in vitro model that can be used to validate effects seen with 
bioactive compounds in single enzyme analysis in a more physiologically relevant 
mixed model. Furthermore model gut analysis provides a well controlled, reproducible 
and cost-effective alternative to in vivo studies. The method presented here describes a 
synthetic gut system designed to simulate the conditions of the GI tract from mouth to 
small intestine. Assay systems are described to analyse fat, carbohydrate and protein 
digestion.  
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6.1.2 Current Model Gut Systems 
As with pharmacological studies, randomised, double blinded control trials in human 
populations are the gold standard of nutrition studies, however cost and complexity are 
often prohibitive [262]. Smaller scale acute human studies may look at the processes of 
digestion by sampling from the stomach and upper small intestine after feeding [263]. 
Ileostomy studies and faecal sampling allow analysis of the the latter parts of the GI 
tract.  
Animal models have played an important part in nutrition research and greatly 
contributed to the understanding of nutrition and nutrient metabolism. Animal studies 
have enabled researchers to solve nutrient-nutrient interactions, look at nutrient 
bioavailability, tolerances and toxicity and to study diet associated disease [264]. 
However ethical concerns over the use of animal testing is a source of continual debate 
and both British and European law ensure strict controls and ethical standards for the 
use of animal testing [265]. Furthermore the relevance of animal studies to human 
digestion is a source of debate and because of perceived negative public attitudes 
towards animal testing, companies will where possible avoid the use of animal testing. 
This is particularly apparent in an industry as public facing as the nutrition, food and 
health sector. 
Due to cost, ethics and scale a wide range of in vitro methods have been developed to 
model the gastrointestinal tract in the lab. Model gut systems aim to provide a 
physiological simulation of normal human digestion, and a number of models have been 
developed to study different aspects of digestion and GI physiology. Models have been 
developed to study; bioavailability and bioaccessibility of contaminants [266], digestion 
of allergens [263], study of pre and probiotics, models of gut motility [267], peristaltic 
motion and physiological mixing and shearing, enzymatic digestion [268], substrate 
digestion and interaction [268], intestinal microbiota [269], water and nutrient 
absorption [270] and drug delivery [271]. 
Wickham et al 2012, define a major distinction in model gut systems between static 
models and dynamic models [272]. Static models are models designed as accurate 
biochemical and enzymatic simulations, but do not accurately model the physical 
processes of digestion and there is no absorptive phase. Dynamic models on the other 
hand aim to replicate the physical forces of shear and mixing and replicate transit times 
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from in vivo data, these dynamic models allow for a fuller simulation of the digestion of 
structured foods and the effects of physical food breakdown on digestion.  
6.1.3 Physical Models 
Model gut systems have provided a methodology for examining the physical aspects of 
digestion; how food is mixed, sheared, propelled and broken down in a model situation. 
In vivo, imaging studies, endoscopy and capsule sensors have been used to model transit 
time, GI motility and food processing, but these studies can be prohibitive due to cost. 
Whickham et al 2012 have developed the Dynamic Gastric Model, a “physical 
simulator…paralleled by in silico modelling of gastric flow patterns, mixing and shears 
[272].  
 
Figure 130  “DGM schematic (not to scale). The unit replicates the internal volumes of the 
average human stomach, and operates in real time and within physiological references ranges” Taken 
from Wickham et al 2012 [272] 
The Dynamic Gastric Model consists of a Flexible main body representing the gastric 
chamber which is contained within a heated water jacket at 37°C. Gastric churning and 
mixing is simulated in the main body by a 0.05Hz pulsing of water in the heated jacket. 
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Gastric secretions are added through a “perforated hoop” according to in silico 
calculations. Rate of gastric emptying into duodenal compartment is controlled by in 
silica calculations. The process is autonomous and a range of data can be obtained as 
shown in Table 21. However as has been pointed out even this modelling of physical 
gastric conditions are not a wholly accurate approximation of the forces food is 
subjected to in the stomach [268].  
 
Table 21 Data that can be obtained from the Dynamic Gastric Model. Taken from Wickham et al 
2012 [272] 
Kong et al 2010, also developed an in vitro model of the stomach which they named as 
the Human Gastric Simulator which aims to more accurately replicate a realistic 
peristaltic action [268]. In this case the peristaltic motion of the stomach is modelled by 
a system of belt driven rollers which agitate a latex vessel at ‘similar amplitude and 
frequency’ to in vivo reports. The rollers mimic peristaltic action by a simultaneous 
movement of the rollers creating a ring shaped contraction. Kong et al argue that this 
mimics the propagation of a peristaltic wave across the stomach, at a physiologically 
relevant rate of 3 cycles per minute with a propagation speed of 2.5mm per second 
[273].  The system is temperature controlled and gastic secretions are pumped in 
through microtubing and an emptying system consisting of a peristaltic pump. The 
simulation of peristaltic action allow studies into the disintegration kinetics and 
breakdown of food, although as is pointed out, the true complexity of the system of 
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physiological controls of digestion and gastric motility such as neurohumoral regulation 
cannot be accurately simulated in this model.  
The TIM (Figure 131) is a multi-compartmental dynamic model of the upper GI tract 
developed by Minekus et al [274]. The TIM model has been used in a range of studies 
looking at food digestion, enzyme supplementation, drug delivery, nutrient 
bioavailability, transit time and probiotic delivery. The TIM model is comprised of four 
compartments progressively representing; the stomach, the duodenum, the jejunum and 
the ileum. Each compartment is comprised of two chambers with flexible walls around 
which is a heated glass water jacket. Pumping of water at varied pressure through the 
water jacket creates movement aiming to simulate peristaltic action. Transit through the 
system is controlled by ‘peristaltic valves’ and the pH is monitored and controlled by 
computer throughout. Samples are collected by pumping through hollow fibre, semi 
permeable membrane into compartments at two sites; in the jejenum and ileum 
chambers in which water and small molecule metabolites are collected. The TIM system 
uses Nitrogen and glucose as markers of protein and carbohydrate digestion 
respectively. As far as can be seen from the literature, no marker of fat digestion has 
been developed in the system.  
Blanquet et al 2004, state that the TIM model meets the following five requirements: 
“(i) sequential use of enzymes in physiological amounts, (ii) appropriate pH for the 
enzymes and addition of relevant cofactors such as bile salts and coenzymes, (iii) 
removal of the products of digestion, (iv) appropriate mixing at each stage of digestion, 
and (v) physiological transit times for each step of digestion.” [271] 
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Figure 131 “Schematic diagram of the dynamic, multi-compartmental model of the stomach and 
small intestine (TIM-1): A. gastric compartment; B. pyloric sphincter; C. duodenal compartment; D. 
peristaltic valve; E. jejunal compartment; F. peristaltic valve; G. ileal compartment; H. ileo-caecal 
valve; I. pH electrodes; J. gastric secretion bottles with acid and enzymes; K. duodenal secretion 
bottles with bile, pancreatin, bicarbonate; L. secretion of bicarbonate to control the intestinal pH; M. 
pre-filter system; N. hollow fibre semi-permeable membrane system; O. water absorption system; P. 
closed dialysing system.” Taken from National Enzyme Company, 2004 [275] 
 
The patented TMI system developed by Minekus et al has also been developed and 
adapted to model the large intestine (Figure 132). The large intestinal reactor was 
inoculated with a microflora population by addition of faeces obtained from healthy 
volunteers and an anaerobic environment was maintained by flushing the system with 
nitrogen gas. This model has been validated for the study of carbohydrate fermentation 
by measuring SCFA (short chain fatty acid) release with pectin, lactulose, lactilol and 
fructo-oligosaccharide substrates [276].  
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Figure 132  “A±J Schematic presentation of the system to simulate conditions in the large 
intestine. A mixing units; B pH electrode; C alkali pump; D dialysis pump; E dialysis light; F dialysis 
circuit with hollow fibres; G level sensor; H water absorption pump; I peristaltic valve pump; J gas outlet 
with water lock.” Taken from Minekus et al 2000 [276] 
6.1.4 Static models of nutrient digestion 
Wickham et al 2009, in a review of the utility of in vitro models of digestion define 
three stages of digestion which model guts must consider; “(i) processing in the mouth, 
(ii) processing in the stomach (cumulative to the mouth) and (iii) processing in the 
duodenum (cumulative of the mouth and stomach)” [263]. 
In vitro gut models of nutrient digestion have been developed before to look at nutrient 
digestion either in specific sections of the GI tract or from mouth to small intestine, but 
to my knowledge, no models have been developed to simulate the digestive tract from 
the buccal cavity to the end of the small intestine in which digestion of the three major 
macronutrients protein, starch and fat can be measured and modelled.  
A simple model of gastric digestion of protein was developed by Savalle et al 1989, to 
model the digestion of milk protein in the calf stomach [277]. This simple model is 
composed of a vessel in a shaken water bath containing a reservoir of calf rennet (the 
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somach enzyme complex) in to which further gastric secretions and HCl were 
peristalticaly pumped. Samples are collected and analysed through TCA-precipitation 
and SDS-Page. While the authors acknowledge that exact reproduction of the in vivo 
processes is technically impossible the model provided a simulation of proteolytic 
digestion taking into account progressive acidification, gastric secretions and gastric 
emptying . 
A similar model of porcine gastric digestion was developed by Chiang et al 2008 which 
they claim was developed into a ‘dynamic model’ by the use of a helical Teflon rod 
which was used to stir the contents of a temperature controlled glass vessel [278]. Use 
of this ‘dynamic’ method was shown to more closely model gastric protein digestion in 
vivo in the initial phases of digestion than the static model, the authors argue that this is 
due to a more realistic and slower mixing process. 
It is acknowledged throughout the literature that completely accurate modelling of the 
GI tract is impossible. Depending upon the aims of individual studies a range of in vitro 
model systems have been developed to study different aspects of digestion.  
The TIM system developed by Mikenus et al 1996, aims to provide a comprehensive 
dynamic modelling of the upper GI tract and has been adapted and validated for use in 
modelling the large intestine [274]. This is a complex and patented system that aims to 
simulate peristaltic motion and GI transit time with computer modelling. However this 
system has its limitations. No modelling or consideration is given to the buccal phase of 
digestion and the physical effects of mastication, which would affect how food arrives 
in the stomach, which does not meet the first criteria of Wichham et al to model 
processing in the mouth.  
Dynamic models often use computer modelling of in vivo data on transit time to model 
GI movement and motility. However, gut motility is a highly complex system under 
neurohumoral control in response to a meal. The postprandial hormone response to a 
meal includes the release of  “insulin, neurotensin, cholecystokinin (CCK), gastrin, 
glucagon-like-peptides (GLP-1 and GLP-2), glucose dependent insulinotropic 
polypeptide (GIP, previously known as gastric inhibitory peptide)” which affect gut 
motility in a number of ways. Furthermore a large number of neurohumoral effector 
molecules have been established which have stimulatory of inhibitory effects on muscle 
GI smooth muscle control in vivo [279]. 
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Therefore, as the physical response to a meal is dictated by a specific postprandial 
response in reaction to feeding, computer modelling will always be a gross 
simplification of the controls of gastric motility.  
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6.2 Methods 
6.2.1 Preperation of Synthetic GI Fluids 
Synthetic GI fluids are not specifically buffered, but have been designed to simulate the 
pH changes and ionic content of the GI tract. Fluids were made up as stock solutions, 
enzymes are added fresh before each run. All chemicals and enzymes were purchased 
from Sigma-Aldrich unless otherwise stated.  
Synthetic Saliva – α-amylase was prepared at 1µl/ml in Salivary Diluent (62mM 
NaHCO3, 6mM  K2HPO4.3H2O, 15mM NaCl, 6.43mM KCl, 3mM CaCl2.2H2O titrated 
to pH 7.4) Prior to assay salivary diluents containing 1µl/ml α-amylase was made up 1:1 
with deionised water to give Synthetic Saliva.  
Synthetic Gastric Juice - 40µg/ml Bacterial Gastric Lipase (Amano Enzyme Inc) and 
0.5mg/ml Porcine Pepsin was prepared in Gastric Diluent (49.6 mM NaCl, 9.4mM KCl, 
2mM KH2PO4, 5mM Urea titrated to pH 2.0).  
Synthetic Pancreatic Juice – 70mg/ml Pancreatin was prepared in Pancreatic Diluent 
(110mM NaHCO₃, 2.5mM K2HPO4, 54.9mM NaCl, 1mM CaCl2.2H2O, 1.67mM Urea 
titrated to pH 8) and filtered through glass wool.  
Fresh Porcine Bile – Gall Bladders are collected on ice from the abattoir, bile is pooled 
(approximately 50 per batch), mixed and frozen in aliquots for storage. 25ml was 
required for each replicate.  
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6.2.2 Substrate Preperation 
All substrates, samples and controls are tested in triplicate. Protein, triglyceride and 
carbohydrate substrates can be tested separately, or in a mixed model, but are described 
here separately. Substrate mixes were made up to 10ml with synthetic saliva as 
described below and incubated on rollers for 10 minutes before addition to the resting 
reservoir of gastric diluent. 
Fat Digestion - Six triglycerides of varying fatty acid chain lengths have been tested in 
the model gut system (Table 1). For triglycerides which release FA’s with low pKa (*) 
Pancreatic Diluent is modified to 322.8mM NaHCO3 to counteract a lowering of pH as 
FAs are released. Glyceryl Trioctanoate has been used as the tryglyceride substrate for 
all assays of fat digestion reported herein. 2mmoles (0.94136g) of Glyceryl Trioctanoate 
is added as Synthetic Saliva Preperations at T[-10]. 
Triglyceride Fatty Acid pKa 
Triacetin* Acetic Acid 4.5 
Glyceryl Tributyrate* Butyric Acid 4.84 
Glyceryl Trioctanoate* Octanoic Acid (Caprylic 
acid) 
4.9 
Glyceryl Tripalmitate Palmitic Acid 9.7 
Glyceryl Trioleoate Oleic Acid 9.95 
Glyceryl Tristearate Stearic Acid 10.15 
Table 1 – Triglyceride substrates and the pKa of their constituent fatty acids 
Carbohydrate Digestion - Corn, wheat and potato starch in both native and gelatanised 
forms have been tested as carbohydrate substrates in the model gut system. Native Corn 
Starch has been used as the carbohydrate substrate for all assays of carbohydrate 
digestion reported herein. 1g of Corn Starch was added to synthetic saliva preperation at 
T[-10]. 
Protein Digestion- In order to distinguish effects on protein digestion from the gastric 
and pancreatic phases of digestion, gastric and pancreatic proteolysis assays are 
described separately. Gastric Protein Digestion -Bovine serum albumin (BSA) and 
casein have both been tested as protein substrates in the model gut system.  BSA was 
purchased from Fisher Scientific and has been used as the protein substrate for all 
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assays of protein digestion reported herein. In the gastric phase 0.5g BSA was added to 
the salivary diluents at T[-10] and the assay was run until the end of the gastric phase at 
T[60].  
Small intestinal Protein Digestion - For assays of protein digestion in the small-
intestinal phase 1g of BSA was added to Synthetic Saliva at T[-10] and gastric pepsin 
was omitted from the gastric diluent to prevent any protein digestion in the gastric 
phase.  
Background Control - For background controls 10ml Synthetic Saliva was prepared 
without substrate. 
 
6.2.3 Samples Preperation 
 
For sample testing substrate was prepared identical to substrate control with a known 
amount of test sample added. For sample controls 10ml synthetic saliva was prepared 
with appropriate amount of test sample, but without substrate.  
For biopolymer testing 125, 250 and 500mg of biopolymer sample was prepared with 
synthetic salivary preperations. Acarbose, orlistat, pentosan polysulphate and soybean 
trypsin inhibitor were used as positive inhibition controls for α-amylase, lipase, pepsin 
and trypsin respectively. Alginate samples were provided by FMC Biopolymer and 
Technostics Ltd. 
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6.2.4 Equipment 
Synthetic GI fluids were pre-incubated in a 37°C water bath. Sample beakers (three 
500ml glass beakers) were prepared in a 37°C water bath with overhead stirrers to 
simulate stomach churning. A Watson Marlow Peristaltic pump was set at 0.5ml/min. A 
BioTek EL808 96 well plate spectrophotometer was used for sample analysis. 
Equipment was set up as shown in Figure 133. 
 
 
 
 
 
 
 
 
Figure 133  Set up of model gut system. 
 
GI Sample Beakers 
Water Bath at 37°C 
Synthetic GI Fluid Reservoirs 
Water Bath at 37°C 
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Juice 
Pancreatic 
Juice 
C 
Peristaltic 
Pump 
(0.5ml/min) 
Porcine Bile 
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6.2.5 Procedure 
 
Salivary Phase - At T[-10], salivary preparations containing substrate/sample/controls 
were prepared as above and incubated for 10 minutes on rollers. Gastric Phase – at T[0] 
salivary preparations were added to a resting reservoir of 50ml Synthetic Gastric Juice 
(pre-incubated to 37°C in a water bath with overhead stirrer for 20 minutes). Additional 
gastric juice was added at a rate of 0.5ml/min with a peristaltic pump. Due to pepsin 
auto-digestion, gastric diluent is prepared immediately prior to addition at T[-20]. 
Pancreatic Phase – At T[60] 25ml of Porcine Bile was added, the pumping of synthetic 
gastric juice was stopped, and filtered synthetic pancreatic juice was pumped in at a rate 
of 0.5ml/min.  In the current examples the small-intestinal phase was continued until 
T[180] however it can be run for longer. A schematic of the procedure is shown in 
Figure 135. 
Figure 134  Schematic of Model gut system  
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6.2.6 Sampling 
Samples of 0.5ml were taken at T0, T5, T10, T15, T30, T45, T60, T60
B
, T65,T70,T75, 
T90, T105, T120, T150 and T180. (T60
B
) represents a second sample at T60 after the 
addition of fresh porcine bile). Samples were immediately precipitated 1:1 in 10% TCA 
(w/v) (Trichloroacetic Acid) to stop enzyme activity and precipitate out undigested 
protein. Samples were stored at 4°C overnight to allow for precipitation and centrifuged 
at 10,000 r.p.m. for 10 minutes, the supernatant was then analysed. Dilution of synthetic 
GI fluid volume and sample dilution in TCA was accounted for in calculations. 
6.2.7 Analysis 
Glycerol analysis – Triglyceride digestion was measured using ZenBio Glycerol 
Reagent A to quantify the release of glycerol. 5µl of sample was incubated with 80µl 
Reagent A for 30 minutes and colour development was measured at 550nm. A standard 
curve was prepared a from stock 2.5mM glycerol solution. 
Starch Analysis – In order to separate maltose products of digestion from undigested 
starch substrate, 50µl of supernatant was mixed with 950µl of 1%KCl (w/v) 75% 
methanol solution (v/v) and after 20 minutes samples were centrifuged at 10,000 rpm 
for 10 minutes. 500µl of the resulting supernatant was then evaporated down to a 
volume of 100µl. Once cooled to 37°C  50ul of 1mg/ml α-glucosidase (Sorachim) was 
added and incubated at 37°C for 2 hours. Liberated glucose was then assayed using the 
Megazyme D-Glucose (glucose oxidase/peroxidase; GOPOD) Assay Kit.  
Proteolysis Analysis - Undigested polypeptides were removed from samples by TCA 
precipitation and centrifugation. Protein digestion was measured by assaying amino 
acids and short oligopeptides remaining in the supernatant with the Pierce BCA Total 
Protein assay kit. Working Reagent (WR) was prepared by mixing Reagent A and 
Reagent B at ratio 50:1. 25µl of samples were incubated with 200µl WR at 37°C for 
30minutes and the colour development measured at 575 nm. A standard curve was 
prepared using a stock solution of BSA at 2mg/ml. 
The Pierce BCA assay is known to under-report amino acid and oligo-peptide 
metabolites of protein digestion [280]. Figure 135 shows that only 37.76% of BSA is 
reported in the BCA assay after complete proteolysis. This can be corrected for by 
multiplying results by a factor of 2.65 as discussed below. 
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Figure 136 shows that in the pancreatic phase, only 60.33% of digested protein is 
detected due to bile binding of protein metabolites. Therefore when analysing protein 
digestion in the small intestinal phase data must be multiplied by a factor of 6.68 which 
corrects for this under-reporting and bile binding.  
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Figure 135  Comparison of BCA reporting of 1.563mg of BSA before and after a 2-step 
pepsin/trypsin digestion (n=3). A known amount of protein (1.563mg/ml aqueous) was tested in the BCA 
protein assay, and then after exhaustive overnight digestion with pepsin pH2 (1mg/ml) and then trypsin 
pH7 (1mg/ml) at 37°C. 
 
Figure 136  Detection of constant, known amount of digested protein in Model Gut system, 
with and without bile. 1g of BSA (in 10ml deionieed water) was exhaustively digested as described in 
Figure 135 and run through the model gut with or without the addition of bile at T[60]. (n=3) 
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6.3 Results  
Four alginate polymers were tested in the model gut system for their effects on fat, 
protein and carbohydrate digestion. Two of these were guluronic acid rich alginates, 
these were FMC3 and SF120. Two of the alginates tested were rich in mannuronic acid, 
these were FMC13 and H120L.  
A number of other bioactive polymers were tested in the system as will be discussed in 
Chapter 7. The alginate LFR560 has also been tested for its effects on fat digestion, as it 
is a High-G alginate that has been used in human trials currently underway in the 
Pearson Lab.   
6.3.1 Fat Digestion in the Model Gut 
 
In vitro assays have shown alginates to reduce fat digestion by up to 75% in vitro [6].  
Preliminary data has shown that alginate when delivered in a bread vehicle can reduce 
fat digestion in humans, and reduce post-prandial circulating blood triglyceride levels 
after supplementation with alginate in a bread vehicle [Unpublished Data].  
Figure 137 shows a control digestion of glycryl trioctanoate in the model gut system. 
The first sample is taken after the salivary phase, and the artificial ‘bolus’ is passed into 
the resting gastric reservoir. T[0] therefore represents the start of the gastric phase of 
digestion, this runs for 60 minutes, during which time further gastric secretions are 
pumped in to the digestion vessel.  
As can be seen from Figure 137, at T[0]  no significant release of glycerol has occurred 
during the salivary phase, prior to addition to the resting gastric reservoir. Throughout 
the gastric phase between T[0] and T[60], there was similarly no release of glycerol. 
At T[60] the system enters the small-intestinal phase. Pig bile was added to the system 
and synthetic pancreatic juices are pumped into the digestion vessel. As can be seen 
from the control digestion in Figure 137, for the first 10 minutes of the small-intestinal 
phase there is little or no change. However, after T[70], there is a gradual release of 
glycerol, which continues throughout the small intestinal phase. The small intestinal 
phase was run for two hours until T[180]. 
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Figure 137 – Glyceryl Trioctanoate digestion in a model gut system. 2mmol of glyceryl trioctanoate was 
digested (Control Digestion). The graph shows total glycerol recovered from model gut system after TCA 
(Trichloroacetic Acid) precipitation to stop enzyme activity. Control digestion is represented as (■). All 
samples were tested in triplicate, errors are shown as standard deviation. The volume of the digestion 
solution varies throughout the assay, therefore total recoverable glycerol is quantifed using ZenBio 
Glycerol Kit to calculate the concentration of each sample, this value is used to extrapolate the total free 
glycerol in the system.  
Fat digestion in the model gut system was validated with Orlistat, as can be seen from 
Figure 138, at all concentrations of Orlistat there was a reduction in fat digestion. 
With 2.5mg/ml Orlistat, by the final time-point at T[180], glyceryl trioctanoate digestion 
was reduced to 54.8±13.6% of control digestion.  With a 5mg/ml concentration of 
Orlistat, glyceryl release was reduced to 37.4±15.7% of control by T[180]. With the 
highest tested concentration of Orlistat, 10mg/ml, total glyceryl trioctanoate digestion 
was reduced to 0.9±3.9% of control. These results showed clearly that the model gut 
system is capable of quantifying dose-dependent inhibition of fat digestion. 
Gastric Phase Pancreatic Phase 
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Figure 138 – Glyceryl Trioctanoate digestion in a model gut system with and without Orlistat. The graph 
shows total glycerol recovered from model gut system after TCA (Trichloroacetic Acid) precipitation to 
stop enzyme activity. 2mmol of Glyceryl Trioctanoate was digested alone (Control Digestion) and in the 
presence of varying concentrations of Orlistat . Control digestion is represented as ( ) and digestion with 
Orlistat at 2.5mg as ( ), 5mg ( ) and 10mg ( ). All samples were tested in triplicate, errors are 
shown as standard deviation. 
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As stated previously, work in this lab has shown that alginate can inhibit lipase activity 
by up to 72.2% in vitro[281].  Five alginates were tested for their regulatory activity 
towards lipase in the model gut system. 
With the Alginates FMC3 and FMC13, there were no significant changes to the 
digestion of glyceryl trioctanoate by the addition of alginate at any of the timepoints 
(Figure 139 & Figure 140 respectively). 
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Figure 139 – Glyceryl Trioctanoate digestion in a model gut system with and without FMC3. The graph 
shows total Glycerol recovered from model gut system after TCA (Trichloroacetic Acid) precipitation to 
stop enzyme activity. 2mmol of Glyceryl Trioctanoate was digested alone (Control Digestion) and in the 
presence of varying concentrations of FMC3. Control digestion is represented as ( ) and digestion with 
FMC3 at 125mg as ( ), 250mg ( ) and 500mg ( ). All samples were tested in triplicate, errors are 
shown as standard deviation. 
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Figure 140  Glyceryl Trioctanoate digestion in a model gut system with and without FMC13. The 
graph shows total Glycerol recovered from model gut system after TCA (Trichloroacetic Acid) 
precipitation to stop enzyme activity. 2mmol of Glyceryl Trioctanoate was digested alone (Control 
Digestion) and in the presence of varying concentrations of FMC13. Control digestion is represented as as 
( ) and digestion with FMC13 at 125mg as ( ), 250mg ( ) and 500mg ( ). All samples were tested in 
triplicate, errors are shown as standard deviation. 
254 
 
 
The alginate LFR560 was the most effective of the alginate inhibitors tested against 
glyceryl trioctanoate. After 90 minutes, the level of glyceryl release from glyceryl 
trioctanoate in the modelgut system was significantly reduced at all three doses of 
alginate (Figure 141).  
At T[90] after half an hour in the small intestinal phase, 125mg of alginate LFR560  had 
reduced the amount of glyceryl trioctanoate digested by 87.7±29.9%, at 250mg 
LFR560, digestion was reduced 91.1±10.9% and at 500 mg of LFR560 alginate 
digestion was reduced by 90.9±11.4%. All of these were shown to be statistically 
significant with a T-Test with P-Values of 0.025, 0.015 and 0.015 respectively.  
By T[180] the inhibition was still apparent but had reduced in magnitude. With 125mg 
LFR560 at T[180] inhibition was 29.0±39.9%, although this was not statistically 
significant. With 250mg LFR560, inhibition was 40.8±17.4% which was shown to be 
statistically significant using a T-Test with a p-value of 0.030696. With 500mg 
LFR560, inhibition was 58.3±22.2% which was shown to be statistically significant 
using a T-Test with a p-value of 0.018.  
With 10mg of Orlistat there was a complete inhibition of fat digestion at each of this 
timepoints, maximum inhibition at T[180] with LFR560 was a reduction of 58.3±22.1% 
with 500mg, suggesting that alginate LFR560 is a weaker inhitor of orlistat by between 
1 and 2 orders of magnitude.  
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Figure 141 – Glyceryl Trioctanoate digestion in a model gut system with and without LFR560. The graph 
shows total Glycerol recovered from model gut system after TCA (Trichloroacetic Acid) precipitation to 
stop enzyme activity. 2mmol of Glyceryl Trioctanoate was digested alone (Control Digestion) and in the 
presence of varying concentrations of LFR560. Control digestion is represented as as ( ) and digestion 
with LFR560 at 125mg as ( ), 250mg ( ) and 500mg ( ).  All samples were tested in triplicate, errors 
are shown as standard deviation. 
 
With the alginate SF120, a guluronic-acid rich alginate, there was no statistically 
significant change in the digestion profile of glyceryl trioctanoate up to 120 minutes 
Figure 142. After 120 minutes, at T[150] and T[180], a plateuaing effect was seen, and at 
all concentrations of alginate there was a reduction in glyceryl trioctanoate digestion. At 
T[150], 125mg SF120 reduced glyceryl trioctanoate digestion by 29.3±0.2%, at 250mg 
digestion was reduced by 32.0±20.0% and at 500mg of SF120 digestion was reduced by 
29.0±4.5%. None of these inhibitions were however statistically significant.  
At T[180] similar levels of inhibition were observed. With 125mg SF120 at T[180], 
glycerol release from glyceryl trioctanoate was reduced by 31.9±0.7%, although this 
was not shown to be statistically significant.  
With 250mg and 500mg, there was a reduction in glycerol release from glyceryl 
trioctanoate of 52.3±18.0% and 38.1±1.6% respectively. Both of these inhibitions were 
shown to be statistically significant with p-values of 0.013 and 0.014 respectively.  
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Figure 142 – Glyceryl Trioctanoate digestion in a model gut system with and without SF120. The graph 
shows total Glycerol recovered from model gut system after TCA (Trichloroacetic Acid) precipitation to 
stop enzyme activity. 2mmol of Glyceryl Trioctanoate was digested alone (Control Digestion) and in the 
presence of varying concentrations of SF120. Control digestion is represented as as ( ) and digestion 
with LFR560 at 125mg as ( ), 250mg ( ) and 500mg ( ).  All samples were tested in triplicate, errors 
are shown as standard deviation. 
A similar inhibition profile was seen with the alginate H120L as shown in Figure 143, 
whereby there was little difference in the digestion of glyceryl trioctanoate with/without 
H120L up until timepoint T[120] after which there was a plateuxing of glycerol release in 
samples containing alginate H120L.  
At T[150], 125mg H120L reduced glyceryl trioctanoate digestion by 29.0±5.3%, at 
250mg digestion was reduced by 30.9±10.2% and at 500mg of SF120 digestion was 
reduced by 42.3±4.3%. However, only the inhibition with 500mg H120L at T[150] was 
shown to be statistically significant using a T-Test, with a p-value of 0.018. 
At T[180] similar levels of inhibition were observed. With 125mg H120L at T[180], 
glycerol release from glyceryl trioctanoate was reduced by 58.2±10.4%, which was 
shown to be statistically significant with a p-value of 0.003. With 250mg H120L there 
was a reduction in glycerol release from glyceryl trioctanoate of 33.4±12.4% which was 
statistically significant, with a p-value of 0.033. With 500mg H120L, there was a 
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35.6±7.4% rediuction in glycerol release from glyceryl trioctanoate which was 
statistically significant 0.018. 
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Figure 143 – Glyceryl Trioctanoate digestion in a model gut system with and without H120L. The graph 
shows total Glycerol recovered from model gut system after TCA (Trichloroacetic Acid) precipitation to 
stop enzyme activity. 2mmol of Glyceryl Trioctanoate was digested alone (Control Digestion) and in the 
presence of varying concentrations of H120L. Control digestion is represented as as ( ) and digestion 
with LFR560 at 125mg as ( ), 250mg ( ) and 500mg ( ).  All samples were tested in triplicate, errors 
are shown as standard deviation. 
 
6.3.2 Carbohydrate Digestion in The Model Gut 
 
In the in vitro microplate assays of alginate regulation of α-amylase activity in Chapter 
5, it was shown that alginate increased the activity of α-amylase by up to 41.1±8.42%. 
While no clear relationship was shown with alginate structure, alginates high in 
mannuronic acid tended to result in a greater increase in maximum reaction velocity.  
As was discussed in Chapter 5, these results contradict what has been shown in the 
literature suggesting that alginates have a hypoglycaemic affect in vivo and blunt post-
prandial blood glucose spikes. From the literature, it is suggested that this may be due to 
a combination of alginate gelling in the stomach and delaying gastric emptying, and 
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reduced sodium uptake in the small intestine inhibiting the action of the sodium-glucose 
co-transporter.  
The current model gut system described is a model of the chemical and absorbative 
phases of digestion, so does not model physiological gastric emptying control, or active 
nutrient uptake. It does however provide a model of physiologically relevant enzymatic 
and chemical digestion, which can be used to see if the activation of α-amylase shown 
in Chapter 5 would occur in a physiologically relevant system.  
Figure 144 shows a control digestion of Corn Starch in the Model Gut system.  
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Figure 144 – Corn Starch digestion in a model gut system. 1g of Native Corn Starch was digested 
(Control Digestion). The graph shows total glucose recovered from model gut system after TCA 
(Trichloroacetic Acid) precipitation to stop enzyme activity and Methanol-KCl precipitation to remove 
undigested starch. Control digestion is represented as (■). All samples were tested in triplicate, errors are 
shown as standard deviation. 1g of native corn starch was added to synthetic saliva; the term ‘native’ 
refers to powdered, un-gelatinised corn starch. Native starch was used in order to prevent inconsistencies 
and the introduction of error in the gelatinisation process. 
As can be seen from Figure 144, at T[0] there has been no significant digestion of starch 
during the salivary phase. Throughout the gastric phase from T[0] to T[60], there is 
similarly no significant release of glucose detected.  
At T[60] as the system enters the small-intestinal phase and synthetic pancreatic 
secretions and bile are added to the digestion mixture. From T[65] the release of glucose 
is detected in the small intestinal phase, and this continues at a more or less constant 
rate until T[75] where digestion levels off and there is no increase in detected glucose. 
This is consistent with the literature which suggests that starch breakdown into maltose, 
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maltotriose and α-limit dextrin occurs very rapidly and within 10 minutes of transit into 
the duodenum [100].  
1g of native corn starch was used as the carbohydrate substrate, however, as is indicated 
on Figure 144, only 25% of this is recovered in the assay, even after the digestion curve 
has plateaued. This indicates that either not all the starch is getting digested, or the assay 
system is under-reporting digestion of carbohydrate. This will be commented upon 
further in the discussion.  
The model of corn starch digestion in the model gut system was validated using the 
inhibitor acarbose (Figure 145).  
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Figure 145 – Corn Starch digestion in a model gut system with and without Acarbose. The graph shows 
total glucose recovered from model gut system after TCA (Trichloroacetic Acid) precipitation to stop 
enzyme activity and Methanol-KCl precipitation to remove undigested starch. 1g of Native Corn Starch 
was digested alone (Control Digestion) and in the presence of varying concentrations of Acarbose . 
Control digestion is represented as as (■) and digestion with acarbose at 125mg as ( ), 250mg ( ) and 
500mg ( ). All samples were tested in triplicate, errors are shown as standard deviation. 
 
Although some variation can be seen in the gastric phase in Figure 145 with the addition 
of acarbose to the model gut system, there was no significant change from the control 
digestion. In the initial 5 minutes of the small intestinal phase between T[60] and T[65], 
there is a visible reduction in the amount of carbohydrate digestion at all three tested 
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concentrations of acarbose, however none of these reductions could be shown to be 
statistically significant.  
From T[65] onwards until T[180], there is a statistically significant reduction in 
carbohydrate digestion relative to control at all time-points at all three tested 
concentrations. With 25mg Acarbose, by the final time point of T[180] carbohydrate 
digestion was reduced to 41.7% of control (P=0.002). With 50mg Acarbose, by T[180] 
carbohydrate digestion was reduced to 3.01% of control (P=0.0009). With 100mg 
Acarbose, by T[180] carbohydrate digestion was reduced to 1.45% of control (P=0.0013). 
As was discussed in Chapter 5, it had been expected from the literature that alginates 
would reduce the rate of carbohydrate digestion, as they had been shown to have anti-
hyperglycaemic effects in vivo. However the results shown in Chapter 5 show a non-
specific activation of α-amylase by alginates. In order to investigate if this activatory 
effect persists in a physiological environment, or if the reaction dynamics are somehow 
different in the milieu of the physiological conditions, the affects of alginate on 
carbohydrate digestion were investigated in the model gut system.  
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Figure 146 – Corn Starch digestion in a model gut system with and without FMC13 Alginate. The graph 
shows total glucose recovered from model gut system after TCA (Trichloroacetic Acid) precipitation to 
stop enzyme activity and Methanol-KCl precipitation to remove undigested starch. 1g of Native Corn 
Starch was digested alone (Control Digestion) and in the presence of varying concentrations of FMC13 . 
Control digestion is represented as as (■) and digestion with FMC13 at 125mg as ( ), 250mg ( ) and 
500mg ( ). All samples were tested in triplicate, errors are shown as standard deviation. 
The digestion profile of corn starch was greatly changed in the presence of alginate. 
With the addition of alginate FMC13, digestion of corn starch was inhibited during the 
first 15 minutes of the small intestinal phase from T[60]-T[75] (Figure 146). At T[75] with 
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all concentrations of FMC13 alginate there was statistically significant inhibition; at 
125mg FMC13 corn starch digestion was reduced by 89.3% (P=0.025), at 250mg 
FMC13 digestion was reduced by 65.4% (P=0.036) and with 500mg FMC13 digestion 
was reduced by 61.9% (P=0.032).  
By T[105], there is no significant difference between samples containing alginate and 
control, suggesting that the glucose yield has recovered to normal levels. From T[105] to 
T[180] there is no significant difference from control with the addition of 125mg or 
250mg of FMC13. With 500mg FMC13 there was no significant variation from control 
digestion between T[105] and T[150], however at T[180] there was a 119.77% increase in 
glucose yield from corn starch which was shown to be statistically significant 
(P=0.042).  
In the presence of alginate FMC3, corn starch showed a similar digestion profile to that 
described with FMC13 (Figure 147). Corn starch digestion was initially blunted in the 
small intestinal phase with a reduction in recovered glucose at T[75] of 75.5% (P=0.030), 
62.7% (P=0.047) and 63.8% (P=0.045) at 125, 250 and 500mg respectively after the 
first 15 minutes of the small intestinal phase.  
With 500mg of FMC3 alginate there were statistically significant increases in the 
amount of glucose recovered at T[120] and T[150] of 57.3%(P=0.007) and 
129.8%(P=0.012) respectively. At 125 and 250mg FMC3 there were no significant 
changes to corn starch digestion between T[90] and T[150]. 
However by the final timepoint T[180] there were statistically significant increases in 
glucose recovered at all concentrations of FMC3 with increases of 45.7% (P=0.024), 
42.2% (P=0.002) and 129.8% (P=0.031) at 125, 250 and 500mg respectively.  
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Figure 147 – Corn Starch digestion in a model gut system with and without FMC3 Alginate. The graph 
shows total glucose recovered from model gut system after TCA (Trichloroacetic Acid) precipitation to 
stop enzyme activity and Methanol-KCl precipitation to remove undigested starch. 1g of Native Corn 
Starch was digested alone (Control Digestion) and in the presence of varying concentrations of FMC3. 
Control digestion is represented as as (■) and digestion with FMC3 at 125mg as ( ), 250mg ( ) and 
500mg ( ). All samples were tested in triplicate, errors are shown as standard deviation. 
Although visually alginates SF120 and H120L shown in Figure 148 and Figure 149 
respectively suggest that they may be following a similar pattern of blunted 
carbohydrate digestion in the initial phase of digestion, and an increase in glucose yield 
in the final stages of the simulated small intestine, there were no statistically significant 
changes. Furthermore the results with 500mg of SF120 were highly variable suggesting 
the possibility of experimental error. 
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Figure 148 – Corn Starch digestion in a model gut system with and without SF120 Alginate. The graph 
shows total glucose recovered from model gut system after TCA (Trichloroacetic Acid) precipitation to 
stop enzyme activity and Methanol-KCl precipitation to remove undigested starch. 1g of Native Corn 
Starch was digested alone (Control Digestion) and in the presence of varying concentrations of SF120. 
Control digestion is represented as as (■) and digestion with SF120 at 125mg as ( ), 250mg ( ) and 
500mg ( ).  All samples were tested in triplicate, errors are shown as standard deviation. 
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Figure 149 – Corn Starch digestion in a model gut system with and without H120L Alginate. The graph 
shows total glucose recovered from model gut system after TCA (Trichloroacetic Acid) precipitation to 
stop enzyme activity and Methanol-KCl precipitation to remove undigested starch. 1g of Native Corn 
Starch was digested alone (Control Digestion) and in the presence of varying concentrations of H120L. 
Control digestion is represented as as (■) and digestion with H120L at 125mg as ( ), 250mg ( ) and 
500mg ( ). All samples were tested in triplicate, errors are shown as standard deviation. 
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6.4 Protein Digestion in The Model Gut 
In order to distinguish the exact site of the effects of exogenous compounds on protein 
digestion, the gastric and pancreatic phases of digestion were analysed separately. This 
was done so there was a known amount of protein substrate entering the small intestinal 
phase.  
6.4.1 Gastric Protein Digestion 
 
Figure 150 shows a control digestion of 0.5g of BSA in the gastric phase of the model 
gut system. Between T[0] and T[45] there is a more or less linear breakdown of the 
protein substrate, after which, digestion begins to plateau in the final 15 minutes of the 
assay up to T[60]. As can be seen, approximately 500mg of digested protein is recovered 
in the assay. This 100% recovery rate suggests that all protein substrate is digested 
within 60 minutes, and is accurately quantified by the assay system. 
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Figure 150 – Bovine Serum Albumin digestion in gastric phase of a model gut system. 0.5g BSA was 
digested (Control Digestion). The graph shows total protein recovered from model gut system after TCA 
(Trichloroacetic Acid) precipitation to stop enzyme activity and remove undigested polypeptides. Control 
digestion is represented as (■). All samples were tested in triplicate, errors are shown as standard 
deviation. 
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Pentosan polysulphate (SP54) was used as the positive inhibition control. Pentosan  
polysulphate is a highly sulphated polysaccharide, and sulphated polysaccharides have 
been shown to have anti-pepsin activity, both in vitro and in vivo. 
Three concentrations of pentosan polysulphate (SP54) were tested in the gastric phase 
of the model gut in order to validate the detection of inhibition (Figure 151). At all 
tested concentrations of 50mg, 100mg and 200mg pentosan polysulphate there was 
significant inhibition of gastric proteolysis at all time points from T[5] onwards.  
At T[5], 50, 100 and 200mg of pentosan polysulphate significantly inhibited the gastric 
digestion of protein by 62.5% (P=0.005), 90.1% (P=0.003) and 90.5% (P=0.002) 
respectively.  
At T[60] by the end of the gastric phase, 50, 100 and 200mg of pentosan polysulphate 
significantly inhibited the gastric digestion of protein by 54.1% (P=0.0001), 78.9% 
(P=0.001) and 87.6% (P=0.0004) respectively. This showed a dose responsive 
inhibition of gastric proteolysis by pentosan polysulphate.  
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Figure 151 – Bovine Serum Albumin digestion in gastric phase of a model gut system with and without 
SP54. The graph shows total protein recovered from model gut system after TCA (Trichloroacetic Acid) 
precipitation to stop enzyme activity and remove undigested polypeptides. 0.5g BSA was digested alone 
(Control Digestion) and in the presence of varying concentrations of SP54. Control digestion is 
represented as as (■) and digestion with SP54 at 125mg as ( ), 250mg ( ) and 500mg ( ). All 
samples were tested in triplicate, errors are shown as standard deviation. 
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In vitro assays described in Chapter 3 demonstrated that alginates were potent inhibitors 
of pepsin activity, and that this inhibition was related to increasing levels of mannuronic 
acid. In order to investigate if this inhibitory effect was likely to persist in vivo, alginate 
inhibition of protein digestion was investigated in the model gut system.  
Four alginates were tested for their effect on the simulated gastric digestion of alginates; 
FMC3, FMC13, SF120 and H120L. With all tested alginates there was a significant 
inhibition of protein digestion in the gastric phase.  
By the end of the simulated gastric phase, FMC13 was the weakest of the four alginates 
tested (Figure 152). By T[60] after an hour of simulated digestion with 125, 250 and 
500mg of FMC13, proteolytic digestion was reduced by 23.4% (P=0.021), 52.2% 
(P=0.040) and 43.5% (P=0.013) respectively, as compared to a control. 
This represented a trend of recovery towards the amount of protein digestion in the 
control. At timepoints T[30] and T[45] there was a larger percentage terms inhibition as 
compared to control. At T[30] after an hour of simulated digestion with 125, 250 and 
500mg of FMC13 proteolytic digestion was reduced by 52.8% (P=0.004), 75.7% 
(P=0.004) and 62.7 (P=0.0008) respectively. At T[45] after an hour of simulated 
digestion with 125, 250 and 500mg of FMC13 proteolytic digestion by 52.8% 
(P=0.004), 70.9% (P=0.001499) and 73.06 (P=0.01846). 
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Figure 152 – Bovine Serum Albumin digestion in gastric phase of a model gut system with and without 
FMC13 Alginate. The graph shows total protein recovered from model gut system after TCA 
(Trichloroacetic Acid) precipitation to stop enzyme activity and remove undigested polypeptides. 0.5g 
BSA was digested alone (Control Digestion) and in the presence of varying concentrations of FMC13. 
Control digestion is represented as as (■) and digestion with FMC13 at 125mg as ( ), 250mg ( ) and 
500mg ( ). All samples were tested in triplicate, errors are shown as standard deviation. 
FMC3 showed a similar inhibition profile to FMC13 (Figure 153). At T[30], protein 
digestion was reduced by 51.9% (P=0.0002), 69.6% (P=0.013) and 48.0% 
(P=0.016002) as compared to control with 125mg, 250mg and 500mg of FMC3 alginate 
respectively. At T[45], protein digestion was reduced by 50.4% (P=0.005263), 64.0 % 
(P=0.015) and 47.2% (P=0.0004) as compared to control with 125mg, 250mg and 
500mg of FMC3 alginate respectively.  By the final timepoint at T[60], protein digestion 
was reduced by 20.2% (P=0.029), 64.8% (P=0.024) and 55.1% (P=0.035) as compared 
to control with 125mg, 250mg and 500mg of FMC3 alginate respectively.   
At all three of these timepoints where significant inhibition was achieved, the highest 
level of inhibition is with the intermediate concentration of alginate 250mg, with 125mg 
and 500mg yielding lower levels of inhibition. It is to be expected that at lower 
concentrations of alginate there would be lower levels of inhibition, however it is 
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somewhat counter-intuitive that at the higher concentration of 500mg FMC3, that the 
inhibition is lower than with 250mg.   
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Figure 153 – Bovine Serum Albumin digestion in gastric phase of a model gut system with and without 
FMC3 Alginate. The graph shows total protein recovered from model gut system after TCA 
(Trichloroacetic Acid) precipitation to stop enzyme activity and remove undigested polypeptides. 0.5g 
BSA was digested alone (Control Digestion) and in the presence of varying concentrations of FMC3. 
Control digestion is represented as as (■) and digestion with FMC3 at 125mg as ( ), 250mg ( ) and 
500mg ( ). All samples were tested in triplicate, errors are shown as standard deviation. 
As can be seen from Figure 154, inhibition of protein digestion with alginate SF120 was 
varied, but at all timepoints after T[15], the highest levels of inhibition were achieved 
with the highest concentration of 500mg SF120. At T[30], protein digestion was reduced 
by 35.4% (P=0.010), 47.3% (P=0.033) and 62.1% (P=0.002) as compared to control 
with 125mg, 250mg and 500mg of SF120 alginate respectively. At T[45], protein 
digestion was reduced by 60.8% (P=0.0033408), 37.5% (P=0.003) and 70.2% 
(P=0.019) as compared to control with 125mg, 250mg and 500mg of SF120 alginate 
respectively.  By the final timepoint at T[60], protein digestion was reduced by 32.9% 
(P=0.0025), 30.8% (P=0.007) and 50.5% (P=0.001) as compared to control with 125mg, 
250mg and 500mg of SF120 alginate respectively.   
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Figure 154 – Bovine Serum Albumin digestion in gastric phase of a model gut system with and without 
SF120 Alginate. The graph shows total Protein recovered from model gut system after TCA 
(Trichloroacetic Acid) precipitation to stop enzyme activity and remove undigested polypeptides. 0.5g 
BSA was digested alone (Control Digestion) and in the presence of varying concentrations of SF120. 
Control digestion is represented as as (■) and digestion with FMC3 at 125mg as ( ), 250mg ( ) and 
500mg ( ). All samples were tested in triplicate, errors are shown as standard deviation. 
 
The results seen from the biopolymer H120L were somewhat different to what was seen 
with the other alginate samples (Figure 155). With the higher concentrations of alginate 
H120L at 250mg and 500mg there was an increase in the rate of protein digestion at 
T[5], and with 500mg an increase also at T[10]. At T[5] there was an increase in protein 
digestion of 71.8% with 250mg H120L and of 154% with 500mg, although neither of 
these increases were statistically significant. At T[10] there was an increase in the 
digested protein yield of 145% with 500mg H120L, this was shown to be statistically 
significant (P=0.038). From T[30] onwards the data for H120L is more similar to what 
was seen with the other alginate samples, whereby there is a reduced level of protein 
digestion at all timepoints for all alginates. At T[60] there were reductions of 55.6%, 
50.4% and 65.25% at 125mg, 250,mg and 500mg respectively. 
It is unclear from the data whether the increases in protein digestion seen in the first 15 
minutes of protein digestion represent a real phenomenon, or are experemental artefacts, 
as only one of the data points was statistically significant. It may be that alginate is 
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interacting with the protein substrate and forming a physical gel that is separating the 
simulated gut contents into two phases and reducing the reaction volume in the 
remaining solution. This could be a possible explanation for an initial increase in rate, 
which is then overcome as the free substrate is depleted and the remaining substrate is 
bound to alginate.  
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Figure 155 – Bovine Serum Albumin digestion in gastric phase of a model gut system with and without 
H120L Alginate. The graph shows total protein recovered from model gut system after TCA 
(Trichloroacetic Acid) precipitation to stop enzyme activity and remove undigested polypeptides. 0.5g 
BSA was digested alone (Control Digestion) and in the presence of varying concentrations of H120L. 
Control digestion is represented as as (■) and digestion with H120L at 125mg as ( ), 250mg ( ) and 
500mg ( ).  All samples were tested in triplicate, errors are shown as standard deviation. 
 
6.4.2 Pancreatic Phase Protein Digestion 
In Chapter 4, the effects of alginate on trypsin were investigated. Only marginal 
variations in trypsin activity could be shown to be statistically significant. It was shown 
that pH dependent viscosity interactions may be the reason why protein substrate was 
unavailable for digestion by pepsin in an acidic environment, but trypsin digestion at a 
neutral pH was unaffected.  
However, the physiological environment in which proteolytic digestion occurs in the 
small-intestine is considerably more complex than the environment simulated in the 
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microplate assays. Firstly, the substrate has passed through the salivary and gastric 
phases and mixed with various digestive secretions and enzymes.  
Figure 156 shows a control digestion of 1g of BSA in the model gut system. During the 
gastric phase of digestion between T[0] and T[60], gastic pepsin has been omitted from 
the simulated gastric juice, and there is consequently no significant protein digestion in 
the gastric phase. After T[60] the simulation enters the small-intestinal phase, porcine 
bile is added to the digestive mixture and pancreatic secretions containing active 
proteolytic enzymes are pumped in. During the first hour of small-intestinal digestion, 
between T[60] and T[120] there is a more or less linear breakdown of the protein substrate, 
after which, digestion begins to plateaux in the final 60 minutes of the assay up to T[180]. 
As can be seen in Figure 156 there is a 100% recovery of protein in the small-intestinal 
phase, although there is some variation.  
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Figure 156 – Bovine serum albumin (BSA) digestion in the small-intestinal phase of a model gut system. 
The graph shows total Protein recovered from model gut system after TCA (Trichloroacetic Acid) 
precipitation to stop enzyme activity and remove undigested polypeptides. Control digestion of 1g BSA is 
represented as (■). All samples were tested in triplicate, errors are shown as standard deviation. 
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Soybean Trypsin Inhibitor (SBTI) was used as the positive inhibition control (Figure 
157). Three concentrations of SBTI were tested in the model gut in order to validate the 
detection of inhibition of proteolysis. At all tested concentrations of 125mg, 250mg and 
500mg SBTI, there was no difference in proteolytic activity throughout the gastric 
phase of digestion.  
However as would be expected, during the small-intestinal phase, the addition of SBTI 
to the digestive mixture downregulated proteolytic activity and reduced the amount of 
digested protein recovered from the assay. From T[70] onwards the addition of 250 and 
500mg yielded statistically significant inhibition at all timepoints until the end of the 
assay. 
With 500mg SBTI, at T[70] inhibition of 79.3% was achieved. From T[75] until T[180], 
inhibition of proteolytic activity was between 90.6 and 100% and statistically 
significant at all time-points. With 250mg SBTI, statistically significant inhibition of 
over  60.1% was achieved at all timepoints after T[70]. With 125mg of SBTI, statistically 
significant inhibition of proteolytic digestion was achieved between T[70] and T[120] 
ranging from 59.25-100%, however at T[150] and T[180] the reduction in protein digestion 
relative to control could not be shown to be statistically significant. These data showed 
a dose responsive inhibition of simulated small intestinal protein digestion, with 
maximum inhibition achieved at 500mg SBTI.  
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Figure 157 – Bovine serum albumin (BSA) digestion in the small-intestinal phase of a model gut system 
with and without SBTI. The graph shows total protein recovered from model gut system after TCA 
(Trichloroacetic Acid) precipitation to stop enzyme activity and remove undigested polypeptides. 1g BSA 
was digested alone (Control Digestion) and in the presence of varying concentrations of SBTI. Control 
digestion is represented as as (■) and digestion with SBTI at 125mg as ( ), 250mg ( ) and 500mg ( ). 
All samples were tested in triplicate, errors are shown as standard deviation. 
 
Four alginates were tested for their effects on protein digestion in the small-intestinal 
phase of the model gut system (Figure 158-Figure 161). While there were variations in 
levels of protein digestion with the addition of alginate, none of these deviations from 
the relative control time-point could be shown to be statistically significant.  
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Figure 158 – Bovine serum albumin (BSA) digestion in the small-intestinal phase of a model gut system 
with and without FMC3 Alginate. The graph shows total protein recovered from model gut system after 
TCA (Trichloroacetic Acid) precipitation to stop enzyme activity and remove undigested polypeptides. 
1gBSA was digested alone (Control Digestion) and in the presence of varying concentrations of FMC3. 
Control digestion is represented as (■) and digestion with FMC3 at 125mg as ( ), 250mg ( ) and 
500mg ( ). All samples were tested in triplicate, errors are shown as standard deviation. 
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Figure 159 – Bovine serum albumin (BSA) digestion in the small-intestinal phase of a model gut system 
with and without FMC13 Alginate. The graph shows total protein recovered from model gut system after 
TCA (Trichloroacetic Acid) precipitation to stop enzyme activity and remove undigested polypeptides. 
1gBSA was digested alone (Control Digestion) and in the presence of varying concentrations of FMC13. 
Control digestion is represented as (■) and digestion with FMC13 at 125mg as ( ), 250mg ( ) and 
500mg ( ). All samples were tested in triplicate, errors are shown as standard deviation. 
275 
 
10 20 30 40 50 60 70 80 90 100 110 120 130 140 150 160 170 180 190
-500
-250
0
250
500
750
1000
1250
1500
Time (min)
D
ig
e
s
te
d
 P
ro
te
in
 (
m
g
)
 
Figure 160 – Bovine serum albumin (BSA) digestion in the small-intestinal phase of a model gut system 
with and without SF120 Alginate. The graph shows total protein recovered from model gut system after 
TCA (Trichloroacetic Acid) precipitation to stop enzyme activity and remove undigested polypeptides. 
1gBSA was digested alone (Control Digestion) and in the presence of varying concentrations of SF120. 
Control digestion is represented as (■) and digestion with SF120 at 125mg as ( ), 250mg ( ) and 
500mg ( ). All samples were tested in triplicate, errors are shown as standard deviation. 
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Figure 161– Bovine serum albumin (BSA) digestion in the small-intestinal phase of a model gut system 
with and without H120L Alginate. The graph shows total protein recovered from model gut system after 
TCA (Trichloroacetic Acid) precipitation to stop enzyme activity and remove undigested polypeptides. 
1gBSA was digested alone (Control Digestion) and in the presence of varying concentrations of H120L. 
Control digestion is represented as (■) and digestion with SF120 at 125mg as ( ), 250mg ( ) and 
500mg ( ). All samples were tested in triplicate, errors are shown as standard deviation. 
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6.5 Discussion 
A novel model gut system has been designed to simulate the conditions of 
macronutrient digestion in vitro.  The digestion and absorption of macronutrients can be 
assayed in a simple, controlled and reproducible system. The inhibition of fat and 
protein digestion by alginate has been demonstrated in a physiologically relevant model.  
Using the synthetic gut model described, the effects of further dietary fibres and 
bioactive compounds on the digestion of macronutrients can be tested. This data can be 
used to inform further studies looking at using bioactive compounds as modulators of 
macronutrient digestion and uptake in the human diet, with potential applications for 
health and disease. 
The conditions of the synthetic digestive tract were based on conditions reported in the 
literature and was a continuation of previous development of the model gut system by 
Dr Mathew Wilcox, Dr Iain Brownlee and Professor Jeffrey Pearson. The purpose of 
the simulated gastrointestinal digestion was to investigate the effects reported in 
Chapter 3-Chapter 5, and to investigate if these effects could be replicated in a 
physiologically relevant system. Some of the regulatory effects were consistent between 
the microplate assays and the synthetic gastrointestinal environment however there were 
instances where the effects of the exogenous regulators differed in the model gut 
system.  
As reported by Dr Matthew Wilcox, specific alginates have been shown to inhibit the 
action of pancreatic lipase in vitro. The inhibitory effect has been shown to be linked to 
alginate structure, with guluronic-acid rich alginates tending to inhibit more strongly. 
Glyceryl Trioctanoate was used as a substrate for fat digestion, and release of free 
glycerol from the triglyceride molecule was used as a marker of digestion. The assay 
system was validated using Orlistat as a positive inhibition control which showed potent 
dose dependent inhibition. Five alginate samples in total were tested in the model gut 
system.  
Alginate samples FMC3 and FMC13 had no significant effect on the digestion of 
glyceryl trioctanoate at any of the tested time points. FMC13 is a mannuronic-acid rich 
alginate, therefore low in G-residues (F[G]=0.34), and therefore would not be expected 
to be a potent inhibitor of fat digestion based on the reports that G-rich alginates make 
the most potent inhibitors. FMC3 alginate on the other hand is a guluronic acid rich 
alginate (F[G]=0.68) and would be predicted to be a strong inhibitor of fat digestion. 
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Alginate LFR560, a guluronic acid rich alginate performed as predicted (F[G]=0.633), 
with a strong dose dependent dependent inhibition of gyceryl trioctanoate digestion.  
Alginates SF120 and H120L showed an inhibitory effect on fat digestion, however the 
effect was not as potent, the inhibition profiles were markedly different and no dose 
dependent effects were seen. Over the first hour of small-intestinal digestion there was 
no significant change to the digestion profile of glyceryl trioctanoate in the presence of 
alginate H120L or SF120. However during the second hour of small intestinal digestion, 
significant reductions in glycerol release were seen as compared to control. This 
culminated in net reductions in fat digestion from 33-58% with alginate H120L 
depending upon dose and 38-52% for alginate SF120. Again this data was inconsistent 
with previous observations that G-rich alginates are more potent inhibitors of fat 
digestion, as SF120 is a g-rich alginate (F[G]=0.664), and H120L is an M-Rich alginate 
(F[G]=0.45), yet they showed very similar inhibition profiles.  
There are a number of potential explanations for the unexpected and varied results seen 
with alginates in the artificial gut system. The lipase assays conducted by Wilcox et al 
which showed the potential of alginate to inhibit lipase were undertaken in highly 
controlled, ‘simple’ single enzyme conditions, so that a distinct effect can be seen, and 
causally related to the test sample. The Simulated model gut system however aims to 
pertain to physiological gastro-intestinal conditions and as such is a much more 
complex environment containing a diverse range of chemicals, enzymes and other 
digestive secretions. Whole porcine bile, and porcine pancreatin were used in the model 
gut system. Bile contains a complex mix of bile salts, cholesterol, billirubin, lecithin and 
mucus and porcine pancreatin contains the full range of enzymes found in the small 
intestine. Alginate has been shown to interact with bile acids  and other digestive 
enzymes [57]. It is therefore possible that these interactions affect or disrupt the ability 
of alginate to inhibit lipase, although the mechanism of alginate inhibition of lipase 
remain unknown.   
Furthermore, the microplate assays conducted by Wilcox et al were conducted in a pH-
buffered environment of pH7.3. However during the Gastric phase of the model gut 
system, the pH is highly acidic, as the simulation passes into the small intestinal phase, 
the pH is raised by the addition of porcine bile, and the addition of pancreatic secretions 
rich in bicarbonate causeing a gradual neutralisation and raising of the pH. As discussed 
in the introduction, alginate forms an acid-gel at an acidic pH during which the alginate 
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molecules form strong interchain reactions. This gelling may provide an explanation in 
the case of SF120 and H120L why the alginate has no effect on fat digestion during the 
initial hour of small-intestinal digestion, but causes significant inhibition over the 
second hour. It may be that over the course of the small intestinal phase as the pH is 
raised by the addition of pancreatic secretion, the gelling effect is lost, and alginate 
becomes free and available to interact with pancreatic lipase in order to inhibit it.  
That LFR560 does not show this same ‘lag’ in inhibition may be explained by the fact 
that it has a considerably lower molecular weight of 34700 as compared to 195000 for 
SF120 and 397000 for H120L and therefore would not form a strongly interlinked gel.  
A further difference between the in vitro microplate assays and the model gut system is 
the motion of the model gut system which is stirred at a frequency of 0.05Hz to simulate 
the motion of the digestive tract. Although this stirring does not accurately model the 
physiological shearing, mixing and churning caused by gastric motility and peristaltic 
motion, it recognises that digestion does not occur in a static environment. This motion 
is therefore a further change from the microplate assays, and the introduction of 
physical forces may have effects on the way alginate is able to form interactions with 
lipase and fat substrates.  
A range of triglyceride substrates have been tested in the model gut system, with 
varying lengths of fatty acid chains (data not included). However in this study, only 
Glyceryl Trioctanoate was investigated in relation to alginate activity due to time 
constraints. In the original work on alginate inhibition of pancreatic lipase, two types of 
assays were carried out; one with Olive Oil as the substrate, containing a varied mix of 
triglycerides, and one with DGGR (1,2 Di-o-laulryl-rac-glycero-3-(glutaric acid 6-
methyl resorufin ester)) a synthetic substrate.  
Alginate showed potent inhibition of fat digestion in both of these assays, however it is 
possible that the inhibition of pancreatic lipase is substrate specific, and favours the 
inhibition of particular triglycerides and that there is a relationship between fatty acid 
chain length and degree of inhibition. The way in which alginate interacts with 
triglycerides of different fatty acid chain lengths is being investigated elsewhere. 
Alginate is not the only biopolymer that has been shown to inhibit the activity of 
pancreatic lipase. Wilcox, 2010 also showed that pectin, carrageenan and cellulose were 
also cpable of inhibiting fat digestion by lipase in vitro.  
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Pectins were capable of inhibiting lipase activity by up to 24.7±6.3%, inhibition of 
lipase by pectin was shown to be related to levels of esterification [5].  This is 
supported in the literature by the findings of Isaksson et al 1982, and Kumar et al 2010, 
who also showed inhibition of lipase by pectin to be linked to lower levels of 
esterification [229, 282] . Kumar et al argue that the carboxyl groups of pectin interact 
with the active site residues of the lipase enzyme, protonating them and disrupting the 
catalytic mechanism. This explains why increasing levels of esterification reduces 
inhibition, as the number of carboxyl groups is decreased. It was argued by Wilcox 
2010, that a similar mechanism may be the cause of alginate inhibition of lipase, as 
alginates are similarly rich in carboxyl groups [5]. No data is available for pectin 
inhibition of lipase in a model gut system, but in a separate study, Isaksson et al, 1983 
showed that the inclusion of 5% pectin in the diet of rats increased, fat content in 
ileostomy effluent samples, suggesting a decrease in fat digestion [283]. Chitan and 
chitosan, both cationic polymers have been shown to inhibit lipase activity [284, 285]. 
However, other polymers including carrageenan have been shown to activate lipase 
activity.  
Pectin, cellulose and carrageenans have not been tested in the model gut system, but 
data from in vitro assays [5], animal studies [283] and unpublished human data suggests 
that alginates and other biopolymers have potential to reduce fat digestion and uptake, 
and may have the potential to be used as a treatment for obesity. ` 
An assay for carbohydrate digestion was developed and validated using Acarbose as the 
positive inhibition control. Corn Starch was used in the assays described herein in the 
native form, but the assay has also been validated with potato starch and wheat starch 
both in the native and gelatinised form [data not included]. 
As was commented upon in the results section, 1g of native corn starch was used as the 
carbohydrate substrate, but in the control digestion, only approximately 25% of this is 
recovered. This may be down to under-reporting of the digestion of carbohydrate in the 
assay system. As described in the methodology, after sampling and removal of 
undigested starch, the digestion products which would consist of mono-,di- and short 
oligo- saccharide chains were exhaustively digested down to monosaccharides using α-
glucosidase. However a major digestion product of starch digestion is α-limit dextrim, 
breakdown of which requires the brush border isomaltse to cleave the α(1-6) bonds of 
α-limit dextrin [286]. As synthetic pancreatin does not contain brush-border isomaltase, 
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it is possible that these breakdown products are not fully broken down to mono-
saccharides. Secondly, it is possible that during the methanol KCl precipitation to 
remove undigested starch, that some digestion products, particularly the larger oligo-
saccharides are also pulled out of solution.  
However, it is possible that not all of the starch is broken down in the assay system. As 
discussed by Zhang et al 2006, starch is classified into rapidly digestible starch, slowly 
digestible starch, and resistant starch, depending upon how quickly glucose is released. 
Starch consists of highly ordered and structured molecules, which in the native 
crystaline form which reduces their solubility and ability to interact with other 
molecules [287]. Digestion of starch generally requires disruption of the crystalline 
structure of starch granules which normally occurs through food processing and 
cooking. Having said this, starch macromolecules – as a source for plant energy storage 
– must be accessible to metabolic enzymes. Hydrolysis of native  starch is accepted as a 
two-phase system; first the rapidly digested non-granular starch, and then the slowly 
digested crystalline granules. Native starch generally contains between 15-45% 
crystalline material, so only between 55-85% of starch would be readily accessible for 
α-amylase hydrolysis [287]. It may therefore be that the initial spike in starch digestion 
seen at the beginning of the small-intestinal phase is the non-crystalline rapidly 
digestable starch being hydrolysed, after which the granular native starch is either 
resistant to digestion, or very slowly digested.  
 
Microplate screening and kinetic assays had shown alginate to be capable of increasing 
the activity of α-amylase in vitro and that alginates high in mannuronic acid tended to 
be better activators.  
Four alginates were tested for their effects on Corn Starch digestion in the model gut 
system; FMC3, FMC13, SF120 and H120L. Although visibly altering the digestion 
kinetics of corn starch digestion, there were no significant changes caused be SF120 or 
H120L. FMC3 and FMC13 on the other hand both showed similar regulatory profiles, 
with an initial inhibition of Corn starch digestion for the first 15 minutes of the small 
intestinal phase, after which digestion recovered to normal control levels. At the lower 
concentrations of alginate of 125mg and 250mg, both FMC3 and FMC13 showed no 
significant changes from control, but at the highest concentration of 500mg with both of 
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these alginates there was an activatory effect, and by the final time-point the amount of 
glucose recovered had significantly increased.  
This activatory affect suggests that the fact that only 25% of starch substrate was 
reported in the control digestion is due in part at least due to some of that substrate 
starch remaining resistant to digestion, and that with the addition of 500mg of FMC13 
there is an interaction which renders the carbohydrate more accessible to digestion. 
With the addition of 500mg FMC13, by the final timepoint of the small intestinal face, 
approximately 60% of substrate starch has been efficiently released. Further 
investigations of this are required, to confirm conclusively that this is the cause of the 
reported levels of starch digestion being lower than expected.  
The initial inhibition of carbohydrate digestion seen in the initial 15 minutes of the 
small intestinal phase is not consistent with the results described in Chapter 5 that 
alginates increase the activity of α-amylase in vitro. It is however consistent with the 
numerous reports in the literature that dietary fibres including alginates have anti-
hyperglycaemic effect in vivo [288]. As discussed in Chapter 5, mechanisms for this 
hypoglaecaemic effect are thought to include delayed gastric emptying and inhibition of 
the sodium-glucose cotransporter. However, neither of these processes are modelled in 
the currently described model gut system. 
In the microplate assays described in Chapter 5, potato starch is used as the substrate, 
whereas corn starch has been used in the gut modelling, therefore further investigations 
are required to see if there are differences in the way in which alginate effects the 
digestion of carbohydrates from different sources. The addition of alginate may reduce 
carbohydrate digestion via a viscosity effect, slowing down the pedisis of particles and 
reducing the accessibility of α-amylase to substrate, decreasing the chance of a 
successful enzyme-substrate reaction [140]. Furthermore the way in which alginate 
interacts with α-amylase and its carbohydrate substrates across the pH range requires 
further investigation.  
The inhibitory effect seen with FMC3 and FMC13 did not continue beyond the first 15 
minutes of the small intestinal phase, after which there were no significant differences 
to control activity at 125 and 250mg alginate. However, with 500mg of both FMC13 
and FMC3 there was an increase in carbohydrate breakdown by the final time-point of 
T[180]. This suggests that there are multiple processes occurring, and that inhibitory 
effects prevail in the initial phase of small-intestinal, but are overcome and with 
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sufficient alginate activation effects are seen. As was discussed in Chapter 4, alginates 
have a pH dependent rheological behaviour, forming gels at low pH and viscous liquids 
at neutral pH, so as alginates pass from the gastric phase to the small intestinal phase, 
the change in pH will alters their structural characteristics, and therefore behaviour. 
Further investigations are reguired to investigate how alginate affects lipase activity 
across the pH range.  
As discussed in Chapter 3 and Chapter 4, alginates had been shown to inhibit pepsin 
activity in in vitro microplate assays, but have no effect on trypsin. Protein digestion 
was investigated in the model gut system in order to investigate the effects of alginate in 
a physiologically relevant system. Gastric pepsin is the enzyme responsible for 
proteolytic digestion in the stomach, it was therefore expected that the results from 
Chapter 3 would be predictive of what occurs in the gastric phase of the simulation.  
Small intestinal protein digestion however is a more complex process mediated by  
multiple proteases secreted from the pancreas and activated in the proteolytic enzyme 
cascade; Trypsin, chymotrypsin, elastase, carboxypeptidases A and B. It was therefore 
important to investigate how alginate interacts with the complex multi-enzyme 
environment.  
As described in section 6.4, the gastric and small-intestinal phases of digestion were 
examined separately, so that the site of any regulatory effects can be identified. 
Inhibition in the gastric phase was validated with pentosan polysulphate as a positive 
inhibition control, and Soybean Trypsin Inhibitor was used as a positive inhibition 
control for small intestinal proteolytic digestion.  
Four alginates were tested in the gastric phase of the model gut system. As predicted 
from the microplate assays in Chapter 3, all four of these alginates (FMC3, FMC13, 
H120L and SF120) caused significant inhibition of pepsin mediated gastric protein 
digestion, with the High-M alginate inhibiting to a significantly greater extent than the 
High-G alginates. While there was variation in small intestinal phase protein digestion, 
none of the alginates tested caused any statistically significant changes.  
These results support the findings discussed in Chapter 5 that there is a pH-dependent 
interaction between alginate and protein substrate which affects proteolytic digestion at 
acidic pH, but has no effect on proteolytic digestion in the neutral environment of the 
small intestine.  
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Further investigations would be required into the effect that alginate has on the other 
proteolytic enzymes of the small intestine, as it may be that alginate is affecting the rate 
of chymotrypsin, elastase or carboxypeptidase, but that the redundant capacity of the 
small intestinal proteases mean that the addition of alginate has no affect on net 
proteolytic digestion.  
The observation of alginate-inhibition of protein digestion occurs in the gastric phase is 
consistent with reports in the literature of pH dependent interactions between proteins 
and carbohydrates [56, 191-193]. The data reported herein supports the theory that 
carbohydrates, and alginates specifically display general protein binding behaviour. 
This adds weight to the theory that inhibitor-substrate interactions between alginate and 
protein are formed as the pH is lowered taking the protein below it’s iso-electric point 
and allowing electrostatic charges to form, leading to protein-alginate gellation. 
Furhermore this theory provides an explanation for the fact that protein digestion is 
inhibited in the gastric phase, as substrate is bound by alginate, but not in the small 
intestinal phase here these interactions do not form at a near neutral pH.  
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Chapter 7 
General Discussion 
7.1 Background & aims 
The  current investigation into the effects of alginate and other bioactive compound was 
based on the work of Wilcox et al 2010 which showed that specific alginates can inhibit 
pancreatic lipase by up to 70% depending upon their structure [5]. Alginate is now 
being investigated as a potential anti-obesity agent in human weight loss trials.  
As the digestion and absorption of the major macronutrients fat, protein and 
carbohydrate is a central factor in health and metabolic diseases, using exogenous 
compounds such as alginate to modulate the activity of the major digestive enzymes 
present a paradigm for treatment of nutrition related disorders.  
This project therefore aimed to develop methodologies which could be used to 
investigate alginate and other bioactive compounds as regulators of digestive enzymes. 
To this end, a 3-step process was developed to test the action of biopolymers on the 
major enzymes of macronutrient digestion, pepsin, trypsin, α-amylase and lipase: 
 
 
 
 
 
 
7.2 Discussion 
 
Alginates have been shown to have the ability to modify the activity of multiple 
digestive enzymes in vitro and affect the digestion profile of major macronutrients in a 
physiologically relevant model gut system. Some of these functional effects have been 
shown to be linked to structural characteristics of alginates [5, 281, 289, 290].  
i. High Throughput Analysis 
iii. Selected Kinetic Analysis 
ii. Model Gut Analysis 
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Through the use of an N-terminal Proteolysis assay it was possible to determine that 
alginate was a potent inhibitor of pepsin activity, but had no significant effect on 
trypsin.  
The strongest inhibition of pepsin observed was with alginate H120L which reduced 
pepsin activity to 53.9% (±9.53SD) of normal activity. It was shown that the potency of 
inhibition correlated with alginate structure, a strong positive correlation between 
alginate F[M] and levels of pepsin inhibition, supporting the findings of Strugala et al 
2005[7]. Furthermore an increasing proportion of contiguous G-Blocks was shown to be 
negatively associated with inhibition of pepsin, with [n(g>1)], F[GG] and F[GGG] all 
negatively correlating with pepsin inhibition. The composition of alginates as large 
negatively charged polymeric molecules able to form gels and intramolecular 
interactions, can result in inhibition flexibility. Alginates have been shown to be capable 
of binding to both enzyme and substrate.  
A small number of the catalogue of tested alginate samples were observed to have a 
statistically significant effect on trypsin, the largest of these effects was only 
approximately a 10% inhibition by FMC5. However generally alginate had no 
statistically significant effects on trypsin activity and those that were observed were 
negligible and not supported by the selected kinetic analysis.  
Protein digestion was investigated in the physiologically relevant model gut system, and 
the results shown were consistent with what was predicted from the single enzyme 
microplate investigations. Protein digestion was inhibited in the gastric phase of 
digestion by up to 46.1%, however no significant changes to proteolytic digestion were 
observed in the simulated small intestinal phase, as would be expected as they do not 
inhibit trypsin. However this data also suggests that alginates do not have any effect on 
the activity on the other proteolytic digestive enzymes of the small intestine. The 
reasons for this will be discussed later.  
Due to the distinctly different inhibition profiles for pepsin and trypsin, the manner in 
which alginates and protein substrates interact across the pH range was investigated 
rheologically. Profound rheological ineractions were observed at acidic pHs, but no 
pattern of rheological interaction was observed at neutral pH; with all alginate samples 
tested, a protein-alginate co-precipitate was formed at acidic pH, but not at a neutral pH.  
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Protein-carbohydrate interactions are common in biology, and widely reported in vitro 
[56]. SP54, heparin sulphate, and other highly sulphated polysaccharides are known to 
inhibit pepsin activity [179, 180]. Non-specific protein binding has also been observed 
with polysaccharides, raising the possibility of inhibitor-substrate interactions being 
involved in pepsin inhibition. Protein-carbohydrate interactions occur at low pH. As the 
pH is lowered and protein is taken below its iso-electric point, negative charges are lost 
and the protein becomes positively charged. Positively charged protein then form 
interactions with negative charges on the carbohydrate and carbohydrate-protein 
complexes form, leading to gelation [196].  
Alginate is a negatively charged polymer, capable of forming such electrostatic 
interactions with positively charged proteins at low pH [197]. Alginate may associate 
with protein through hydrogen bonding at hydroxyl groups; charge-charge interactions 
with δ- carboxyl groups, and the negatively charged COO- group of the alginate, 
although this group would become protonated at low pH.  The pH sensitivity of the 
synergism between alginate and proteins suggests that these electrostatic interactions are 
important in inhibition and that ionisation plays a key role.  
This theory also provides a clue as to why high-M alginates tend to be better inhibitors 
of pepsin activity than high-G alginates. High-G alginates form stiff rigid gels at low pH 
and strongly bind divalent cations, forming strong interchain associations. High-M 
alginates on the other hand form much weaker gels, with more flexible alginate chains. 
Cations would compete for COO- groups on the alginate chain, meaning less COO- 
groups will be free to interact with a protein substrate. Furthermore alginate gels with 
stronger interchain associations, will be freer to interact with protein substrate. The 
chain flexibility of High-M alginates will also allow the polymer chain to be more 
supple and therefore be more capable of mirroring the structure of the protein molecules 
and forming interactions. 
The binding to protein and formation of a precipitate with alginate would remove 
protein substrate from solution and make the protein substrate unavailable to pepsin, 
thereby inhibiting pepsin activity. While at neutral pH the protein substrate remains 
available for proteolysis. This explains why no inhibition of trypsin activity was 
observed. Furthermore this supports the model gut data described in Chapter 6 whereby 
inhibition of proteolysis by alginate was reported in the gastric phase of digestion, but 
not in the small intestinal phase.  
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Trypsin is not the only enzyme present in the small intestine responsible for proteolytic 
digestion (Table 3), yet no significant change in protein digestion in the small intestinal 
phase of the model gut was observed. This suggests that alginate has no effect on the 
cumulative activity of trypsin, chymotrypsin, elastase and the carboxypeptidases. It also 
confirms the theory that at the pH levels seen in the small intestinal phase, there are no 
protein-alginate interactions that make substrate unavailable for enzymatic digestion. 
A number of other biopolymers were tested for regulatory activity towards the 
proteolytic enzymes [Data not included]. Some were shown to be potent inhibitors of 
pepsin activity in the order Fucoidan>Carrageenan>Alginate. Alginates higher in 
mannuronic acid residues tended to be stronger inhibitors, and with fucoidan and 
carrageenan a relationship was observed whereby a high degree of sulphation was 
associated with potent inhibition of pepsin activity.  
Sulphated polysaccharides have previously been shown to inhibit pepsin as was 
discussed with SP54 and heparin. Furthermore, anti-peptic effects have been observed 
in vivo, with heparin reducing peptic ulceration in rats and guinea-pigs [179, 185, 186]. 
Th mechanism of sulphated polysaccharide inhibition of pepsin is also due to 
electrostatic interactions forming between molecules, but in this case between the 
sulphate groups of the carrageenan and positively charged regions of the protein [194, 
195]. The interactions between substrate and biopolymer were again shown to be pH 
sensitive, as neither carrageenan or fucoidan significantly affected trypsin activity. This 
further supports the argument that at low pH, interactions occur between positively 
charged protein molecules and negative charges on carbohydrate polymers. 
Sunderland et al 2000 reported a direct interaction between alginate and pepsin whereby 
pepsin was pulled out of solution by alginate during centrifugation. This suggested 
direct binding of pepsin as a possible mechanism of inhibition [57]. However, a more 
general protein binding interaction has been described herein. This does not however 
rule out a direct interaction between alginate and pepsin, and it may be that both 
alginate binding of substrate and enzyme occur in concert to inhibit proteolysis.  
Alginates rich in hydroxyl and carboxyl groups capable of forming hydrogen bonding 
and charge:charge interactions with pepsin active site residues in a similar mechanism 
to pepstatin inhibition. Pepstatin inhibits pepsin activity by strongly binding and 
blocking access to the active site. By forming electrostatic interactions alginate may 
similarly block substrate binding.  
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Furthermore, these interactions with active site residues may act to disrupt the catalytic 
mechanism.  Carboxyl groups have been shown to be important in enzyme inhibition, as 
in the case of pectin and lipase, and similarly it is possible that similar interactions may 
form with the active site Asp32 residue of pepsin, disrupting the acid-base pair of 
Asp32-Asp215, and preventing nucleophillic attack on the scissile peptide bond. Even if 
direct interactions are not formed, the presence of large negative charges in proximity of 
the active site may be sufficient to disrupt the charge relay mechanism or prevent 
regeneration of the catalytic nucleophile. 
It is unlikely that these same interactions would occur with trypsin at a near neutral pH 
as the carboxyl groups of alginate would not be protonated, and would therefore be 
unable to act as proton donors. Furthermore substrate binding by trypsin is highly 
specific and has a strong preference for cleavage sites, it is therefore unlikely that an 
alginate molecule could form a stable interaction and mimic substrate binding in the 
same way that soyabean trypsin inhibitor does. Furthermore the active site of trypsin is 
enclosed within the centre of the two domains of the globular trypsin protein and has a 
negatively charged substrate binding pocket, as alginates are large negatively charged 
polymers, they would be repelled from the trypsin substrate binding site due to 
charge:charge repulsion and moreover have poor accessibility to the active site binding 
pocket due to size [291]. 
As discussed in the Aims & Approaches section in Chapter 2, the ability to modulate 
protein digestion and absorption by eliciting an increase or decrease in pepsin activity 
has potential therapuetic benefits. However what has been reported in the current study 
is that alginates, fucoidan and sulphated carrageenans have the ability to inhibit gastric 
proteolysis, but have no effect on small-intestinal protein digestion.  
Gastric emptying depends upon the breakdown of the food matrix by pepsin hydrolysis, 
inhibition of pepsin activity by alginates will impair this breakdown. Delayed gastric 
emptying has been reported with the administration of Proton Pump Inhibitors, a 
reduction in proteolytic activity slows the gastric breakdown of food, which is thought 
to have implication for GORD as well as human nutrition [292]. PPIs are administered 
in order suppress gastric secretion and reduce acidity of refluxate, however the reduced 
acidity decreases pepsin activity and slows the process of gastric proteolysis. 
It has previously been asserted that protein malabsorption due to gastric acid 
suppression is probably negligible, this assertion is based on the fact that total protein 
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digestion has been shown to be largely unaffected by total gastrectomy or pernicious 
anemia [293]. However in a separate study of 16 healthy subjects, it was shown that 
gastric acid suppression with the PPI Omeprazole delayed and reduced protein 
assimilation. Protein digestion was measured using 
14
C-octanoic acid/
13
C-egg white 
breath test. Evenepoel et al 1998, suggest that impaired gastric digestion means 
substrates passing into the small intestine are less accessible to small-intestinal 
hydrolytic enzymes. Furthermore an increase in phenol and p-cresol production by 
fermentation of unabsorbed protein by the colonic microflora is indicative of protein 
malabsorption [294].  
While this observation was not supported by the observations seen in the model gut 
system in Chapter 6 that small intestinal proteolysis was unaffected by addition of 
alginate or fucoidan, it must be remembered that the model gut simulation is an 
incomplete model of the physiological complexity of digestion. Firstly the model does 
not attempt to and is not capable of simulating the processes that mediate gastric 
emptying in vivo; the model therefore does not have the capacity to mimic how a 
resilient food matrix in the gastric phase of digestion would delay food delivery into the 
simulated small intestinal phase. Furthermore, small intestinal proteolytic digestion was 
examined independently of gastric protein digestion by the complete omission of gastric 
pepsin. Therefore, in the small intestinal analysis of protein digestion, neither sample 
nor control had been exposed to gastric pepsin hydrolysis. This means that the model 
does not account for a more intact test meal reaching the small intestinal phase of the 
simulation. Therefore in vivo alginate and fucoidan may have an anti-proteolytic effect 
in the small intestinal phase through both delayed gastric emptying and protection of 
protein substrate in the food matrix after passage into the small intestine. In order to 
investigate these hypotheses, in vivo studies would be required.  
Accelerated gastric emptying has been implicated in a particular subset of patients with 
functional dyspepsia, and the retardation of gastric emptying may be of clinical value to 
them [295]. Furthermore, if alginate and fucoidan can be used to affect the rate of food 
delivery to the small intestine through delayed gastric emptying, and retard the 
degredation of the food matrix they have potential to slow the rate of nutrient release 
and uptake, which has implications beyond just protein digestion. 
It has been shown that the initial rise in post-prandial blood glucose is directly related to 
the rate of gastric emptying and that rapid gastric emptying can be an excaserbating 
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factor in diabetes [296]. PPI administration has been shown to improve glycaemic 
control, although the exact mechanism remains unclear [297].  
Furthermore delayed gastric emptying has been associated with increased sensation of 
fullness and satiety following a meal, which may have implications for decreasing 
calorific intake and energy yield of a meal [298].  
 
Carbohydrate digestion was also affected by the presence of alginate in the reaction 
mixture. In the microplate assays of α-amylase activity, addition of alginate increased 
α-amylase by a maximum of 41.1±8.42%. In the microplate high-throughput assays, no 
statistically significant relationship was shown between any of the structural 
characteristics of alginate and levels of activation. However from the kinetic testing, 
significant positive correlations were shown between maximum velocity of reaction and 
frequency of mannuronic acid residues of alginate.  
Alginates chelate divalent cations such as calcium, and it is possible that alginate 
present Ca++ to the α-amylase enzyme, or interaction with the α-amylase enzyme 
through this calcium binding site and stabilise calcium binding [255].  
As was seen with protein and alginate, it is possible that alginate-substrate interactions 
play a role in this regulatory effect. Interactions between alginate and starch have been 
previously reported; Richardson et al showed that alginate can interact with starch so as 
to disrupt gellation [256]. Furthermore it was shown in the current experiments that the 
addition of corn, wheat and potato starch to an H120L alginate solution greatly reduced 
alginate viscosity. It may be therefore that a mechanism by which alginate increases the 
activity of α-amylase is by disrupting the gel network of starch, increasing the surface 
area of starch substrate that is available for α-amylase to act upon.  
These reports of α-amylase activation go against what has widely been reported in the 
literature stating that dietary fibres have protective affects against diabetes [44]. 
However, these reports of activation were in a pH controlled single-enzyme 
environment, and as can be seen from the model gut system, this activation was not 
wholly replicated in a physiological simulation. In the first 15 minutes of the small-
intestinal phase of the model gut simulation there was a short-lived inhibition, after 
which carbohydrate digestion returned to control levels. With two of the alginates 
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tested, there was an increase in carbohydrate digestion by the final time-point at the 
highest tested dose of alginate, but not at lower doses.  
The data for the model gut simulations is more consistent with data that has been 
presented in the literature, suggesting that dietary fibres including alginate have anti 
hyperglycaemic effects in vivo. Epidemioplogical studies have shown high long term 
intake of dietary fibre is associated with decreased risk of diabetes [44], and specific 
anti-hyperglycaemic effects have been shown with certain dietary fibres. Anti-diabetic 
and anti-hyperglycaemic effects have widely been reported in vivo. Guar gum, partially 
hydrolysed guar gum and alginate have been shown to reduce post-prandial 
hyperglycaemia if diabetic rats and have a significant hypoglycaemic effect in humans 
[139, 252]. 
Suggested mechanisms for these anti-diabetic and anti-hyperglycaemic effects include; 
delayed gastric emptying, stabilisation of the food matrix, viscosity effects and 
inhibition of sodium-glucose cotransporter. Gastric emptying presents a rate limiting 
step on carbohydrates being delivered to the small intestine for breakdown and 
subsequent uptake. Stabilisation of the food matrix is thought to both delay gastric 
emptying, and retard the action of enzymatic hydrolysis after transit to the small 
intestine. Fibre viscosity is thought to affect carbohydrate digestion both through a 
delaying effect on gastrointestinal transit time, and by viscous fibre reducing the 
accessibility of carbohydrolytic enzymes to the substrate, and also by reducing the rate 
of glucose diffusion through the lumen for uptake [140]. Kimura et al 1996, advance a 
theory for a specific mechanism by which alginate exerts its hypoglycaemic effect by 
inhibiting the sodium glucose transporter [252].  
Breakdown of starch into maltose, maltotriose and α-limit dextrin is thought to occur 
very rapidly and within 10 minutes of transit into the duodenum; because duodenal 
digestion of carbohydrate is so rapid, an increase in amylolytic activty will have a 
marginal effect on the speed of carbohydrate digestion and other factors such as gastric 
emptying will be the rate limiting step [258]. As carbohydrate digestion predominantly 
occurs in the duodenum, the rate at which carbohydrates are delivered to the duodenum 
will therefore be the determining factor in the rate of carbohydrate digestion. Torsdottir 
et al 1991 showed that gastric emptying was significantly delayed by alginate 
supplementation This is likely to be the determining factor which resulted in the anti 
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hyper-glycaemic effect, as reduced blood glucose rise correlated with slowed gastric 
emptying [257].  
Alginate has been shown to inhibit sodium absorption in the small intestine and increase 
Na+ excretion during digestion [252, 259]. Sodium is essential for intestinal absorption 
of glucose, as glucose uptake occurs through the sodium glucose co-transporter and 
reduced glucose uptake and the hypoglycaemic effect of alginates may be due to in part 
to alginate making sodium unavailable to the NaGluc Cotransporter [260]. It was 
suggested by Kimura et al 1996, suggest that the net hypoglycaemic effect of alginate 
may be due to a combination of alginate gelling in the stomach, delaying gastric 
emptying, and reduced sodium uptake in the small intestine inhibiting the action of the 
sodium-glucose co-transporter [252]. Furthermore increased viscosity of the gut lumen 
contents caused by alginate may reduce the accessibility of amylase to it’s substrate, and 
reduces the rate of glucose diffusion through the lumen for uptake [140].  
The gastrointestinal tract is a complex environment with these multiple, physical, 
physiological and chemical processes working in transit, and it is therefore likely that 
while alginate has an activatory effect on α-amylase activity in isolation, in the complex 
environment of the GI tract, this activation is overcome by the cumulative inhibitory 
effects described above. These results further underline the need to look at the processes 
of digestion in their totality, and test effects in physically relevant situations and 
ultimately in vivo. 
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The way in which alginate and other bioactive compounds affect the digestion of fat has 
been studied by this research group at length previously. Alginates have shown the 
ability to inhibit the action of pancreatic lipase by up to 70% in vitro, this has been 
correlated to the structure, with alginates high in guluronic acid tending to be the more 
potent inhibitors [5, 299]. 
Alginate is now being investigated in human trials as a potential treatment for obesity. 
Using bread as a delivery vehicle, the effects of alginate on total fat digestion and post-
prandial blood triglycerides has been investigated (unpublished data). A further 
investigation is due to be undertaken titled “Designing the most effective vehicle to 
deliver alginate to effectively reduce fat digestion and absorption”.  
In Chapter 6 of this current study an assay is described to investigate the digestion of 
triglycerides in the simulated model gut system. Data reported in the current study is for 
how alginate affects the digestion of a single triglyceride (glycerol trioctanoate), and 
only one of the alginates tested was shown to yield dose-responsive inhibition of 
alginate. However, other work undertaken in this lab using the methodology has 
investigated the was alginate effects the digestion of other triglyceride substrates, and a 
mixed-triglyceride substrate mixture.  
While alginates have been previously shown to be potent inhibitors of pancreatic lipase 
in vitro, model gut analysis described herein was varied. Alginate samples FMC3 and 
FMC13 had no significant effect on the digestion of glyceryl trioctanoate. Alginates 
LFR560, SF120 and H120L all showed significant inhibition of glyceryl trioctanoate 
digestion. Only glyceryl trioctanosate was tested as a substrate for inhibition of fat 
digestion, therefore further investigations are necessary to investigate the specificity of 
alginate inhibition to different triglycerides.  
It was argued by Wilcox, 2010, that alginate inhibits lipase activity according to a 
similar mechanism reported in pectin inhibition of lipase, whereby carboxyl groups of 
the polymer protonate key active site residues of the Lipase enzyme, disrupting catalytic 
activity [5] [229].  
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7.3 Future Scope 
As stated previously, the aim of this project was to develop a 3-step methodology to 
investigate the effects of exogenous compounds on the digestion of the major 
macronutrients. These assays were developed and used to analyse the bioactive 
properties of alginate, fucoidan, pectin and carrageenan. These assays have 
demonstrated wider utility in a number of collaborations including the analysis of the 
bioactive properties of seaweed and seaweed extracts and the investigation of pepsin as 
an aggressor in GORD. 
These assay systems and methodological approach provide a template for investigating 
the paradigm of exogenous compounds as inhibitors of digestive enzyme activity and 
the development of novel therapeutics and food additives targeting macronutrient 
digestion.  
Furthermore the model gut system developed in this lab provides a physiologically 
relevant model of the digestive tract. The Royal Society of Edinburgh has recognised 
the value of this model to industry and awarded an Enterprise Fellowship to continue 
development of the model as a commercial venture.  
Nutrition research has been identified as a key strategic priority by the BBSRC both in 
terms of food security and in understanding the role of diet and the mechanisms that 
underpin health and disease [8]. The MGS provides a controlled, reproducible and cost-
effective method of investigating dietary therapeutic interventions in a physiologically 
relevant system. In vitro MGS are an ethical alternative to animal studies and therefore 
appeal to companies who wish to avoid the negative publicity of animal studies. MGS 
also provide robust physiologically relevant mixed model which can be used to inform 
and improve human studies.  
The MGS provides a higher-throughput primary screening method by which 
compounds can be ruled in or out as effective therapeutic agents and a system of 
analysis for looking at bioactive effects. As with pharmacological studies, randomised, 
double blinded control trials in human populations are the gold standard of nutrition 
studies, however cost and complexity are often prohibitive [262]. Smaller scale human 
studies can also be costly and difficult.  A small outlay in cost on preliminary MGS 
trials will provide companies and research groups with data that can be used to 
investigate efficacy, dosage, delivery methods and allow them to make decisions that 
will potentially save costs and improve results without using animal models.  
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Due to the cost, ethics and scale of in vivo studies a range of in vitro methods have been 
developed to model digestion. Single enzyme analysis can identify novel enzyme 
inhibitors, but is insufficient to draw conclusions about the effects in vivo. A number of 
model gut systems have been developed to study different aspects of digestion and GI 
physiology, however this is the only known model in which a continuous profile of fat, 
carbohydrate and protein digestion from mouth to small intestine can be gained. Other 
models that have been developed look at; bioavailability and bioaccessibility of 
contaminants [300], digestion of allergens [301] study of pre and probiotics [302], 
models of gut motility, peristaltic motion and physiological mixing and shearing [303], 
enzymatic digestion [303], substrate digestion and interaction [269], intestinal 
microbiota [304], water and nutrient absorption [276]and drug delivery [305]. 
Nutrition research is also of great interest to industry. In 2012 the global consumer 
health market was US$203 Billion, with $87 billion of the market being vitamin and 
dietary supplements, and $13billion in weight management products [306]. 
Furthermore, the ‘Health and Wellness’ food industry is worth a further US$628 billion 
with weight management food and beverages valued at US$144 billion globally [307, 
308]. A key aim of industry is therefore to develop novel health foods and dietary 
interventions.  
According to Euromoniter International, “Consumer health innovation is thriving, as 
manufacturers introduce creative new formulations, delivery formats and positioning”. 
In a study of the Research and Development spending of 25 of the world’s largest food 
companies with turnovers ranging from 11-256 $billion, 6 companies responded with 
R&D spends of; Unilever 2.6%, Cadbury Schweppes 0.9%, Kraft 1.2%, Nestlé 1.6%, 
Yum! 0.3% [309]. 
Furthermore the introduction of EFSA (European Food Standards Agency) requires a 
much higher threshold of scientific evidence for food health claims in the EU. This 
means that costly and financially risky human studies must be undertaken to support 
health claims. A key benefit of this methodological approach is therefore that it 
provides a robust and physiologically relevant in vitro approach for the identification 
and validation of potential bioactive samples, and can be used to provide data that can 
be used to improve and inform human studies.  
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In terms of progressing the current work, there are a number of areas requiring further 
investigation. It would be of interest to investigate the way in which each enzyme 
responds to the presence of biopolymer samples across the pH range at which each 
enzyme is active. It would also be useful to investigate inhibition and activation with 
smaller blocks of alginate of 10-20 residues. This would help to elucidate if the effects 
seen were due to large intermolecular interactions with substrate, or by specific 
interaction with the enzyme active sites or allosteric regulation.  
As the data in Error! Reference source not found. showed, whole seaweeds and non-
alginate extracts of seaweed were capable of regulating enzyme activity, it would 
therefore be of value to further investigate the purity of alginate samples to ensure there 
is no contamination with other molecules such as polyphenols.  
It would also be of value to further investigate the mechanism of inhibition using 
Fourier Transform Infrared Spectroscopy (FTIR) and Quartz-Crystal Microbalance with 
Dissipation (QCM-D). These techniques would allow clear determination of which 
components of the reaction the bioactive is interacting with.  
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8.1 Alginate Structural Characteristics   Figure 162a-f  Structural characteristics of all alginate samples 
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8.2 Models of Enzyme Inhibition  
 
 
 
 
Figure 163a          Reversible competitive inhibition 
 
 
 
 
Figure 164b          Non-Competitive Reversible inhibition 
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Figure 165c          Uncompetetive Inhibition 
 
 
 
 
 
 
 
 
 
 
Figure 166d          Mixed Inhibition 
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8.3 Enzyme Activation 
Enzyme activation is a less well studied field than inhibition, but shares many of the 
principles and methods of analysis.  
8.3.1 Non-essential Activation 
Enzyme activation can be described as essential or non-essential. Essential activation 
occurs when the presence of the activator is required for the reaction to take place, for 
example if the binding of a metal ion is essential for enzyme activity. The current study 
does not deal with essential activators. 
Non-essential activation is when the reaction would take place without the presence of 
the activator, although at a slower rate.  
Non-essential activation occurs in the same manner as enzyme inhibition with regard to 
the enzyme kinetics. Just that rather than decreasing the activity of the enzyme, activity 
is enhanced. A similar model of activation can be employed: 
 
 
 
As can be seen from the diagram above, the product can be produced via two alternative 
paths; the non-activated route, which is the normal enzyme reaction, or the activated 
route.  
8.3.2 Affect on Enzyme Kinetics  
Three possible scenarios of activation are hypothesised below: 
8.3.2.1 Increased affinity of enzyme for substrate.  
This would cause an increased rate of reaction at low substrate concentrations, but 
would be saturated out at higher substrate concentrations and the   would be 
unchanged: 
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Figure 167 Generalised kinetic model for activation with increased affinity. 
8.3.2.2 Increased enzyme activity with no change in affinity: 
In this scenario, the enzyme becomes more active towards the substrate and the 
maximum velocity is increased, but there is no change in enzyme-substrate affinity and 
the Km remains the same. This would occur when the rate of ES complex formation and 
dissociation are at in the same proportions in the activated and unactivated scenarios: 
   
 
 
Figure 168 Generalised kinetic model for activation with no increase in affinity 
8.3.2.3 Mixed Activation 
When both substrate-enzyme affinity and maximum velocity are increased.  
 
Figure 169 Generalised kinetic model for mixed activation 
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